🏷

Classifications

Harrison's Part

◆

Subtypes

5

Faucial (pharyngeal and tonsillar) diphtheria MONDO:0020860

The classical and most common respiratory presentation, in which the pseudomembrane forms over the tonsils and posterior pharynx. It carries the greatest risk of systemic toxin absorption and therefore of myocarditis and neuropathy, and extensive cervical oedema produces the characteristic "bull neck".

Show evidence (1 reference)

PMID:31804499 SUPPORT Human Clinical

"Diphtheria is generally an acute respiratory infection, characterized by the formation of a pseudomembrane in the throat, but cutaneous infections are possible."

Establishes pharyngeal pseudomembrane formation as the classical respiratory presentation this subtype names.

Laryngeal diphtheria MONDO:0020863

Extension of the membrane into the larynx and trachea, historically called "membranous croup". Hoarseness and stridor progress to airway obstruction, and this is the presentation for which tracheotomy or intubation is life-saving.

Show evidence (1 reference)

DOI:10.3201/eid3008.231671 SUPPORT Human Clinical

"The classical clinical manifestation of diphtheria is a pseudomembrane in the upper respiratory airways (tonsils, pharynx, or larynx) that can cause possible fatal airway obstruction."

Names the larynx as a site of pseudomembrane formation and links laryngeal involvement to fatal airway obstruction, the defining hazard of this subtype.

Anterior nasal diphtheria MONDO:0020838

A mild, often chronic form limited to the anterior nares, presenting with serosanguineous or mucopurulent nasal discharge and excoriation of the upper lip. It is classically described as the mildest respiratory presentation, with systemic toxin-mediated complications uncommon relative to faucial disease, while affected individuals remain infectious.

Show evidence (1 reference)

PMID:31804499 SUPPORT INDIRECT Human Clinical

"Diphtheria is generally an acute respiratory infection, characterized by the formation of a pseudomembrane in the throat, but cutaneous infections are possible."

Supports the respiratory grouping this subtype belongs to. Graded INDIRECT because the review states the respiratory presentation generally rather than the anterior nasal localization specifically.

Nasopharyngeal diphtheria MONDO:0020866

Involvement of the nasopharynx, often contiguous with faucial disease. It is recognized separately in treatment guidelines because posterior extension is associated with a larger toxin burden, and WHO dosing schedules assign it a higher antitoxin dose than pharyngeal or cutaneous disease of comparable duration.

Show evidence (1 reference)

PMID:39841756 SUPPORT Human Clinical

"For example, in WHO current guidelines, cutaneous or pharyngeal/laryngeal cases of two days duration require 20,000 eDAT IU; nasopharyngeal diseases less than 48 h duration require 40,000 IU."

WHO guidance treats nasopharyngeal disease as a distinct anatomical presentation with its own antitoxin dose, which is the basis for modelling it as a subtype.

Cutaneous diphtheria MONDO:0001479

Infection of skin, typically a chronic non-healing ulcer with a rolled or "punched-out" edge and a dirty grey membrane, most often on the lower limbs and usually polymicrobial with Staphylococcus aureus or Streptococcus pyogenes. It is now the presentation most frequently reported in high-income countries, is an important reservoir for transmission, and can still produce toxin-mediated systemic disease when the isolate is toxigenic.

Show evidence (2 references)

PMID:39324172 SUPPORT Human Clinical

"Lesions involved the lower limbs (86.9%), corresponded to ulcerations in 82% of cases."

Characterizes the cutaneous form as lower-limb ulceration in a contemporary 63-patient metropolitan French series.

PMID:39324172 SUPPORT Human Clinical

"They represent 57-86% of cases in literature and play an important role in the epidemiology of the disease"

Establishes that cutaneous infections outnumber respiratory ones in the reported literature and contribute materially to transmission.

?

Discussions and Knowledge Gaps

2

Can a human monoclonal antitoxin replace equine diphtheria antitoxin, and does earlier availability translate into lower mortality?

KNOWLEDGE GAP human_monoclonal_antitoxin_replacement

Attached to

treatments#Diphtheria Antitoxin pathophysiology#Systemic Toxin Dissemination

Equine antitoxin is a 130-year-old product with frequent hypersensitivity reactions and a chronically constrained global supply, and antitoxin shortage is repeatedly identified as a contributor to outbreak mortality. A recombinant human replacement would remove both the adverse-effect burden and the animal-dependent manufacturing bottleneck. S315 has completed phase I in healthy volunteers, but no efficacy trial in patients exists, and because the mechanism is time-critical neutralization of extracellular toxin, an efficacy trial has to measure time-to-administration as well as the agent itself.

Show evidence (2 references)

PMID:39841756 SUPPORT Human Clinical

"The resurgence of diphtheria cases, associated with poor vaccination coverage in multiple settings and shortage of existing eDAT products, underlines the urgent need for alternative DAT strategies."

States the supply-driven need for an antitoxin alternative that this gap describes.

DOI:10.1038/s41598-019-57103-5 SUPPORT In Vitro

"These recombinant antibody combinations are candidates for further clinical and regulatory development to replace equine DAT."

Preclinical recombinant-antibody work proposing replacement of equine antitoxin, the line of development this gap asks about.

Mice and rats are naturally resistant to diphtheria toxin because their proHB-EGF binds it poorly; how far can rodent work be trusted to describe human diphtheria?

HUMAN MODEL MISMATCH rodent_hbegf_species_barrier

Attached to

pathophysiology#Diphtheria Toxin Binding to the proHB-EGF Receptor

The species barrier sits at the very first step of the toxin cascade. Wild-type rodents cannot be intoxicated at physiological doses, so rodent studies either use transgenic animals expressing a toxin-sensitive receptor or bypass the receptor entirely, and neither reproduces the natural respiratory colonization that precedes intoxication. Guinea pigs are toxin-sensitive and remain the potency and neutralization model, but they are intoxication models rather than infection models. Claims about tissue tropism and the relative vulnerability of cardiomyocytes and Schwann cells therefore rest largely on human autopsy and biopsy material rather than on a faithful animal model.

Show evidence (1 reference)

PMID:1606612 SUPPORT In Vitro

"Mouse cells are naturally resistant to DT, because they lack functional cell surface receptors for the toxin."

Establishes the receptor-level species difference that limits rodent modelling of this disease.

⚙

Pathophysiology

16

Lysogenic Conversion by a tox-Bearing Corynebacteriophage

The structural gene for diphtheria toxin is not chromosomal in origin. It is carried by a beta-corynephage that integrates into the bacterial genome, so that toxigenic and non-toxigenic strains of the same species coexist and a non-toxigenic isolate can be converted by phage infection. This was the first virulence factor shown to be phage-encoded, and it is why toxigenicity, not species identity, determines whether a patient develops toxin-mediated disease.

Downstream

Iron-Regulated Diphtheria Toxin Expression Lysogeny supplies the tox structural gene that the host iron-responsive regulatory circuit then controls.

Show evidence (1 reference)

PMID:31294205 SUPPORT Other

"Since the ability to produce the diphtheria toxin is a result of β-corynephages infection, for each species toxigenic as well as non-toxigenic strains exist."

Establishes that toxin production is a consequence of phage lysogeny and that both toxigenic and non-toxigenic strains therefore exist within each species.

Iron-Regulated Diphtheria Toxin Expression

Transcription of tox is repressed by DtxR, an iron-dependent DNA-binding protein that occupies the tox operator when loaded with ferrous iron. In the iron-restricted environment of host mucosa the repressor is unloaded and derepresses tox along with a wider iron-acquisition regulon, so the bacterium makes most toxin precisely where it is establishing infection.

cellular response to iron ion starvation GO:0010106

Downstream

Diphtheria Toxin Binding to the proHB-EGF Receptor Derepressed transcription yields secreted toxin that reaches host cell surfaces.

Show evidence (2 references)

PMID:8106325 SUPPORT In Vitro

"DtxR is an iron-dependent sequence-specific DNA-binding protein that binds to the tox operator, an inverted-repeat nucleotide sequence located upstream from the diphtheria toxin gene."

Identifies DtxR as the iron-dependent repressor acting at the tox operator, the regulatory step this node represents.

PMID:8106325 SUPPORT In Vitro

"Transcription from both promoters was strongly repressed in high-iron medium in the presence of the cloned dtxR gene; however, transcription in the absence of dtxR was 50- to 100-fold greater, regardless of the iron concentration."

Demonstrates the iron dependence of DtxR-mediated repression, which is what makes toxin expression rise under the iron restriction of host mucosa.

Mucosal Colonization and Adherence

Before any toxin is made the organism must attach to and colonize the pharyngeal or cutaneous epithelium. Adherence is multifactorial: C. diphtheriae carries three sortase-assembled pilus gene clusters, and pilus type determines which epithelial cell lines a strain attaches to. Adherence is independent of the tox gene, which is why non-toxigenic strains colonize and transmit just as effectively.

nasopharyngeal epithelial cell CL:1001573

cell adhesion GO:0007155 ↑ INCREASED

pharynx UBERON:0006562

Downstream

Pseudomembrane Formation Colonization of the mucosal surface establishes the site at which the pseudomembrane subsequently forms.

Show evidence (2 references)

PMID:31294205 SUPPORT In Vitro

"C. diphtheriae, C. pseudotuberculosis and C. ulcerans are able to colonize different types of epithelial cells in a strain-specific manner, independent of the presence of the tox gene."

Establishes epithelial colonization as a tox-independent step, which is why this node sits upstream of and separate from the toxin cascade.

PMID:31294205 SUPPORT In Vitro

"Genomic analysis of C. diphtheriae revealed the identification of three distinct pili clusters (spaABC, spaDEF, spaGHI) together with five sortase-encoding genes"

Identifies the sortase-assembled pilus clusters that mediate the adherence this node represents.

Diphtheria Toxin Binding to the proHB-EGF Receptor

The receptor-binding (R) domain of diphtheria toxin binds the membrane-anchored precursor of heparin-binding EGF-like growth factor. proHB-EGF was identified by expression cloning as the diphtheria toxin sensitivity determinant, and it associates with the tetraspanin CD9 (DRAP27), which increases the number of functional receptors and raises toxin sensitivity by more than an order of magnitude. Species differences in this receptor explain why mice and rats are naturally resistant to the toxin.

receptor-mediated endocytosis GO:0006898

Animal models

Guinea pig diphtheria toxin intoxication and lethality model Guinea pig measures Because protection in this model tracks the ability of an antibody to keep toxin off its receptor, the assay is a functional readout of the receptor-binding step. The lead human monoclonal was shown to act precisely there, blocking toxin binding to HB-EGF.

Downstream

Endocytosis and Catalytic Domain Translocation Receptor engagement commits the bound toxin to the endocytic uptake route.

Show evidence (3 references)

PMID:1606612 SUPPORT In Vitro

"The cDNA is predicted to encode an integral membrane protein that is identical to the precursor of a heparin-binding EGF-like growth factor."

Expression cloning identifying the diphtheria toxin receptor as the HB-EGF precursor, the binding partner this node names.

PMID:1606612 SUPPORT In Vitro

"Mouse cells are naturally resistant to DT, because they lack functional cell surface receptors for the toxin."

Supports the receptor as the determinant of cellular and species susceptibility, which is the basis for the model-system caveat recorded in this entry.

PMID:8194524 SUPPORT In Vitro

"We conclude that DRAP27/CD9 associates tightly with DTR/HB-EGF and up-regulates the number of functional DTRs and DT sensitivity, and that HB-EGF is identical to DTR."

Establishes the CD9 co-receptor relationship that modulates the number of functional receptors and therefore cellular toxin sensitivity.

Endocytosis and Catalytic Domain Translocation

Receptor-bound toxin is internalized into an endosome. Acidification triggers a conformational change in the translocation (T) domain, which inserts into the endosomal membrane and chaperones the catalytic (C) domain across it into the cytosol. A single translocated catalytic domain is sufficient to kill a cell, and the estimated human lethal dose is on the order of 100 ng/kg.

receptor-mediated endocytosis GO:0006898 ↑ INCREASED

Downstream

eEF2 Diphthamide ADP-Ribosylation Delivery of the catalytic domain into the cytosol places it in contact with its substrate, eEF2.

Show evidence (2 references)

PMID:39841756 SUPPORT Other

"After invading the cell cytoplasm through endocytosis and translocation, DT inhibits protein synthesis and provokes cell death by apoptosis. DT is very potent towards humans, with an estimated lethal dose of 100 ng/kg."

Describes the endocytosis-then-translocation route this node represents and quantifies the resulting potency.

PMID:699044 SUPPORT In Vitro

"The results demonstrated that a single molecule of fragment A was sufficient to kill a cell."

Single-molecule experiment establishing that one translocated catalytic domain suffices to kill a cell, the claim made in this node's description.

eEF2 Diphthamide ADP-Ribosylation

The catalytic domain is a NAD+-dependent ADP-ribosyltransferase that transfers ADP-ribose onto diphthamide, a modified histidine unique to eukaryotic elongation factor 2. Diphthamide normally supports reading-frame fidelity; once ADP-ribosylated, eEF2 can no longer catalyse translocation of the peptidyl-tRNA-mRNA complex from the ribosomal A site to the P site. The reaction is catalytic rather than stoichiometric, which is why a single translocated catalytic domain is enough to kill the cell.

NAD+-diphthamide ADP-ribosyltransferase activity GO:0047286 ↑ INCREASED

Downstream

Translational Arrest and Host Cell Death Loss of eEF2 translocase activity halts the elongation phase of protein synthesis.

Show evidence (4 references)

PMID:23853096 SUPPORT In Vitro

"ADP-ribosylation (ADP(R)) of eEF2 by bacterial toxins on a unique diphthamide residue inhibits its translocation activity, but the mechanism is unclear."

States that ADP-ribosylation occurs on the diphthamide residue and inhibits eEF2 translocase activity, which is the reaction this node represents.

PMID:23853096 SUPPORT In Vitro

"Eukaryotic translation elongation factor 2 (eEF2) facilitates the movement of the peptidyl tRNA-mRNA complex from the A site of the ribosome to the P site during protein synthesis."

Defines the normal eEF2 translocase step that ADP-ribosylation abolishes.

PMID:38097404 SUPPORT Other

"Diphthamide, a complex modification on eukaryotic translation elongation factor 2 (eEF2), assures reading-frame fidelity during translation."

Establishes the identity and normal function of the diphthamide residue that diphtheria toxin targets.

+ 1 more reference

Translational Arrest and Host Cell Death

Elongation stalls, total protein synthesis falls, and the affected cell dies by apoptosis. This single lesion accounts for every toxin-attributable feature of the disease: epithelial necrosis under the membrane locally, and cardiomyocyte and Schwann cell injury at distant sites. Nothing about the mechanism is tissue-specific, so which organs are damaged is set by toxin delivery and by which cell types are least able to tolerate a translational block.

translational elongation GO:0006414 ↓ DECREASED negative regulation of translation GO:0017148 ↑ INCREASED apoptotic process GO:0006915 ↑ INCREASED

Animal models

Guinea pig diphtheria toxin intoxication and lethality model Guinea pig partially recapitulates Parenteral toxin challenge reproduces the systemic toxin-mediated illness and death that follow translational arrest in host tissues, and it is sensitive enough to grade antitoxin potency quantitatively.

Downstream

Pseudomembrane Formation Death of the colonized mucosal epithelium supplies the necrotic material that, with fibrin, inflammatory cells and bacteria, constitutes the pseudomembrane.

Systemic Toxin Dissemination Toxin not consumed locally is absorbed into the circulation and carried to distant organs.

Show evidence (2 references)

PMID:31804499 SUPPORT Human Clinical

"Systemic effects, such as myocarditis and neuropathy, which are associated with increased fatality risk, are due to diphtheria toxin, an exotoxin produced by the pathogen that inhibits protein synthesis and causes cell death."

States the protein-synthesis inhibition and cell death that define this node and links them to the fatal systemic manifestations.

PMID:39841756 SUPPORT Other

"After invading the cell cytoplasm through endocytosis and translocation, DT inhibits protein synthesis and provokes cell death by apoptosis."

Identifies apoptosis as the mode of toxin-induced cell death recorded on this node.

Pseudomembrane Formation

Necrotic epithelium, fibrin, leukocytes, erythrocytes and bacteria coalesce into a tough grey-white membrane that adheres to the underlying mucosa and bleeds if stripped. On the tonsils and pharynx it is the diagnostic sign of respiratory diphtheria, and it is found in roughly three quarters of clinically diagnosed cases in outbreak settings.

inflammatory response GO:0006954 ↑ INCREASED

pharynx UBERON:0006562 larynx UBERON:0001737

Downstream

Upper Airway Obstruction Extension of the membrane into the larynx and trachea narrows the airway lumen.

Show evidence (2 references)

DOI:10.3201/eid3008.231671 SUPPORT Human Clinical

"The classical clinical manifestation of diphtheria is a pseudomembrane in the upper respiratory airways (tonsils, pharynx, or larynx) that can cause possible fatal airway obstruction."

Names the membrane as the classical manifestation and gives its anatomical distribution.

PMID:36633113 SUPPORT Human Clinical

"Pseudomembrane was present in 245 (77%) cases."

Quantifies how frequently the membrane is found in a 318-child outbreak cohort.

Upper Airway Obstruction

Progressive narrowing of the larynx and trachea by membrane and oedema. It is the most immediately lethal local complication and, unlike the toxin-mediated injuries, it is mechanical: it is relieved by bypassing the obstruction rather than by neutralizing toxin. In outbreak cohorts it occurred in 22.6% of children and carried roughly thirteenfold higher odds of death.

larynx UBERON:0001737

Show evidence (2 references)

PMID:36633113 SUPPORT Human Clinical

"Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6% (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12), thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases."

Quantifies airway compromise in a 318-child outbreak cohort.

DOI:10.52225/narra.v4i2.776 SUPPORT Human Clinical

"Patients with airway obstruction were 13 times more likely to have an increase in mortality compared to patients without airway obstruction."

Quantifies the mortality attributable to this node.

Systemic Toxin Dissemination

Toxin absorbed from the membrane-covered mucosa enters the bloodstream and reaches the heart, peripheral nerves and kidney. The distinction between local spread and haematogenous dissemination is clinically load-bearing: early palatal weakness reflects direct local toxin action, whereas the generalized demyelinating neuropathy that follows weeks later reflects blood-borne delivery. Only free toxin is neutralizable, so antitoxin given after dissemination and cellular uptake cannot reverse established injury.

Downstream

Diphtheritic Myocarditis Circulating toxin is taken up by cardiomyocytes, where the same translational block produces myocyte necrosis.

Toxin-Mediated Schwann Cell Injury and Demyelination Blood-borne toxin reaches peripheral nerve, where it is taken up by Schwann cells.

Show evidence (2 references)

PMID:39324172 SUPPORT Human Clinical

"The severity of diphtheria is linked to the presence of diphtheria toxin, responsible for cardiac and neurological complications after its diffusion away from the infectious site."

States that cardiac and neurological complications follow diffusion of toxin away from the primary site, which is the claim this node makes.

PMID:26962337 SUPPORT Human Clinical

"The period between the appearance of first symptom of diphtheria and the development of DP is termed latency, which varies from 10 days to 3 months."

Documents the latency between local infection and distant neurological disease that dissemination-then-uptake predicts.

Diphtheritic Myocarditis

Toxin taken up by cardiomyocytes produces patchy myocyte necrosis with mononuclear infiltration, interstitial oedema and fibrosis, typically appearing about two weeks after the pharyngeal illness. Ultrastructurally the mitochondria are swollen with disorganized cristae and glycogen is depleted, consistent with a cell whose protein synthesis has been arrested. Cardiac involvement is the leading cause of death in diphtheria, and it is potentially reversible if the patient survives the acute phase.

cardiac muscle cell CL:0000746

inflammatory response GO:0006954 ↑ INCREASED apoptotic process GO:0006915 ↑ INCREASED

myocardium UBERON:0002349

Downstream

Cardiac Conduction System Injury The inflammatory and necrotic process extends into the specialized conduction tissue.

Show evidence (5 references)

PMID:36589640 SUPPORT Human Clinical

"Cardiac involvement, in the form of myocarditis, is the most serious manifestation of diphtheria and is the most common cause of mortality in these patients."

Establishes myocarditis as the dominant cause of death, the clinical weight this node carries.

PMID:36589640 SUPPORT Human Clinical

"The EMB showed patchy areas of myocyte necrosis with mononuclear cell infiltration accompanied by interstitial fibrosis and edema suggestive of acute myocarditis"

Endomyocardial biopsy describing the exact histological lesion this node represents.

PMID:36633113 SUPPORT Human Clinical

"Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6% (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12), thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases."

Quantifies cardiac involvement alongside the other toxin-mediated complications in a contemporary outbreak cohort.

+ 2 more references

Cardiac Conduction System Injury

Extension of the myocarditic process into the conduction system produces a spectrum of electrocardiographic abnormalities; about half of patients with diphtheritic myocarditis develop severe conduction disturbance, of which complete heart block is the most dangerous. Left bundle branch block and T-wave inversion have been reported to predict poor long-term survival.

heart UBERON:0000948

Show evidence (2 references)

PMID:36589640 SUPPORT Human Clinical

"Almost half of the patients with diphtheritic myocarditis develop severe conduction disturbances, the most serious being complete heart block."

Quantifies the frequency and names the most serious form of the conduction injury this node represents.

PMID:36589640 SUPPORT Human Clinical

"It was observed in a study that the presence of left bundle branch block pattern and T-wave inversions predicts poor long-term survival in these patients."

Source for the prognostic significance of specific conduction patterns recorded in this node's description.

Toxin-Mediated Schwann Cell Injury and Demyelination

Diphtheria toxin enters Schwann cells and blocks synthesis of myelin proteolipid protein and myelin basic protein, producing segmental demyelination without primary axonal loss. Because myelin maintenance depends on ongoing protein synthesis, the Schwann cell is among the cell types least able to tolerate a translational block. The clinical consequence is a descending neuropathy beginning with palatal and other bulbar weakness, later oculomotor and ciliary paralysis, and in severe cases limb weakness, with recovery in most survivors because axons are preserved.

myelinating Schwann cell CL:0000218

myelination GO:0042552 ↓ DECREASED

peripheral nervous system UBERON:0000010

Show evidence (3 references)

PMID:26962337 SUPPORT Human Clinical

"Diptheritic toxin penetrates into Schwann cells and it inhibits the synthesis of myelin proteolipid and basic protein."

States the Schwann cell target and the specific myelin proteins whose synthesis is blocked, which is the mechanism this node represents.

PMID:26962337 SUPPORT Human Clinical

"All the children presented with bulbar palsy and had h/o membranous tonsillitis. Isolated palatal palsy was seen in 7 children (53%). 6 (46.1%) children developed quadriparesis."

Case series documenting the bulbar-onset, descending distribution that follows from local then haematogenous toxin delivery to Schwann cells.

PMID:7477070 SUPPORT Human Clinical

"A 29-year-old Haitian man had a sore throat with a marked tonsillar exudate followed by the onset of increasingly blurred vision with swallowing difficulties and, then, a diffuse acute demyelinating neuropathy."

Documents the demyelinating character of the neuropathy and its temporal sequence after pharyngeal disease.

Absent or Waning Antitoxin Immunity

Toxoid-induced neutralizing antibody is the only established host protection. It does not prevent colonization, but it neutralizes toxin before it reaches its receptor, so unimmunized and partially immunized hosts develop the toxin-mediated syndrome that immunized hosts largely escape. Outbreak cohorts are dominated by unvaccinated young children, and in C. ulcerans disease vaccination status separates those who develop a classical pseudomembrane from those who do not.

adaptive immune response GO:0002250 ↓ DECREASED

Downstream

Diphtheria Toxin Binding to the proHB-EGF Receptor Without neutralizing antitoxin, secreted toxin survives in the extracellular space long enough to engage its receptor.

Show evidence (2 references)

PMID:36633113 SUPPORT Human Clinical

"Young children (median age 5 year) were predominantly affected, and only 8 (2.5%) children were fully immunized."

Shows that the outbreak burden fell almost entirely on incompletely immunized children, the susceptibility state this node represents.

PMID:39841756 SUPPORT Human Clinical

"none of 39 fully vaccinated cases presented with classic respiratory diphtheria with pseudomembrane, whereas 14 out of 43 unvaccinated or incompletely vaccinated cases presented with these symptoms (p < 0.001)."

Directly contrasts vaccinated and unvaccinated cases on the presence of the defining toxin-mediated lesion, supporting antitoxin immunity as the determining host factor.

Bacterial mRNA Translation by the Ribosome (Macrolide Target)

Corynebacterium diphtheriae depends on 70S-ribosome translation. Macrolides (azithromycin, erythromycin, clarithromycin) bind the 50S subunit and arrest bacterial protein synthesis. WHO's 2024 clinical management guideline places macrolides ahead of penicillin as first-line therapy. Because diphtheria toxin is itself a translated secreted product, this target has an anti-toxin rationale in addition to bacterial clearance, but antibiotics do not neutralize toxin already released, so they never substitute for antitoxin.

translation GO:0006412

Downstream

Iron-Regulated Diphtheria Toxin Expression Diphtheria toxin is itself a translated, secreted protein, so arresting bacterial protein synthesis suppresses further toxin output as well as killing the organism. This is the anti-toxin component of antibiotic therapy, and it is why antibiotics shorten the window during which new toxin is being made without doing anything about toxin already released.

Show evidence (2 references)

PMID:39841756 SUPPORT Human Clinical

"In February 2024, in the context of the 2023 West African diphtheria outbreak, WHO published a new guideline for the clinical management of diphtheria, where the first-line use of macrolide antibiotics (azithromycin, erythromycin) is recommended in preference to penicillin."

Identifies the macrolides, which act on this ribosomal target, as WHO first-line therapy for diphtheria.

PMID:39841756 SUPPORT Human Clinical

"Antimicrobial treatment reduces transmission, but to improve survival, patients with toxinic symptoms do need DAT."

Delimits what antibiotic therapy achieves, supporting the note on this node that ribosomal targeting does not substitute for antitoxin.

Bacterial Peptidoglycan Cross-Linking (Beta-Lactam Target)

Penicillins acylate the penicillin-binding protein transpeptidases and halt peptidoglycan cross-linking. Benzylpenicillin remains a standard alternative or partner agent, and in the only randomized comparison in diphtheria it cleared fever faster than erythromycin with equivalent membrane and bacteriological clearance. UK guidance combines intravenous benzylpenicillin with a macrolide for severe disease.

cell wall organization GO:0071555

Downstream

Iron-Regulated Diphtheria Toxin Expression Killing the organism removes the cells that are transcribing tox, so toxin output falls with the bacterial population. This is a different route to the same node than the macrolide edge takes: a ribosome inhibitor suppresses synthesis of the toxin protein in cells that are still alive, whereas a beta-lactam reduces output only by reducing the number of producers. The distinction is why protein-synthesis inhibitors are the preferred agents in toxin-mediated disease, and neither route touches toxin that has already been released.

Show evidence (2 references)

PMID:9798043 SUPPORT Human Clinical

"There were no differences in times to membrane clearance or bacteriologic clearance, but median times to fever clearance were 27 hours (95% confidence interval [CI], 19-30; range, 0-124 hours) for penicillin recipients and 46 hours (95% CI, 34-54; range, 0-148 hours) for erythromycin recipients..."

Randomized head-to-head trial establishing penicillin's clinical effect on this organism relative to a ribosome-targeting comparator.

PMID:9798043 SUPPORT Human Clinical

"All isolates were susceptible to penicillin, but for isolates (27%), all of which were from patients who received penicillin treatment, were resistant to erythromycin (minimum inhibitory concentrations, > 64 mg/L)."

Documents retained penicillin susceptibility alongside macrolide resistance, which is why this beta-lactam target remains clinically relevant.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

22

Blood 1

Thrombocytopenia OCCASIONAL HP:0001873

Show evidence (2 references)

PMID:36633113 SUPPORT Human Clinical

"Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6% (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12), thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases."

Direct frequency measurement of thrombocytopenia supporting the OCCASIONAL band.

DOI:10.52225/narra.v4i2.776 SUPPORT Human Clinical

"There was also a significant association between thrombocytopenia (p=0.020) and mortality in diphtheria patients."

Independent cohort linking thrombocytopenia to mortality.

Cardiovascular 4

Cervical Lymphadenopathy HP:0025289

Show evidence (1 reference)

PMID:39841756 SUPPORT Human Clinical

"Symptoms range from the classical pseudomembranous pharyngitis and cervical lymphadenopathy to skin inflammatory ulceration; they develop with toxigenic or non-toxigenic strains."

Names cervical lymphadenopathy as part of the classical respiratory presentation.

Myocarditis OCCASIONAL HP:0012819

Show evidence (2 references)

PMID:36589640 SUPPORT Human Clinical

"Cardiac involvement, in the form of myocarditis, is the most serious manifestation of diphtheria and is the most common cause of mortality in these patients."

Establishes myocarditis as the dominant fatal complication.

PMID:36633113 SUPPORT Human Clinical

"Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6% (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12), thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases."

Direct frequency measurement of cardiac involvement supporting the OCCASIONAL band.

Congestive Heart Failure HP:0001635

Show evidence (2 references)

PMID:36589640 SUPPORT Human Clinical

"At admission, he was in acute decompensated heart failure with elevated jugular venous pulse and pedal edema."

Documents acute decompensated heart failure as the presenting cardiac syndrome of diphtheritic myocarditis.

PMID:36589640 SUPPORT Human Clinical

"Myocardial involvement is the most serious manifestation of diphtheria which may present as acute heart failure with dysrhythmias."

States that myocardial involvement presents as acute heart failure, the phenotype recorded here.

Atrioventricular Block HP:0001678

Show evidence (1 reference)

PMID:36589640 SUPPORT Human Clinical

"Almost half of the patients with diphtheritic myocarditis develop severe conduction disturbances, the most serious being complete heart block."

Establishes the frequency and severity of conduction block among patients with diphtheritic myocarditis.

Digestive 1

Dysphagia HP:0002015

Show evidence (1 reference)

PMID:7477070 SUPPORT Human Clinical

"A 29-year-old Haitian man had a sore throat with a marked tonsillar exudate followed by the onset of increasingly blurred vision with swallowing difficulties and, then, a diffuse acute demyelinating neuropathy."

Documents swallowing difficulty as part of the bulbar phase of diphtheritic neuropathy.

Genitourinary 1

Acute Kidney Injury VERY_RARE HP:0001919

Show evidence (1 reference)

PMID:36633113 SUPPORT Human Clinical

"Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6% (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12), thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases."

Direct frequency measurement of acute kidney injury supporting the VERY_RARE band.

Head and Neck 1

Bull Neck (Anterior Cervical Swelling) Anterior neck swelling HP:6000176

Show evidence (2 references)

PMID:36633113 SUPPORT Human Clinical

"Mortality was high in unimmunized or partially immunized young children and those with bull neck, pseudomembrane, delayed (≥5 days) administration of ADS, acute kidney injury, thrombocytopenia and leukocytosis."

Identifies bull neck as a recorded clinical finding associated with mortality in this cohort.

PMID:39841756 SUPPORT Human Clinical

"A dose of 80,000 eDAT IU is recommended for any disease of more than 48 h duration, or diffuse swelling of the neck or severe disease (respiratory distress, shock)."

WHO dosing places diffuse neck swelling in the highest antitoxin tier, the claim made in this phenotype's description.

Integument 1

Skin Ulcer VERY_FREQUENT HP:0200042

The frequency band applies within cutaneous diphtheria, not across all diphtheria presentations.

Show evidence (1 reference)

PMID:39324172 SUPPORT Human Clinical

"Lesions involved the lower limbs (86.9%), corresponded to ulcerations in 82% of cases."

Direct frequency measurement of ulceration among cutaneous cases, supporting the VERY_FREQUENT band within this subtype.

Metabolism 1

Fever HP:0001945

Show evidence (2 references)

PMID:36589640 SUPPORT Human Clinical

"he accepted to have had an episode of fever that lasted for 4 days associated with throat pain and swelling 2 weeks before the onset of his heart failure symptoms"

Documents the febrile pharyngeal illness that opened this patient's course.

PMID:9798043 SUPPORT INDIRECT Human Clinical

"There were no differences in times to membrane clearance or bacteriologic clearance, but median times to fever clearance were 27 hours (95% confidence interval [CI], 19-30; range, 0-124 hours) for penicillin recipients and 46 hours (95% CI, 34-54; range, 0-148 hours) for erythromycin recipients..."

Fever clearance was a trial endpoint in 86 children with diphtheria, so fever was present at enrolment. Graded INDIRECT because the trial measures its resolution rather than reporting its frequency.

Nervous System 1

Peripheral Demyelination HP:0011096

Show evidence (2 references)

PMID:7477070 SUPPORT Human Clinical

"Diphtheritic neuropathy should be considered in the differential diagnosis of Guillain-Barré syndrome in nonvaccinated patients."

Frames diphtheritic neuropathy as a demyelinating differential of Guillain-Barre syndrome in unvaccinated patients.

PMID:26962337 SUPPORT Human Clinical

"Diptheritic toxin penetrates into Schwann cells and it inhibits the synthesis of myelin proteolipid and basic protein."

States the Schwann cell mechanism that produces this demyelinating phenotype.

Respiratory 4

Pharyngitis HP:0025439

Show evidence (1 reference)

PMID:39841756 SUPPORT Human Clinical

"Symptoms range from the classical pseudomembranous pharyngitis and cervical lymphadenopathy to skin inflammatory ulceration; they develop with toxigenic or non-toxigenic strains."

Names pseudomembranous pharyngitis as the classical presentation.

Stridor HP:0010307

Show evidence (1 reference)

PMID:39324172 SUPPORT INDIRECT Human Clinical

"Although the classical and most severe clinical presentation of diphtheria is respiratory and ear nose and throat (ENT) damages (pseudomembranous angina and laryngeal respiratory distress known as “croup”) which represent 10–30% of cases in literature, cutaneous infections are more common."

Names laryngeal respiratory distress ("croup") as the severe respiratory presentation of which stridor is the cardinal sign. Graded INDIRECT because the paper names the syndrome rather than the individual sign.

Upper Airway Obstruction OCCASIONAL HP:0002781

Show evidence (2 references)

PMID:36633113 SUPPORT Human Clinical

"Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6% (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12), thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases."

Direct frequency measurement of airway compromise supporting the OCCASIONAL band.

DOI:10.52225/narra.v4i2.776 SUPPORT Human Clinical

"Patients with airway obstruction were 13 times more likely to have an increase in mortality compared to patients without airway obstruction."

Quantifies the mortality associated with this phenotype.

Nasal Discharge Rhinorrhea HP:0031417

Show evidence (1 reference)

DOI:10.3201/eid3008.231671 SUPPORT INDIRECT Human Clinical

"The third patient (72 years of age) experienced a nasal mucosal form (superinfection of a chronic injury confirmed by mucus sampling)."

Documents a nasal mucosal presentation of C. diphtheriae infection. Graded INDIRECT because the case report establishes the nasal site and that mucus was sampled, rather than characterizing the discharge itself.

Voice 1

Hoarse Voice HP:0001609

Show evidence (1 reference)

DOI:10.3201/eid3008.231671 SUPPORT INDIRECT Human Clinical

"The classical clinical manifestation of diphtheria is a pseudomembrane in the upper respiratory airways (tonsils, pharynx, or larynx) that can cause possible fatal airway obstruction."

Establishes laryngeal involvement as part of the disease. Graded INDIRECT because hoarseness is inferred from laryngeal membrane rather than reported as such.

Other 6

Pharyngeal Pseudomembrane FREQUENT Abnormal pharynx morphology HP:0033151

HPO has no term for a diphtheritic pseudomembrane. HP:0033151 (Abnormal pharynx morphology) is the most specific accurate ancestor available; the specific lesion is carried by preferred_term.

Show evidence (1 reference)

PMID:36633113 SUPPORT Human Clinical

"Pseudomembrane was present in 245 (77%) cases."

Direct frequency measurement in a 318-child outbreak cohort, supporting the FREQUENT band.

Palatal Palsy Bulbar palsy HP:0001283

HPO has no term for palatal palsy specifically. HP:0001283 (Bulbar palsy) is the most specific accurate term available and is what the cited series reports; the narrower localization is carried by preferred_term. HP:0000220 (Velopharyngeal insufficiency) was considered and rejected: it names a speech-time functional deficit rather than a paralysis, and its manifestation is already recorded separately as Hypernasal speech.

Show evidence (1 reference)

PMID:26962337 SUPPORT Human Clinical

"All the children presented with bulbar palsy and had h/o membranous tonsillitis. Isolated palatal palsy was seen in 7 children (53%). 6 (46.1%) children developed quadriparesis."

Direct measurement of isolated palatal palsy frequency in a diphtheritic polyneuropathy cohort.

Nasal Regurgitation and Hypernasal Speech HP:0001611

Show evidence (1 reference)

PMID:36589640 SUPPORT Human Clinical

"While awaiting biopsy result in the ward, an astute resident doctor noticed that the patient had a nasal twang to his voice."

Documents the hypernasal voice quality in a patient whose diphtheria was recognized from it.

Impaired Visual Accommodation Reduced visual accommodation HP:0030801

Show evidence (1 reference)

PMID:26962337 SUPPORT Human Clinical

"Oculomotor nerve involvement in the form of accommodation paralysis was seen in 3 children."

Directly reports accommodation paralysis in the cohort.

Polyneuropathy HP:0001271

Show evidence (2 references)

PMID:26962337 SUPPORT Human Clinical

"DP is seen in 20% and 75% of patients with mild and severe infection, respectively."

Provides the severity-stratified frequency of diphtheritic polyneuropathy recorded in this description.

PMID:24365424 SUPPORT Human Clinical

"Diphtheritic polyneuropathy can be a serious complication in patients who have a severe infection."

Independent confirmation that polyneuropathy is a recognized serious complication of severe disease.

Tetraparesis HP:0002273

Show evidence (1 reference)

PMID:26962337 SUPPORT Human Clinical

"All the children presented with bulbar palsy and had h/o membranous tonsillitis. Isolated palatal palsy was seen in 7 children (53%). 6 (46.1%) children developed quadriparesis."

Direct measurement of quadriparesis frequency in the cohort.

💊

Medical Actions

5

Diphtheria Antitoxin

Action: immunoglobulin therapy Ontology label: Immunoglobulin Therapy NCIT:C62710

Equine hyperimmune serum containing polyclonal antibody against diphtheria toxin. It is the only treatment that addresses the toxin itself and it neutralizes only toxin that has not yet entered cells, so benefit falls sharply with delay; administration five or more days after onset is associated with higher mortality. Adverse reactions to horse protein are frequent, and global supply has been constrained for years, which is itself a recognized contributor to outbreak mortality.

Mechanism Target:

Diphtheria Toxin Binding to the proHB-EGF Receptor — Circulating antibody binds free toxin and prevents it engaging proHB-EGF, which is why antitoxin cannot help once toxin has been internalized.

Show evidence (1 reference)

PMID:39841756 SUPPORT Other

"The pathological effects caused by its main virulence factor, diphtheria toxin, can be diminished by passive transfer of antibodies."

States that passively transferred antibody diminishes the toxin's pathological effects, the neutralization step this link targets.

Show evidence (3 references)

PMID:39841756 SUPPORT Human Clinical

"Equine diphtheria antitoxin (eDAT), the cornerstone of treatment against toxinic complications of diphtheria, was invented more than 130 years ago, in 1890, and is still in use today."

Establishes equine antitoxin as the cornerstone treatment for the toxin-mediated complications.

PMID:39841756 SUPPORT Human Clinical

"But eDAT, being produced from horse serum, has frequent adverse effects, including anaphylactic reactions to horse proteins, fever and serum sickness."

Source for the adverse-effect burden recorded in this treatment description.

PMID:36633113 SUPPORT Human Clinical

"Mortality was high in unimmunized or partially immunized young children and those with bull neck, pseudomembrane, delayed (≥5 days) administration of ADS, acute kidney injury, thrombocytopenia and leukocytosis."

Supports the time-dependence of antitoxin benefit: delayed administration is associated with higher mortality.

Macrolide Antibiotic Therapy

Action: Pharmacotherapy NCIT:C15986

Agent: azithromycin CHEBI:2955 erythromycin CHEBI:48923 clarithromycin CHEBI:3732

Azithromycin, erythromycin or clarithromycin, recommended by WHO in 2024 as first-line antimicrobial therapy in preference to penicillin. Antibiotics eradicate the organism, stop further toxin production and end transmissibility, but they do not neutralize toxin already released and are never a substitute for antitoxin. Macrolide resistance is documented and susceptibility testing should guide therapy where available.

Mechanism Target:

Bacterial mRNA Translation by the Ribosome (Macrolide Target) — Macrolides bind the 50S ribosomal subunit and arrest bacterial protein synthesis, killing or suppressing the organism and cutting off further toxin production.

Show evidence (1 reference)

PMID:39841756 SUPPORT Human Clinical

"In February 2024, in the context of the 2023 West African diphtheria outbreak, WHO published a new guideline for the clinical management of diphtheria, where the first-line use of macrolide antibiotics (azithromycin, erythromycin) is recommended in preference to penicillin."

Identifies the macrolides that act on this ribosomal target as WHO first-line therapy.

Show evidence (2 references)

PMID:39841756 SUPPORT Human Clinical

"Antibiotics should be administered alongside eDAT, and should not be delayed. Penicillin (penicillin G intravenous or intramuscular; penicillin V oral) or macrolides (azithromycin, erythromycin) have been recommended as first line antimicrobial therapies."

Establishes macrolides as recommended first-line antimicrobial therapy given alongside antitoxin.

PMID:9798043 SUPPORT DIRECT Human Clinical

"All isolates were susceptible to penicillin, but for isolates (27%), all of which were from patients who received penicillin treatment, were resistant to erythromycin (minimum inhibitory concentrations, > 64 mg/L)."

Documents erythromycin resistance among clinical isolates, which is the caveat this treatment's description records: susceptibility testing should guide macrolide use where it is available. Graded DIRECT because the trial reports the resistance itself rather than something the caveat is inferred from.

Benzylpenicillin

Action: Pharmacotherapy NCIT:C15986

Agent: benzylpenicillin CHEBI:18208

Intravenous or intramuscular benzylpenicillin, used as an alternative to a macrolide and combined with one in severe disease under UK guidance. In the only randomized comparison in diphtheria, penicillin cleared fever significantly faster than erythromycin with no difference in membrane or bacteriological clearance, and all isolates in that trial remained penicillin-susceptible.

Mechanism Target:

Bacterial Peptidoglycan Cross-Linking (Beta-Lactam Target) — Benzylpenicillin acylates the penicillin-binding protein transpeptidase and halts peptidoglycan cross-linking.

Show evidence (1 reference)

PMID:9798043 SUPPORT INDIRECT Human Clinical

"All isolates were susceptible to penicillin, but for isolates (27%), all of which were from patients who received penicillin treatment, were resistant to erythromycin (minimum inhibitory concentrations, > 64 mg/L)."

Documents retained penicillin susceptibility of the isolates, establishing that this drug target is intact. Graded INDIRECT because susceptibility is reported rather than the transpeptidase mechanism, which is carried on the target node.

Show evidence (2 references)

PMID:9798043 SUPPORT Human Clinical

"Penicillin is recommended as first-line treatment for diphtheria in Vietnam."

Trial conclusion recommending penicillin as first-line therapy in that setting.

PMID:39841756 SUPPORT Human Clinical

"For severe disease, intravenous benzylpenicillin should be combined with a macrolide; in patients who are both extremely and systemically unwell, a third agent such as IV vancomycin or linezolid is considered until local susceptibility results are available."

Source for the combination use of benzylpenicillin with a macrolide in severe disease.

Diphtheria Toxoid Vaccination

Action: vaccination Ontology label: Vaccination NCIT:C15346

Agent: diphtheria and tetanus toxoids vaccine NCIT:C91718

Formaldehyde-inactivated diphtheria toxin, given in combination vaccines through childhood with life-course boosters. It induces neutralizing antitoxin and prevents toxin-mediated disease rather than colonization, and the antibody it raises also recognizes the toxin of C. ulcerans. It is the intervention that turned diphtheria from a leading cause of childhood death into a disease of immunization-programme failure.

Mechanism Target:

Absent or Waning Antitoxin Immunity — Toxoid immunization converts the susceptible, antitoxin-negative host state into a protected one by raising neutralizing antibody.

Show evidence (1 reference)

PMID:39841756 SUPPORT Human Clinical

"Diphtheria toxoid vaccination, which is prepared from detoxified DT of C. diphtheriae strain Park-Williams 8, raises antibodies that recognise DT from C. ulcerans."

States that toxoid vaccination raises anti-toxin antibody, the host state this treatment restores.

Show evidence (3 references)

PMID:31804499 SUPPORT Human Clinical

"Although effective vaccines are available, this disease has the potential to re-emerge in countries where the recommended vaccination programmes are not sustained, and increasing proportions of adults are becoming susceptible to diphtheria."

Establishes vaccine effectiveness and identifies programme failure and waning adult immunity as the conditions for re-emergence.

PMID:39841756 SUPPORT INDIRECT Human Clinical

"none of 39 fully vaccinated cases presented with classic respiratory diphtheria with pseudomembrane, whereas 14 out of 43 unvaccinated or incompletely vaccinated cases presented with these symptoms (p < 0.001)."

Comparative evidence that vaccination prevents the defining toxin-mediated lesion. Graded INDIRECT because the comparison is restricted to Corynebacterium ulcerans cases, so reading it as evidence about diphtheria toxoid generally takes an inference step. Separately from directness, it is an uncontrolled observational comparison, and the review reporting it states there is no randomised trial of vaccine efficacy for that species.

PMID:24365424 SUPPORT Human Clinical

"Vaccination against diphtheria and pertussis in children and booster vaccination in adults is recommended."

Supports the childhood-plus-booster schedule described here.

Tracheotomy

Action: tracheotomy Ontology label: Tracheotomy NCIT:C15341

Surgical airway control for laryngeal obstruction by membrane and oedema, required in 17.9% of children in a large outbreak cohort. It treats the mechanical consequence of the local lesion, not the toxin. Endotracheal intubation serves the same purpose where it is feasible, but it is a separate, non-surgical intervention and is not covered by this entry's NCIT binding or modality.

Mechanism Target:

Upper Airway Obstruction — Bypassing the obstructed larynx relieves the airway compromise caused by the membrane without affecting the underlying toxin-mediated process.

Show evidence (1 reference)

PMID:36633113 SUPPORT Human Clinical

"Tracheostomy was done in (n=57) (17.9%) children. Case fatality rate was 17.9%."

Quantifies how often surgical airway control was required in an outbreak cohort with 22.6% airway compromise.

Show evidence (1 reference)

PMID:36633113 SUPPORT Human Clinical

"Tracheostomy was done in (n=57) (17.9%) children. Case fatality rate was 17.9%."

Documents the use of surgical airway control in the management of this outbreak.

🌍

Environmental Factors

2

Person-to-person respiratory transmission of toxigenic Corynebacterium diphtheriae

Bound to ECTO:3000000 exposure to organism, the most specific applicable ECTO term: ECTO has no Corynebacterium class and no class for a bacterial pathogen acquired by respiratory droplet, so the organism and the route are carried by preferred_term. Same general-but-accurate-ancestor pattern as the Brucellosis livestock exposure and as the HP:0033151 binding on the pseudomembrane phenotype in this entry.

Classical diphtheria is a human-to-human respiratory infection: humans are the only reservoir of C. diphtheriae, and it spreads by respiratory secretions and by contact with skin lesions. Crowding, displacement and collapsed immunization programmes are the conditions under which it propagates, which is why outbreaks track conflict and humanitarian crisis rather than any change in the organism.

Show evidence (2 references)

DOI:10.4314/ajcem.v24i2.2 SUPPORT Human Clinical

"Humans are the only hosts of the organism and is present in the upper respiratory tract."

Establishes humans as the sole reservoir of C. diphtheriae, which is what makes person-to-person spread the transmission route for classical diphtheria.

DOI:10.4314/ajcem.v24i2.2 SUPPORT Human Clinical

"The predisposing factor for this disease is the failure to immunize"

Identifies failure of immunization as the predisposing condition under which this exposure produces disease.

Mechanism Target:

TRIGGERS Mucosal Colonization and Adherence — Acquisition of the organism from another person is the route by which the pharyngeal or cutaneous surface becomes colonized, the first step of the pathograph.

Show evidence (1 reference)

PMID:39841756 SUPPORT Human Clinical

"However, the exclusively zoonotic transmission of C. ulcerans, which is typically transmitted to humans through domestic dogs and cats, implies its exclusion as an agent of classical diphtheria, defined as the toxigenic C. diphtheriae respiratory infection transmitted among humans."

Defines classical diphtheria as a respiratory infection transmitted between humans, the exposure route this link encodes.

Contact with companion or farm animals carrying toxigenic Corynebacterium ulcerans

Bound to ECTO:3000000 for the same reason as the respiratory exposure above: ECTO has no Corynebacterium class and no animal-contact class for a bacterial pathogen, so the organism and the route stay in preferred_term.

C. ulcerans is acquired from animals rather than from other people; dogs, cats and farm livestock are the documented reservoirs. This is the route by which diphtheria still reaches well-vaccinated populations, and it is why C. ulcerans is now the species most often reported in high-income countries.

Show evidence (1 reference)

PMID:39841756 SUPPORT Human Clinical

"However, the exclusively zoonotic transmission of C. ulcerans, which is typically transmitted to humans through domestic dogs and cats, implies its exclusion as an agent of classical diphtheria, defined as the toxigenic C. diphtheriae respiratory infection transmitted among humans."

States the zoonotic route and names dogs and cats as the usual sources.

Mechanism Target:

TRIGGERS Mucosal Colonization and Adherence — Animal contact delivers toxigenic C. ulcerans to the human respiratory or cutaneous surface, where it colonizes and, if toxigenic, initiates the same toxin cascade.

Show evidence (1 reference)

PMID:37957801 SUPPORT Human Clinical

"We successfully identified companion canines as probable sources for the human case, with WGS confirming the link."

Genomically confirmed animal-to-human acquisition, the exposure route this link encodes.

🔬

Biochemical Markers

2

Serum diphtheria antitoxin titre (PRESENT)

Context: Population serosurveillance and individual susceptibility assessment

Reference Ranges

– IU/mL (General population, toxin neutralization test)

Susceptible (–0.01 IU/mL) Above the lower reference cut-off (0.01– IU/mL)

Susceptible: Titres below 0.01 IU/mL identify the susceptible fraction of a population.

Above the lower reference cut-off: At or above the lower TNT cut-off. The source names 0.1 IU/mL as a second reference cut-off without defining a category for it, so no finer band is asserted.

The source establishes 0.01 and 0.1 IU/mL as the two reference cut-offs used in TNT and identifies titres below 0.01 IU/mL as the susceptible fraction. It does not label the 0.01-0.1 IU/mL interval, so no protective category is asserted for it here.

Show evidence (1 reference)

DOI:10.1099/jmm.0.001721 SUPPORT Human Clinical

"The cut-off values for ELISA measurement corresponding to the TNT cut-off values of 0.01 IU ml−1 were 0.060 IU ml−1 in serum samples, and 0.044 IU ml−1 in DBS samples."

Establishes 0.01 IU/mL as a TNT reference cut-off and gives the ELISA values that correspond to it.

Show evidence (2 references)

DOI:10.1099/jmm.0.001721 SUPPORT Human Clinical

"The correlation between the ELISA results against diphtheria toxoid and the gold standard diphtheria toxin neutralization test (TNT) values is poor when ELISA values are <0.1 IU ml−1, which results in inaccurate estimates of susceptibility in populations when ELISA is used for measuring antibody levels."

Identifies TNT as the reference method and states the ELISA limitation recorded in this marker's notes.

DOI:10.1099/jmm.0.001721 SUPPORT Human Clinical

"DBS is an effective low-cost alternative to serum for future serological studies for diphtheria."

Source for the dried-blood-spot recommendation recorded here.

Brain natriuretic peptide and creatine kinase MB (INCREASED)

Context: Cardiac involvement in respiratory diphtheria

Show evidence (2 references)

PMID:36589640 SUPPORT Human Clinical

"The brain-type natriuretic peptide level at presentation was 1200 pg/mL, and the creatine kinase myocardial band was 35 U/L, both of which were elevated."

Reports both cardiac markers as elevated at presentation in diphtheritic myocarditis.

PMID:36589640 SUPPORT Human Clinical

"EMB or cardiac MRI is not necessary for its diagnosis."

Supports treating cardiac imaging and biopsy as monitoring rather than diagnostic steps, as recorded in this marker's notes.

🔬

Diagnosis

1

Culture and toxigenicity testing

Diagnosis is clinical and is confirmed by isolating a member of the C. diphtheriae species complex and then demonstrating toxin production. Species identification alone is insufficient, because tox-bearing isolates may still fail to express toxin: in the French Guiana series five isolates were tox-positive by PCR yet all were negative by Elek test. Phenotypic toxigenicity testing therefore governs whether antitoxin is indicated.

Show evidence (3 references)

DOI:10.3390/pathogens11111264 SUPPORT Other

"However, ‘nontoxigenic tox gene-bearing’ (NTTB) strains, which are genotypically tox-positive but do not express the protein, have been described."

Names the NTTB phenomenon that makes phenotypic toxigenicity testing, rather than tox PCR alone, the step that governs treatment.

PMID:31804499 SUPPORT Human Clinical

"Clinical diagnosis is confirmed by the isolation and identification of the causative Corynebacterium spp., usually by bacterial culture followed by enzymatic and toxin detection tests."

Describes the culture-then-toxin-detection sequence this diagnostic entry represents.

DOI:10.3201/eid3008.231671 SUPPORT Human Clinical

"5 tested positive for the diphtheria toxin gene, and all results were negative by Elek test"

Demonstrates the gap between tox gene carriage and toxin expression that makes phenotypic testing necessary.

📈

Progression

4

Bulbar phase

Duration: First 2 weeks after the onset of oropharyngeal disease

Palatal and posterior pharyngeal weakness is the first neurological manifestation and reflects local toxin action on adjacent nerves rather than haematogenous spread.

Show evidence (1 reference)

PMID:26962337 SUPPORT Human Clinical

"Bulbar dysfunction typically develops during the first 2 weeks."

Directly dates the bulbar phase recorded here.

Oculomotor and ciliary phase

Duration: After about 3 weeks

Accommodation paralysis and other oculomotor findings appear later than the bulbar signs and are regarded as distinctive for diphtheritic neuropathy.

Show evidence (1 reference)

PMID:26962337 SUPPORT Human Clinical

"Oculomotor and ciliary paralyses seen after 3 weeks are common and distinctive features of DP."

Dates the oculomotor phase and identifies it as characteristic.

Generalized peripheral neuritis

Duration: 10 days to 3 months after the onset of oropharyngeal disease

The descending symmetric polyneuropathy that follows haematogenous toxin dissemination. Its long and variable latency is why patients need neurological follow-up for months after the acute illness resolves.

Show evidence (1 reference)

PMID:26962337 SUPPORT Human Clinical

"Peripheral neuritis develops later, from 10 days to 3 months after the onset of oropharyngeal disease."

Source for the latency window recorded on this phase.

Neurological recovery

Duration: 2 to 6 weeks from the onset of neurological symptoms

Recovery is usually complete because the lesion is demyelinating and axons are preserved; children with isolated bulbar palsy recover faster than those who progress to quadriparesis.

Show evidence (1 reference)

PMID:26962337 SUPPORT Human Clinical

"Children with isolated bulbar palsy recovered within 2 to 4 weeks while children with quadriparesis recovered within 5-6 wks."

Source for the recovery intervals and their dependence on severity.

📊

Prevalence

3

Worldwide

Cases In Literature Unknown

Global burden is reported as annual case counts from endemic countries rather than as a population rate; thousands of cases are still notified each year, concentrated in Asia and Africa.

Show evidence (1 reference)

PMID:31804499 SUPPORT Human Clinical

"Thousands of diphtheria cases are still reported annually from several countries in Asia and Africa, along with many outbreaks."

Source for the continuing global case burden recorded in this entry.

West and Southern Africa (2023-2024 outbreak)

Cases In Literature Unknown

Suspected-case and death counts aggregated across five reporting countries, with Nigeria accounting for most of them. Recorded as a case count rather than a rate because the source reports suspected cases across five national denominators it does not give, so no rate per 100,000 is derivable from it.

Show evidence (1 reference)

DOI:10.1186/s12982-024-00352-1 SUPPORT DIRECT Human Clinical

"As of January 14, 2024, Nigeria, Guinea, Niger, Mauritania, and South Africa have reported a total of 27,991 suspected cases of diphtheria, with 828 deaths."

Source for the outbreak case and death counts recorded here.

Yemen (2017-2020 outbreak)

Cases In Literature Unknown

Outbreak case and death counts illustrating the scale reachable where routine immunization collapses.

Show evidence (1 reference)

PMID:35544196 SUPPORT Human Clinical

"The Yemen diphtheria outbreak affected almost all governorates (provinces), with 5701 probable cases and 330 deaths recorded up to April 26, 2020."

Source for the outbreak case count and mortality recorded here.

🦠

Infectious Agent

2

Corynebacterium diphtheriae

A gram-positive, non-spore-forming, club-shaped bacillus transmitted between humans by respiratory droplets and by contact with skin lesions. Only isolates lysogenized by a tox-bearing corynebacteriophage produce diphtheria toxin; non-toxigenic strains still colonize and can cause invasive disease such as endocarditis but do not produce the toxin-mediated syndrome.

Corynebacterium diphtheriae NCBITaxon:1717

Show evidence (1 reference)

PMID:31804499 SUPPORT Human Clinical

"Diphtheria is a potentially fatal infection mostly caused by toxigenic Corynebacterium diphtheriae strains and occasionally by toxigenic C. ulcerans and C. pseudotuberculosis strains."

Identifies toxigenic C. diphtheriae as the principal causative organism.

Corynebacterium ulcerans

A zoonotic member of the C. diphtheriae species complex acquired from companion and farm animals rather than from other humans. Toxigenic isolates produce a diphtheria toxin that is neutralized by the same equine antitoxin and recognized by toxoid-induced antibody, and they cause a clinically similar respiratory or cutaneous illness. It is now the species most often reported in human diphtheria in high-income countries.

Corynebacterium ulcerans NCBITaxon:65058

Show evidence (3 references)

PMID:37957801 SUPPORT Human Clinical

"Diphtheria caused by toxin-producing Corynebacterium ulcerans is a re-emerging human disease that can cause local and systemic sequelae."

Establishes toxigenic C. ulcerans as a cause of human diphtheria with both local and systemic manifestations.

PMID:37957801 SUPPORT Human Clinical

"We successfully identified companion canines as probable sources for the human case, with WGS confirming the link."

Whole-genome-sequencing-confirmed animal-to-human transmission, supporting the zoonotic route that distinguishes C. ulcerans from C. diphtheriae.

PMID:39841756 SUPPORT Human Clinical

"Among these species, C. ulcerans is the most frequently reported in human infections in high-income countries."

Supports the statement that C. ulcerans now dominates reported human cases in high-income settings.

⚖️

Clinical Burden

High

Untreated toxin-mediated diphtheria kills. Contemporary outbreak cohorts report case fatality of 17.9% in a 318-child Indian series and 330 deaths among 5701 probable cases in Yemen, with cardiac involvement the leading cause of death and airway obstruction carrying roughly thirteenfold higher odds of dying. Survivors of severe disease face weeks of bulbar and limb weakness before recovery. The burden is almost entirely preventable by toxoid vaccination, which is what makes it a burden of programme failure rather than of the organism.

Show evidence (2 references)

PMID:36633113 SUPPORT Human Clinical

"Tracheostomy was done in (n=57) (17.9%) children. Case fatality rate was 17.9%."

Contemporary paediatric outbreak case fatality supporting the HIGH burden level.

PMID:35544196 SUPPORT Human Clinical

"The Yemen diphtheria outbreak affected almost all governorates (provinces), with 5701 probable cases and 330 deaths recorded up to April 26, 2020."

Independent outbreak mortality figures corroborating the burden assessment.

🔬

Clinical Trials

1

NCT04075175 PHASE_I COMPLETED

First-in-human, randomized, triple-masked, dose-escalating study of S315, a fully human monoclonal antibody against diphtheria toxin, in 41 healthy adults. It evaluates safety and pharmacokinetics only, not efficacy in patients, but it is the lead candidate to replace the equine antitoxin whose supply and adverse-effect profile currently limit diphtheria care.

Show evidence (1 reference)

clinicaltrials:NCT04075175 SUPPORT Human Clinical

"S315 is a monoclonal antibody that is being developed for treatment of diphtheria."

Registry record establishing S315 as a monoclonal antitoxin in clinical development for diphtheria.

🐁

Animal Models

1

Guinea pig diphtheria toxin intoxication and lethality model Toxin challenge model

Subcutaneous challenge with a calibrated dose of purified diphtheria toxin in Hartley guinea pigs, monitored for 30 days for dehydration, hind-limb weakness, lethargy and death. It is the accepted in vivo system for diphtheria intoxication and the standardized assay by which antitoxin potency is measured in international units. Guinea pigs are used because mice and rats are naturally resistant, a difference that traces to the toxin receptor itself.

Species

Guinea pig

Publication

PMID:23940209

Pathograph links

Translational Arrest and Host Cell Death partially recapitulates fidelity: moderate Parenteral toxin challenge reproduces the systemic toxin-mediated illness and death that follow translational arrest in host tissues, and it is sensitive enough to grade antitoxin potency quantitatively.

Limitations: This is an intoxication model, not an infection model. Toxin is injected rather than elaborated by an adherent organism, so it bypasses mucosal colonization, pseudomembrane formation and the local-versus-haematogenous distinction that governs the clinical sequence in humans. It therefore speaks to what the toxin does, not to how much toxin a colonized patient actually absorbs.

Readouts

30-day survival after calibrated toxin challenge

Survival and symptom-free status at day 30 after subcutaneous challenge, with and without neutralizing antibody.

Direction: RESTORED

Interpretation: Complete protection by a neutralizing antibody establishes that lethality in this model is attributable to the toxin acting on this node.

Show evidence (1 reference)

PMID:23940209 SUPPORT Model Organism

"In addition, 25 μg of 315C4 completely protected guinea pigs from intoxication in an in vivo lethality model, yielding an estimated relative potency of 64 IU/mg."

Reports the survival readout and its quantification in potency units.

Symptoms of diphtheria intoxication

Dehydration, hind-limb weakness and lethargy scored over 30 days of observation.

Direction: INCREASED

Interpretation: Hind-limb weakness in the challenged animal is the model counterpart of the toxin-mediated neuropathy seen in patients.

Show evidence (1 reference)

PMID:23940209 SUPPORT Model Organism

"Animals were closely monitored over 30 days for symptoms of diphtheria intoxication which includes symptoms such as dehydration, hind-limb weakness, and lethargy."

Names the clinical signs scored as the symptomatic readout in this model.

Show evidence (1 reference)

PMID:23940209 SUPPORT Model Organism

"A guinea pig lethality model has been well established and standardized for the measurement of DAT potency of neutralizing diphtheria toxin and subsequently preventing mortality"

Establishes this model as the standardized in vivo system for measuring toxin neutralization, which is what makes it informative for the translational-arrest and cell-death node.

Diphtheria Toxin Binding to the proHB-EGF Receptor measures fidelity: high Because protection in this model tracks the ability of an antibody to keep toxin off its receptor, the assay is a functional readout of the receptor-binding step. The lead human monoclonal was shown to act precisely there, blocking toxin binding to HB-EGF.

Limitations: The model reports the net consequence of blocking receptor engagement rather than measuring binding directly; the receptor-blockade mechanism was established in a separate in vitro assay.

Readouts

Blockade of toxin binding to HB-EGF

Antibody-mediated inhibition of diphtheria toxin binding to recombinant human HB-EGF, mapped to the toxin receptor-binding domain.

Direction: ABOLISHED

Interpretation: Confirms that neutralization acts at the receptor-binding step modelled by this node.

Show evidence (1 reference)

PMID:23940209 SUPPORT In Vitro

"We further established that our lead candidate hMAb binds to the receptor-binding domain of diphtheria toxin and physically blocks the toxin from binding to the putative receptor, heparin-binding epidermal growth factor-like growth factor."

Demonstrates that the neutralizing antibody acts by blocking the toxin-receptor interaction this node represents.

Show evidence (1 reference)

PMID:23940209 SUPPORT Model Organism

"In addition, 25 μg of 315C4 completely protected guinea pigs from intoxication in an in vivo lethality model, yielding an estimated relative potency of 64 IU/mg."

In-animal protection by an antibody whose only established action is blocking toxin binding to HB-EGF is what makes this model informative for the receptor-binding node.

Show evidence (1 reference)

PMID:23940209 SUPPORT Model Organism

"The guinea pig is the accepted model system for the study of diphtheria intoxication due to its sensitivity to the toxin compared to the highly resistant mouse and rat."

Establishes the guinea pig as the accepted in vivo model and names the rodent resistance that excludes mice and rats.

{ }

Source YAML

click to show

name: Diphtheria
creation_date: '2026-08-28T00:00:00Z'
description: >-
  Diphtheria is an acute, toxin-mediated infection of the upper respiratory mucosa or
  the skin caused by toxigenic strains of Corynebacterium diphtheriae and, less often,
  by toxigenic C. ulcerans. Toxigenicity is conferred by a lysogenic corynebacteriophage
  carrying the tox gene, whose transcription is derepressed when the iron-dependent
  repressor DtxR loses its ferrous cofactor. The secreted exotoxin binds the
  membrane-anchored heparin-binding EGF-like growth factor precursor (proHB-EGF), is
  taken up by receptor-mediated endocytosis, and delivers its catalytic domain to the
  cytosol, where it ADP-ribosylates the diphthamide residue of eukaryotic elongation
  factor 2. Translational arrest and host cell death produce the adherent grey-white
  pseudomembrane at the site of colonization and, after toxin dissemination, myocarditis
  with conduction disturbance and a descending demyelinating polyneuropathy at distant
  sites. Antitoxin neutralizes only toxin that has not yet entered cells, which is why
  the outcome depends on how early it is given.
category: Infectious Disease
disease_term:
  preferred_term: diphtheria
  term:
    id: MONDO:0005504
    label: diphtheria
parents:
- Bacterial Infection
- Bacterial Respiratory Infection
references:
- reference: PMID:31804499
  title: "Diphtheria."
- reference: PMID:39841756
  title: "Diphtheria antitoxin treatment: from pioneer to neglected."
classifications:
  harrisons_chapter:
  - classification_value: INFECTIOUS_DISEASES
    evidence:
    - reference: PMID:31804499
      reference_title: "Diphtheria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Diphtheria is a potentially fatal infection mostly caused by toxigenic
        Corynebacterium diphtheriae strains and occasionally by toxigenic C. ulcerans
        and C. pseudotuberculosis strains.
      explanation: >-
        Diphtheria is a bacterial infection of humans, placing it in Harrison's
        Infectious Diseases Part.
has_subtypes:
- name: Faucial
  display_name: Faucial (pharyngeal and tonsillar) diphtheria
  description: >-
    The classical and most common respiratory presentation, in which the pseudomembrane
    forms over the tonsils and posterior pharynx. It carries the greatest risk of
    systemic toxin absorption and therefore of myocarditis and neuropathy, and extensive
    cervical oedema produces the characteristic "bull neck".
  subtype_term:
    preferred_term: faucial diphtheria
    term:
      id: MONDO:0020860
      label: faucial diphtheria
  evidence:
  - reference: PMID:31804499
    reference_title: "Diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diphtheria is generally an acute respiratory infection, characterized by the
      formation of a pseudomembrane in the throat, but cutaneous infections are
      possible.
    explanation: >-
      Establishes pharyngeal pseudomembrane formation as the classical respiratory
      presentation this subtype names.
- name: Laryngeal
  display_name: Laryngeal diphtheria
  description: >-
    Extension of the membrane into the larynx and trachea, historically called
    "membranous croup". Hoarseness and stridor progress to airway obstruction, and this
    is the presentation for which tracheotomy or intubation is life-saving.
  subtype_term:
    preferred_term: laryngeal diphtheria
    term:
      id: MONDO:0020863
      label: laryngeal diphtheria
  evidence:
  - reference: DOI:10.3201/eid3008.231671
    reference_title: "Retrospective Study of Infections with Corynebacterium diphtheriae Species Complex, French Guiana, 2016-2021"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The classical clinical manifestation of diphtheria is a pseudomembrane in the
      upper respiratory airways (tonsils, pharynx, or larynx) that can cause possible
      fatal airway obstruction.
    explanation: >-
      Names the larynx as a site of pseudomembrane formation and links laryngeal
      involvement to fatal airway obstruction, the defining hazard of this subtype.
- name: Anterior nasal
  display_name: Anterior nasal diphtheria
  description: >-
    A mild, often chronic form limited to the anterior nares, presenting with
    serosanguineous or mucopurulent nasal discharge and excoriation of the upper lip. It is
    classically described as the mildest respiratory presentation, with systemic
    toxin-mediated complications uncommon relative to faucial disease, while affected
    individuals remain infectious.
  subtype_term:
    preferred_term: anterior nasal diphtheria
    term:
      id: MONDO:0020838
      label: anterior nasal diphtheria
  evidence:
  - reference: PMID:31804499
    reference_title: "Diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      Diphtheria is generally an acute respiratory infection, characterized by the
      formation of a pseudomembrane in the throat, but cutaneous infections are
      possible.
    explanation: >-
      Supports the respiratory grouping this subtype belongs to. Graded INDIRECT because
      the review states the respiratory presentation generally rather than the anterior
      nasal localization specifically.
- name: Nasopharyngeal
  display_name: Nasopharyngeal diphtheria
  description: >-
    Involvement of the nasopharynx, often contiguous with faucial disease. It is
    recognized separately in treatment guidelines because posterior extension is
    associated with a larger toxin burden, and WHO dosing schedules assign it a higher
    antitoxin dose than pharyngeal or cutaneous disease of comparable duration.
  subtype_term:
    preferred_term: nasopharyngeal diphtheria
    term:
      id: MONDO:0020866
      label: nasopharyngeal diphtheria
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For example, in WHO current guidelines, cutaneous or pharyngeal/laryngeal cases of
      two days duration require 20,000 eDAT IU; nasopharyngeal diseases less than 48 h
      duration require 40,000 IU.
    explanation: >-
      WHO guidance treats nasopharyngeal disease as a distinct anatomical presentation
      with its own antitoxin dose, which is the basis for modelling it as a subtype.
- name: Cutaneous
  display_name: Cutaneous diphtheria
  description: >-
    Infection of skin, typically a chronic non-healing ulcer with a rolled or
    "punched-out" edge and a dirty grey membrane, most often on the lower limbs and
    usually polymicrobial with Staphylococcus aureus or Streptococcus pyogenes. It is now
    the presentation most frequently reported in high-income countries, is an important
    reservoir for transmission, and can still produce toxin-mediated systemic disease when
    the isolate is toxigenic.
  subtype_term:
    preferred_term: cutaneous diphtheria
    term:
      id: MONDO:0001479
      label: cutaneous diphtheria
  evidence:
  - reference: PMID:39324172
    reference_title: "Cutaneous diphtheria from 2018 to 2022: an observational, retrospective study of epidemiological, microbiological, clinical, and therapeutic characteristics in metropolitan France."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lesions involved the lower limbs (86.9%), corresponded to ulcerations in 82% of
      cases.
    explanation: >-
      Characterizes the cutaneous form as lower-limb ulceration in a contemporary
      63-patient metropolitan French series.
  - reference: PMID:39324172
    reference_title: "Cutaneous diphtheria from 2018 to 2022: an observational, retrospective study of epidemiological, microbiological, clinical, and therapeutic characteristics in metropolitan France."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      They represent 57-86% of cases in literature and play an important role in the
      epidemiology of the disease
    explanation: >-
      Establishes that cutaneous infections outnumber respiratory ones in the reported
      literature and contribute materially to transmission.
infectious_agent:
- name: Corynebacterium diphtheriae
  infectious_agent_term:
    preferred_term: Corynebacterium diphtheriae
    term:
      id: NCBITaxon:1717
      label: Corynebacterium diphtheriae
  description: >-
    A gram-positive, non-spore-forming, club-shaped bacillus transmitted between humans
    by respiratory droplets and by contact with skin lesions. Only isolates lysogenized
    by a tox-bearing corynebacteriophage produce diphtheria toxin; non-toxigenic strains
    still colonize and can cause invasive disease such as endocarditis but do not produce
    the toxin-mediated syndrome.
  evidence:
  - reference: PMID:31804499
    reference_title: "Diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diphtheria is a potentially fatal infection mostly caused by toxigenic
      Corynebacterium diphtheriae strains and occasionally by toxigenic C. ulcerans
      and C. pseudotuberculosis strains.
    explanation: >-
      Identifies toxigenic C. diphtheriae as the principal causative organism.
- name: Corynebacterium ulcerans
  infectious_agent_term:
    preferred_term: Corynebacterium ulcerans
    term:
      id: NCBITaxon:65058
      label: Corynebacterium ulcerans
  description: >-
    A zoonotic member of the C. diphtheriae species complex acquired from companion and
    farm animals rather than from other humans. Toxigenic isolates produce a diphtheria
    toxin that is neutralized by the same equine antitoxin and recognized by toxoid-induced
    antibody, and they cause a clinically similar respiratory or cutaneous illness. It is
    now the species most often reported in human diphtheria in high-income countries.
  evidence:
  - reference: PMID:37957801
    reference_title: "Zoonotic transmission of diphtheria toxin-producing Corynebacterium ulcerans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diphtheria caused by toxin-producing Corynebacterium ulcerans is a re-emerging
      human disease that can cause local and systemic sequelae.
    explanation: >-
      Establishes toxigenic C. ulcerans as a cause of human diphtheria with both local
      and systemic manifestations.
  - reference: PMID:37957801
    reference_title: "Zoonotic transmission of diphtheria toxin-producing Corynebacterium ulcerans."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We successfully identified companion canines as probable sources for the human
      case, with WGS confirming the link.
    explanation: >-
      Whole-genome-sequencing-confirmed animal-to-human transmission, supporting the
      zoonotic route that distinguishes C. ulcerans from C. diphtheriae.
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among these species, C. ulcerans is the most frequently reported in human
      infections in high-income countries.
    explanation: >-
      Supports the statement that C. ulcerans now dominates reported human cases in
      high-income settings.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: UNKNOWN
  notes: >-
    Global burden is reported as annual case counts from endemic countries rather than as
    a population rate; thousands of cases are still notified each year, concentrated in
    Asia and Africa.
  evidence:
  - reference: PMID:31804499
    reference_title: "Diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Thousands of diphtheria cases are still reported annually from several countries
      in Asia and Africa, along with many outbreaks.
    explanation: >-
      Source for the continuing global case burden recorded in this entry.
- population: West and Southern Africa (2023-2024 outbreak)
  measure_type: CASES_IN_LITERATURE
  prevalence_class: UNKNOWN
  notes: >-
    Suspected-case and death counts aggregated across five reporting countries, with
    Nigeria accounting for most of them. Recorded as a case count rather than a rate
    because the source reports suspected cases across five national denominators it does
    not give, so no rate per 100,000 is derivable from it.
  evidence:
  - reference: DOI:10.1186/s12982-024-00352-1
    reference_title: "Global strategies for addressing diphtheria resurgence epidemiology clinical impact and prevention"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      As of January 14, 2024, Nigeria, Guinea, Niger, Mauritania, and South Africa have
      reported a total of 27,991 suspected cases of diphtheria, with 828 deaths.
    explanation: >-
      Source for the outbreak case and death counts recorded here.
- population: Yemen (2017-2020 outbreak)
  measure_type: CASES_IN_LITERATURE
  prevalence_class: UNKNOWN
  notes: >-
    Outbreak case and death counts illustrating the scale reachable where routine
    immunization collapses.
  evidence:
  - reference: PMID:35544196
    reference_title: "Ongoing diphtheria outbreak in Yemen: a cross-sectional and genomic epidemiology study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Yemen diphtheria outbreak affected almost all governorates (provinces), with
      5701 probable cases and 330 deaths recorded up to April 26, 2020.
    explanation: >-
      Source for the outbreak case count and mortality recorded here.
pathophysiology:
- name: Lysogenic Conversion by a tox-Bearing Corynebacteriophage
  description: >-
    The structural gene for diphtheria toxin is not chromosomal in origin. It is carried
    by a beta-corynephage that integrates into the bacterial genome, so that toxigenic
    and non-toxigenic strains of the same species coexist and a non-toxigenic isolate can
    be converted by phage infection. This was the first virulence factor shown to be
    phage-encoded, and it is why toxigenicity, not species identity, determines whether a
    patient develops toxin-mediated disease.
  biological_scale: MOLECULAR
  role: susceptibility_factor
  downstream:
  - target: Iron-Regulated Diphtheria Toxin Expression
    description: >-
      Lysogeny supplies the tox structural gene that the host iron-responsive regulatory
      circuit then controls.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Toxigenic isolates generally carry the tox gene, which codes for the diphtheria
        toxin precursor, on a prophage, discovered back in the early 1950s, the first
        example of a phage-encoded virulence factor.
      explanation: >-
        States that the prophage carries the tox gene encoding the toxin precursor, the
        transition this edge encodes.
  evidence:
  - reference: PMID:31294205
    reference_title: "Adhesion properties of toxigenic corynebacteria."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Since the ability to produce the diphtheria toxin is a result of β-corynephages
      infection, for each species toxigenic as well as non-toxigenic strains exist.
    explanation: >-
      Establishes that toxin production is a consequence of phage lysogeny and that both
      toxigenic and non-toxigenic strains therefore exist within each species.
- name: Iron-Regulated Diphtheria Toxin Expression
  description: >-
    Transcription of tox is repressed by DtxR, an iron-dependent DNA-binding protein that
    occupies the tox operator when loaded with ferrous iron. In the iron-restricted
    environment of host mucosa the repressor is unloaded and derepresses tox along with a
    wider iron-acquisition regulon, so the bacterium makes most toxin precisely where it
    is establishing infection.
  biological_scale: MOLECULAR
  downstream:
  - target: Diphtheria Toxin Binding to the proHB-EGF Receptor
    description: >-
      Derepressed transcription yields secreted toxin that reaches host cell surfaces.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        These isolates produce DT, released into the culture medium as a 535 amino acid
        single chain protein, following cleavage of its 25 amino acid signal sequence.
      explanation: >-
        Establishes that the expressed toxin is secreted as a single-chain protein,
        making it available to bind host receptors.
  biological_processes:
  - preferred_term: cellular response to iron ion starvation
    term:
      id: GO:0010106
      label: cellular response to iron ion starvation
  evidence:
  - reference: PMID:8106325
    reference_title: "Cloning, sequence, and footprint analysis of two promoter/operators from Corynebacterium diphtheriae that are regulated by the diphtheria toxin repressor (DtxR) and iron."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      DtxR is an iron-dependent sequence-specific DNA-binding protein that binds to the
      tox operator, an inverted-repeat nucleotide sequence located upstream from the
      diphtheria toxin gene.
    explanation: >-
      Identifies DtxR as the iron-dependent repressor acting at the tox operator, the
      regulatory step this node represents.
  - reference: PMID:8106325
    reference_title: "Cloning, sequence, and footprint analysis of two promoter/operators from Corynebacterium diphtheriae that are regulated by the diphtheria toxin repressor (DtxR) and iron."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Transcription from both promoters was strongly repressed in high-iron medium in the
      presence of the cloned dtxR gene; however, transcription in the absence of dtxR was
      50- to 100-fold greater, regardless of the iron concentration.
    explanation: >-
      Demonstrates the iron dependence of DtxR-mediated repression, which is what makes
      toxin expression rise under the iron restriction of host mucosa.
- name: Mucosal Colonization and Adherence
  description: >-
    Before any toxin is made the organism must attach to and colonize the pharyngeal or
    cutaneous epithelium. Adherence is multifactorial: C. diphtheriae carries three
    sortase-assembled pilus gene clusters, and pilus type determines which epithelial cell
    lines a strain attaches to. Adherence is independent of the tox gene, which is why
    non-toxigenic strains colonize and transmit just as effectively.
  biological_scale: CELLULAR
  locations:
  - preferred_term: pharynx
    term:
      id: UBERON:0006562
      label: pharynx
  cell_types:
  - preferred_term: nasopharyngeal epithelial cell
    term:
      id: CL:1001573
      label: nasopharyngeal epithelial cell
  biological_processes:
  - preferred_term: cell adhesion
    modifier: INCREASED
    term:
      id: GO:0007155
      label: cell adhesion
  downstream:
  - target: Pseudomembrane Formation
    description: >-
      Colonization of the mucosal surface establishes the site at which the
      pseudomembrane subsequently forms.
    evidence:
    - reference: PMID:31294205
      reference_title: "Adhesion properties of toxigenic corynebacteria."
      supports: SUPPORT
      evidence_source: IN_VITRO
      directness: INDIRECT
      snippet: >-
        C. diphtheriae is the classical etiological agent of diphtheria, an inflammatory
        disease of the upper respiratory tract, but also cases of cutaneous diphtheria
        occur.
      explanation: >-
        Locates the infection at the upper respiratory tract and skin, the sites where the
        membrane forms. Graded INDIRECT because the review establishes the site of
        colonization rather than the membrane-forming step itself.
  evidence:
  - reference: PMID:31294205
    reference_title: "Adhesion properties of toxigenic corynebacteria."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      C. diphtheriae, C. pseudotuberculosis and C. ulcerans are able to colonize different
      types of epithelial cells in a strain-specific manner, independent of the presence
      of the tox gene.
    explanation: >-
      Establishes epithelial colonization as a tox-independent step, which is why this
      node sits upstream of and separate from the toxin cascade.
  - reference: PMID:31294205
    reference_title: "Adhesion properties of toxigenic corynebacteria."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Genomic analysis of C. diphtheriae revealed the identification of three distinct
      pili clusters (spaABC, spaDEF, spaGHI) together with five sortase-encoding genes
    explanation: >-
      Identifies the sortase-assembled pilus clusters that mediate the adherence this node
      represents.
- name: Diphtheria Toxin Binding to the proHB-EGF Receptor
  description: >-
    The receptor-binding (R) domain of diphtheria toxin binds the membrane-anchored
    precursor of heparin-binding EGF-like growth factor. proHB-EGF was identified by
    expression cloning as the diphtheria toxin sensitivity determinant, and it associates
    with the tetraspanin CD9 (DRAP27), which increases the number of functional receptors
    and raises toxin sensitivity by more than an order of magnitude. Species differences in
    this receptor explain why mice and rats are naturally resistant to the toxin.
  biological_scale: MOLECULAR
  downstream:
  - target: Endocytosis and Catalytic Domain Translocation
    description: >-
      Receptor engagement commits the bound toxin to the endocytic uptake route.
    evidence:
    - reference: PMID:1606612
      reference_title: "Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        Intoxication of the transfected cells requires receptor-mediated endocytosis of
        the bound toxin.
      explanation: >-
        States that receptor-bound toxin must be endocytosed to intoxicate the cell, which
        is the transition this edge encodes.
  biological_processes:
  - preferred_term: receptor-mediated endocytosis
    term:
      id: GO:0006898
      label: receptor-mediated endocytosis
  evidence:
  - reference: PMID:1606612
    reference_title: "Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The cDNA is predicted to encode an integral membrane protein that is identical to
      the precursor of a heparin-binding EGF-like growth factor.
    explanation: >-
      Expression cloning identifying the diphtheria toxin receptor as the HB-EGF
      precursor, the binding partner this node names.
  - reference: PMID:1606612
    reference_title: "Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Mouse cells are naturally resistant to DT, because they lack functional cell surface
      receptors for the toxin.
    explanation: >-
      Supports the receptor as the determinant of cellular and species susceptibility,
      which is the basis for the model-system caveat recorded in this entry.
  - reference: PMID:8194524
    reference_title: "Heparin-binding EGF-like growth factor, which acts as the diphtheria toxin receptor, forms a complex with membrane protein DRAP27/CD9, which up-regulates functional receptors and diphtheria toxin sensitivity."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      We conclude that DRAP27/CD9 associates tightly with DTR/HB-EGF and up-regulates the
      number of functional DTRs and DT sensitivity, and that HB-EGF is identical to DTR.
    explanation: >-
      Establishes the CD9 co-receptor relationship that modulates the number of functional
      receptors and therefore cellular toxin sensitivity.
- name: Endocytosis and Catalytic Domain Translocation
  description: >-
    Receptor-bound toxin is internalized into an endosome. Acidification triggers a
    conformational change in the translocation (T) domain, which inserts into the
    endosomal membrane and chaperones the catalytic (C) domain across it into the cytosol.
    A single translocated catalytic domain is sufficient to kill a cell, and the estimated
    human lethal dose is on the order of 100 ng/kg.
  biological_scale: MOLECULAR
  downstream:
  - target: eEF2 Diphthamide ADP-Ribosylation
    description: >-
      Delivery of the catalytic domain into the cytosol places it in contact with its
      substrate, eEF2.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        After invading the cell cytoplasm through endocytosis and translocation, DT
        inhibits protein synthesis and provokes cell death by apoptosis.
      explanation: >-
        Places cytosolic entry immediately upstream of protein-synthesis inhibition, the
        transition this edge encodes.
  biological_processes:
  - preferred_term: receptor-mediated endocytosis
    modifier: INCREASED
    term:
      id: GO:0006898
      label: receptor-mediated endocytosis
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      After invading the cell cytoplasm through endocytosis and translocation, DT inhibits
      protein synthesis and provokes cell death by apoptosis. DT is very potent towards
      humans, with an estimated lethal dose of 100 ng/kg.
    explanation: >-
      Describes the endocytosis-then-translocation route this node represents and
      quantifies the resulting potency.
  - reference: PMID:699044
    reference_title: "One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      The results demonstrated that a single molecule of fragment A was sufficient to
      kill a cell.
    explanation: >-
      Single-molecule experiment establishing that one translocated catalytic domain
      suffices to kill a cell, the claim made in this node's description.
- name: eEF2 Diphthamide ADP-Ribosylation
  description: >-
    The catalytic domain is a NAD+-dependent ADP-ribosyltransferase that transfers ADP-ribose
    onto diphthamide, a modified histidine unique to eukaryotic elongation factor 2.
    Diphthamide normally supports reading-frame fidelity; once ADP-ribosylated, eEF2 can no
    longer catalyse translocation of the peptidyl-tRNA-mRNA complex from the ribosomal A
    site to the P site. The reaction is catalytic rather than stoichiometric, which is why a
    single translocated catalytic domain is enough to kill the cell.
  biological_scale: MOLECULAR
  role: central_effector
  molecular_functions:
  - preferred_term: NAD+-diphthamide ADP-ribosyltransferase activity
    modifier: INCREASED
    term:
      id: GO:0047286
      label: NAD+-diphthamide ADP-ribosyltransferase activity
  downstream:
  - target: Translational Arrest and Host Cell Death
    description: >-
      Loss of eEF2 translocase activity halts the elongation phase of protein synthesis.
    evidence:
    - reference: PMID:23853096
      reference_title: "ADP-ribosylation of translation elongation factor 2 by diphtheria toxin in yeast inhibits translation and cell separation."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: >-
        ADP(R) of eEF2 resulted in a decrease in total protein synthesis consistent with a
        defect in translation elongation.
      explanation: >-
        Directly measures the fall in protein synthesis caused by eEF2 ADP-ribosylation,
        the transition this edge encodes.
  evidence:
  - reference: PMID:23853096
    reference_title: "ADP-ribosylation of translation elongation factor 2 by diphtheria toxin in yeast inhibits translation and cell separation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      ADP-ribosylation (ADP(R)) of eEF2 by bacterial toxins on a unique diphthamide residue
      inhibits its translocation activity, but the mechanism is unclear.
    explanation: >-
      States that ADP-ribosylation occurs on the diphthamide residue and inhibits eEF2
      translocase activity, which is the reaction this node represents.
  - reference: PMID:23853096
    reference_title: "ADP-ribosylation of translation elongation factor 2 by diphtheria toxin in yeast inhibits translation and cell separation."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Eukaryotic translation elongation factor 2 (eEF2) facilitates the movement of the
      peptidyl tRNA-mRNA complex from the A site of the ribosome to the P site during
      protein synthesis.
    explanation: >-
      Defines the normal eEF2 translocase step that ADP-ribosylation abolishes.
  - reference: PMID:38097404
    reference_title: "Diphthamide - a conserved modification of eEF2 with clinical relevance."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Diphthamide, a complex modification on eukaryotic translation elongation factor 2
      (eEF2), assures reading-frame fidelity during translation.
    explanation: >-
      Establishes the identity and normal function of the diphthamide residue that
      diphtheria toxin targets.
  - reference: PMID:38097404
    reference_title: "Diphthamide - a conserved modification of eEF2 with clinical relevance."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      Originally identified as target for diphtheria toxin (DT) in humans, its clinical
      relevance now proves to be broader than the link to pathogenic bacteria.
    explanation: >-
      Confirms diphthamide as the original and defining target of diphtheria toxin.
- name: Translational Arrest and Host Cell Death
  description: >-
    Elongation stalls, total protein synthesis falls, and the affected cell dies by
    apoptosis. This single lesion accounts for every toxin-attributable feature of the
    disease: epithelial necrosis under the membrane locally, and cardiomyocyte and Schwann
    cell injury at distant sites. Nothing about the mechanism is tissue-specific, so which
    organs are damaged is set by toxin delivery and by which cell types are least able to
    tolerate a translational block.
  biological_scale: CELLULAR
  role: central_effector
  biological_processes:
  - preferred_term: translational elongation
    modifier: DECREASED
    term:
      id: GO:0006414
      label: translational elongation
  - preferred_term: negative regulation of translation
    modifier: INCREASED
    term:
      id: GO:0017148
      label: negative regulation of translation
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  downstream:
  - target: Pseudomembrane Formation
    description: >-
      Death of the colonized mucosal epithelium supplies the necrotic material that, with
      fibrin, inflammatory cells and bacteria, constitutes the pseudomembrane.
    evidence:
    - reference: PMID:31804499
      reference_title: "Diphtheria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Diphtheria is generally an acute respiratory infection, characterized by the
        formation of a pseudomembrane in the throat, but cutaneous infections are
        possible.
      explanation: >-
        Establishes the membrane as the defining local lesion. Graded INDIRECT because the
        review states the clinical finding rather than tracing it to toxin-induced
        epithelial death.
  - target: Systemic Toxin Dissemination
    description: >-
      Toxin not consumed locally is absorbed into the circulation and carried to distant
      organs.
    evidence:
    - reference: PMID:31804499
      reference_title: "Diphtheria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Systemic effects, such as myocarditis and neuropathy, which are associated with
        increased fatality risk, are due to diphtheria toxin, an exotoxin produced by the
        pathogen that inhibits protein synthesis and causes cell death.
      explanation: >-
        Attributes the distant organ effects to the same protein-synthesis-inhibiting
        toxin, which is the transition from local to systemic injury this edge encodes.
  evidence:
  - reference: PMID:31804499
    reference_title: "Diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Systemic effects, such as myocarditis and neuropathy, which are associated with
      increased fatality risk, are due to diphtheria toxin, an exotoxin produced by the
      pathogen that inhibits protein synthesis and causes cell death.
    explanation: >-
      States the protein-synthesis inhibition and cell death that define this node and
      links them to the fatal systemic manifestations.
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      After invading the cell cytoplasm through endocytosis and translocation, DT inhibits
      protein synthesis and provokes cell death by apoptosis.
    explanation: >-
      Identifies apoptosis as the mode of toxin-induced cell death recorded on this node.
- name: Pseudomembrane Formation
  description: >-
    Necrotic epithelium, fibrin, leukocytes, erythrocytes and bacteria coalesce into a
    tough grey-white membrane that adheres to the underlying mucosa and bleeds if stripped.
    On the tonsils and pharynx it is the diagnostic sign of respiratory diphtheria, and it
    is found in roughly three quarters of clinically diagnosed cases in outbreak settings.
  biological_scale: TISSUE
  locations:
  - preferred_term: pharynx
    term:
      id: UBERON:0006562
      label: pharynx
  - preferred_term: larynx
    term:
      id: UBERON:0001737
      label: larynx
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  downstream:
  - target: Upper Airway Obstruction
    description: >-
      Extension of the membrane into the larynx and trachea narrows the airway lumen.
    evidence:
    - reference: DOI:10.3201/eid3008.231671
      reference_title: "Retrospective Study of Infections with Corynebacterium diphtheriae Species Complex, French Guiana, 2016-2021"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The classical clinical manifestation of diphtheria is a pseudomembrane in the upper
        respiratory airways (tonsils, pharynx, or larynx) that can cause possible fatal
        airway obstruction.
      explanation: >-
        Links the membrane directly to fatal airway obstruction, the transition this edge
        encodes.
  evidence:
  - reference: DOI:10.3201/eid3008.231671
    reference_title: "Retrospective Study of Infections with Corynebacterium diphtheriae Species Complex, French Guiana, 2016-2021"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The classical clinical manifestation of diphtheria is a pseudomembrane in the upper
      respiratory airways (tonsils, pharynx, or larynx) that can cause possible fatal
      airway obstruction.
    explanation: >-
      Names the membrane as the classical manifestation and gives its anatomical
      distribution.
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pseudomembrane was present in 245 (77%) cases.
    explanation: >-
      Quantifies how frequently the membrane is found in a 318-child outbreak cohort.
- name: Upper Airway Obstruction
  description: >-
    Progressive narrowing of the larynx and trachea by membrane and oedema. It is the most
    immediately lethal local complication and, unlike the toxin-mediated injuries, it is
    mechanical: it is relieved by bypassing the obstruction rather than by neutralizing
    toxin. In outbreak cohorts it occurred in 22.6% of children and carried roughly
    thirteenfold higher odds of death.
  biological_scale: ORGANISM
  role: consequence
  locations:
  - preferred_term: larynx
    term:
      id: UBERON:0001737
      label: larynx
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6%
      (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12),
      thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases.
    explanation: >-
      Quantifies airway compromise in a 318-child outbreak cohort.
  - reference: DOI:10.52225/narra.v4i2.776
    reference_title: "Determinants of mortality in relationship between clinical and laboratory characteristics with the outcomes of children with diphtheria"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with airway obstruction were 13 times more likely to have an increase in
      mortality compared to patients without airway obstruction.
    explanation: >-
      Quantifies the mortality attributable to this node.
- name: Systemic Toxin Dissemination
  description: >-
    Toxin absorbed from the membrane-covered mucosa enters the bloodstream and reaches the
    heart, peripheral nerves and kidney. The distinction between local spread and
    haematogenous dissemination is clinically load-bearing: early palatal weakness reflects
    direct local toxin action, whereas the generalized demyelinating neuropathy that
    follows weeks later reflects blood-borne delivery. Only free toxin is neutralizable,
    so antitoxin given after dissemination and cellular uptake cannot reverse established
    injury.
  biological_scale: ORGANISM
  downstream:
  - target: Diphtheritic Myocarditis
    description: >-
      Circulating toxin is taken up by cardiomyocytes, where the same translational block
      produces myocyte necrosis.
    evidence:
    - reference: PMID:36589640
      reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Fluorescent antibody staining of tissue sections demonstrates diphtheria toxin in a
        patchy distribution within the myocardial fibers, which could possibly explain the
        role of the toxin in mediating myocardial injury.
      explanation: >-
        Places toxin inside myocardial fibres, which is the delivery step this edge
        encodes.
  - target: Toxin-Mediated Schwann Cell Injury and Demyelination
    description: >-
      Blood-borne toxin reaches peripheral nerve, where it is taken up by Schwann cells.
    evidence:
    - reference: PMID:26962337
      reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Local toxic effects occur by direct spread of toxin and result in the early bulbar
        problems while the ensuing generalized demyelinating neuropathy arises from
        hematogenous dissemination.
      explanation: >-
        Explicitly attributes the generalized demyelinating neuropathy to haematogenous
        dissemination, the transition this edge encodes.
  evidence:
  - reference: PMID:39324172
    reference_title: "Cutaneous diphtheria from 2018 to 2022: an observational, retrospective study of epidemiological, microbiological, clinical, and therapeutic characteristics in metropolitan France."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The severity of diphtheria is linked to the presence of diphtheria toxin, responsible
      for cardiac and neurological complications after its diffusion away from the
      infectious site.
    explanation: >-
      States that cardiac and neurological complications follow diffusion of toxin away
      from the primary site, which is the claim this node makes.
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The period between the appearance of first symptom of diphtheria and the development
      of DP is termed latency, which varies from 10 days to 3 months.
    explanation: >-
      Documents the latency between local infection and distant neurological disease that
      dissemination-then-uptake predicts.
- name: Diphtheritic Myocarditis
  description: >-
    Toxin taken up by cardiomyocytes produces patchy myocyte necrosis with mononuclear
    infiltration, interstitial oedema and fibrosis, typically appearing about two weeks
    after the pharyngeal illness.
    Ultrastructurally the mitochondria are swollen with disorganized cristae and glycogen
    is depleted, consistent with a cell whose protein synthesis has been arrested. Cardiac
    involvement is the leading cause of death in diphtheria, and it is potentially
    reversible if the patient survives the acute phase.
  biological_scale: TISSUE
  role: consequence
  locations:
  - preferred_term: myocardium
    term:
      id: UBERON:0002349
      label: myocardium
  cell_types:
  - preferred_term: cardiac muscle cell
    term:
      id: CL:0000746
      label: cardiac muscle cell
  biological_processes:
  - preferred_term: inflammatory response
    modifier: INCREASED
    term:
      id: GO:0006954
      label: inflammatory response
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  downstream:
  - target: Cardiac Conduction System Injury
    description: >-
      The inflammatory and necrotic process extends into the specialized conduction tissue.
    evidence:
    - reference: PMID:36589640
      reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The myocarditis process also involves the cardiac conduction tissue and results in
        a spectrum of electrocardiographic changes.
      explanation: >-
        States that the myocarditic process extends into conduction tissue, which is the
        transition this edge encodes.
  evidence:
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cardiac involvement, in the form of myocarditis, is the most serious manifestation of
      diphtheria and is the most common cause of mortality in these patients.
    explanation: >-
      Establishes myocarditis as the dominant cause of death, the clinical weight this node
      carries.
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The EMB showed patchy areas of myocyte necrosis with mononuclear cell infiltration
      accompanied by interstitial fibrosis and edema suggestive of acute myocarditis
    explanation: >-
      Endomyocardial biopsy describing the exact histological lesion this node represents.
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6%
      (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12),
      thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases.
    explanation: >-
      Quantifies cardiac involvement alongside the other toxin-mediated complications in a
      contemporary outbreak cohort.
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Electron micrography shows striking ultrastructural changes within involved myofibers
      predominantly involving the mitochondria which appear swollen with loss of matrix and
      disorganized cristae which is also associated with the depletion of glycogen and
      accumulation of lipid droplets.
    explanation: >-
      Source for the ultrastructural changes described on this node.
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      he accepted to have had an episode of fever that lasted for 4 days associated with
      throat pain and swelling 2 weeks before the onset of his heart failure symptoms
    explanation: >-
      Dates the cardiac presentation about two weeks after the pharyngeal illness. Graded
      INDIRECT because it is a single case, so reading a typical interval off it takes an
      inference step.
- name: Cardiac Conduction System Injury
  description: >-
    Extension of the myocarditic process into the conduction system produces a spectrum of
    electrocardiographic abnormalities; about half of patients with diphtheritic myocarditis
    develop severe conduction disturbance, of which complete heart block is the most
    dangerous. Left bundle branch block and T-wave inversion have been reported to predict
    poor long-term survival.
  biological_scale: TISSUE
  role: consequence
  locations:
  - preferred_term: heart
    term:
      id: UBERON:0000948
      label: heart
  evidence:
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Almost half of the patients with diphtheritic myocarditis develop severe conduction
      disturbances, the most serious being complete heart block.
    explanation: >-
      Quantifies the frequency and names the most serious form of the conduction injury
      this node represents.
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It was observed in a study that the presence of left bundle branch block pattern and
      T-wave inversions predicts poor long-term survival in these patients.
    explanation: >-
      Source for the prognostic significance of specific conduction patterns recorded in
      this node's description.
- name: Toxin-Mediated Schwann Cell Injury and Demyelination
  description: >-
    Diphtheria toxin enters Schwann cells and blocks synthesis of myelin proteolipid protein
    and myelin basic protein, producing segmental demyelination without primary axonal loss.
    Because myelin maintenance depends on ongoing protein synthesis, the Schwann cell is
    among the cell types least able to tolerate a translational block. The clinical
    consequence is a descending neuropathy beginning with palatal and other bulbar
    weakness, later oculomotor and ciliary paralysis, and in severe cases limb weakness,
    with recovery in most survivors because axons are preserved.
  biological_scale: CELLULAR
  role: consequence
  locations:
  - preferred_term: peripheral nervous system
    term:
      id: UBERON:0000010
      label: peripheral nervous system
  cell_types:
  - preferred_term: myelinating Schwann cell
    term:
      id: CL:0000218
      label: myelinating Schwann cell
  biological_processes:
  - preferred_term: myelination
    modifier: DECREASED
    term:
      id: GO:0042552
      label: myelination
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diptheritic toxin penetrates into Schwann cells and it inhibits the synthesis of
      myelin proteolipid and basic protein.
    explanation: >-
      States the Schwann cell target and the specific myelin proteins whose synthesis is
      blocked, which is the mechanism this node represents.
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All the children presented with bulbar palsy and had h/o membranous tonsillitis.
      Isolated palatal palsy was seen in 7 children (53%). 6 (46.1%) children developed
      quadriparesis.
    explanation: >-
      Case series documenting the bulbar-onset, descending distribution that follows from
      local then haematogenous toxin delivery to Schwann cells.
  - reference: PMID:7477070
    reference_title: "Diphtheritic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 29-year-old Haitian man had a sore throat with a marked tonsillar exudate followed
      by the onset of increasingly blurred vision with swallowing difficulties and, then, a
      diffuse acute demyelinating neuropathy.
    explanation: >-
      Documents the demyelinating character of the neuropathy and its temporal sequence
      after pharyngeal disease.
- name: Absent or Waning Antitoxin Immunity
  description: >-
    Toxoid-induced neutralizing antibody is the only established host protection. It does
    not prevent colonization, but it neutralizes toxin before it reaches its receptor, so
    unimmunized and partially immunized hosts develop the toxin-mediated syndrome that
    immunized hosts largely escape. Outbreak cohorts are dominated by unvaccinated young
    children, and in C. ulcerans disease vaccination status separates those who develop a
    classical pseudomembrane from those who do not.
  biological_scale: ORGANISM
  role: susceptibility_factor
  biological_processes:
  - preferred_term: adaptive immune response
    modifier: DECREASED
    term:
      id: GO:0002250
      label: adaptive immune response
  downstream:
  - target: Diphtheria Toxin Binding to the proHB-EGF Receptor
    description: >-
      Without neutralizing antitoxin, secreted toxin survives in the extracellular space
      long enough to engage its receptor.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The pathological effects caused by its main virulence factor, diphtheria toxin, can
        be diminished by passive transfer of antibodies.
      explanation: >-
        Establishes that antitoxin antibody blocks the toxin's pathological effects, so its
        absence is what permits receptor engagement.
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Young children (median age 5 year) were predominantly affected, and only 8 (2.5%)
      children were fully immunized.
    explanation: >-
      Shows that the outbreak burden fell almost entirely on incompletely immunized
      children, the susceptibility state this node represents.
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      none of 39 fully vaccinated cases presented with classic respiratory diphtheria with
      pseudomembrane, whereas 14 out of 43 unvaccinated or incompletely vaccinated cases
      presented with these symptoms (p < 0.001).
    explanation: >-
      Directly contrasts vaccinated and unvaccinated cases on the presence of the defining
      toxin-mediated lesion, supporting antitoxin immunity as the determining host factor.
- name: Bacterial mRNA Translation by the Ribosome (Macrolide Target)
  description: >-
    Corynebacterium diphtheriae depends on 70S-ribosome translation. Macrolides
    (azithromycin, erythromycin, clarithromycin) bind the 50S subunit and arrest bacterial
    protein synthesis. WHO's 2024 clinical management guideline places macrolides ahead of
    penicillin as first-line therapy. Because diphtheria toxin is itself a translated
    secreted product, this target has an anti-toxin rationale in addition to bacterial
    clearance, but antibiotics do not neutralize toxin already released, so they never
    substitute for antitoxin.
  biological_scale: MOLECULAR
  role: therapeutic_vulnerability
  conforms_to: "bacterial_protein_synthesis_inhibition#Bacterial mRNA Translation by the Ribosome"
  biological_processes:
  - preferred_term: translation
    term:
      id: GO:0006412
      label: translation
  downstream:
  - target: Iron-Regulated Diphtheria Toxin Expression
    description: >-
      Diphtheria toxin is itself a translated, secreted protein, so arresting bacterial
      protein synthesis suppresses further toxin output as well as killing the organism.
      This is the anti-toxin component of antibiotic therapy, and it is why antibiotics
      shorten the window during which new toxin is being made without doing anything about
      toxin already released.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Antimicrobial treatment reduces transmission, but to improve survival, patients with
        toxinic symptoms do need DAT.
      explanation: >-
        Establishes that antimicrobial therapy acts on the organism and its spread while
        leaving already-elaborated toxin to antitoxin. Graded INDIRECT because it states the
        clinical division of labour rather than measuring toxin output directly.
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In February 2024, in the context of the 2023 West African diphtheria outbreak, WHO
      published a new guideline for the clinical management of diphtheria, where the
      first-line use of macrolide antibiotics (azithromycin, erythromycin) is recommended
      in preference to penicillin.
    explanation: >-
      Identifies the macrolides, which act on this ribosomal target, as WHO first-line
      therapy for diphtheria.
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antimicrobial treatment reduces transmission, but to improve survival, patients with
      toxinic symptoms do need DAT.
    explanation: >-
      Delimits what antibiotic therapy achieves, supporting the note on this node that
      ribosomal targeting does not substitute for antitoxin.
- name: Bacterial Peptidoglycan Cross-Linking (Beta-Lactam Target)
  description: >-
    Penicillins acylate the penicillin-binding protein transpeptidases and halt
    peptidoglycan cross-linking. Benzylpenicillin remains a standard alternative or partner
    agent, and in the only randomized comparison in diphtheria it cleared fever faster than
    erythromycin with equivalent membrane and bacteriological clearance. UK guidance
    combines intravenous benzylpenicillin with a macrolide for severe disease.
  biological_scale: MOLECULAR
  role: therapeutic_vulnerability
  conforms_to: "bacterial_cell_wall_synthesis_inhibition#Peptidoglycan Cross-Linking by Penicillin-Binding Proteins"
  biological_processes:
  - preferred_term: cell wall organization
    term:
      id: GO:0071555
      label: cell wall organization
  downstream:
  - target: Iron-Regulated Diphtheria Toxin Expression
    description: >-
      Killing the organism removes the cells that are transcribing tox, so toxin output
      falls with the bacterial population. This is a different route to the same node than
      the macrolide edge takes: a ribosome inhibitor suppresses synthesis of the toxin
      protein in cells that are still alive, whereas a beta-lactam reduces output only by
      reducing the number of producers. The distinction is why protein-synthesis inhibitors
      are the preferred agents in toxin-mediated disease, and neither route touches toxin
      that has already been released.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        Antimicrobial treatment reduces transmission, but to improve survival, patients with
        toxinic symptoms do need DAT.
      explanation: >-
        Establishes that antimicrobial therapy acts on the organism and its spread while
        already-elaborated toxin is left to antitoxin. Graded INDIRECT because the review
        states this for antimicrobial therapy as a class rather than measuring the effect
        of bacterial killing on toxin output.
  evidence:
  - reference: PMID:9798043
    reference_title: "Penicillin vs. erythromycin in the treatment of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There were no differences in times to membrane clearance or bacteriologic clearance,
      but median times to fever clearance were 27 hours (95% confidence interval [CI],
      19-30; range, 0-124 hours) for penicillin recipients and 46 hours (95% CI, 34-54;
      range, 0-148 hours) for erythromycin recipients (P = .0004).
    explanation: >-
      Randomized head-to-head trial establishing penicillin's clinical effect on this
      organism relative to a ribosome-targeting comparator.
  - reference: PMID:9798043
    reference_title: "Penicillin vs. erythromycin in the treatment of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All isolates were susceptible to penicillin, but for isolates (27%), all of which
      were from patients who received penicillin treatment, were resistant to erythromycin
      (minimum inhibitory concentrations, > 64 mg/L).
    explanation: >-
      Documents retained penicillin susceptibility alongside macrolide resistance, which is
      why this beta-lactam target remains clinically relevant.
phenotypes:
- name: Pharyngeal Pseudomembrane
  category: Respiratory
  subtype: Faucial
  description: >-
    An adherent grey-white membrane over the tonsils, pharynx or soft palate that bleeds
    when forcibly detached. It is the diagnostic sign of respiratory diphtheria and is
    present in roughly three quarters of clinically diagnosed cases in outbreak settings.
  phenotype_term:
    preferred_term: Pharyngeal pseudomembrane
    term:
      id: HP:0033151
      label: Abnormal pharynx morphology
  frequency: FREQUENT
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Pseudomembrane was present in 245 (77%) cases.
    explanation: >-
      Direct frequency measurement in a 318-child outbreak cohort, supporting the FREQUENT
      band.
  notes: >-
    HPO has no term for a diphtheritic pseudomembrane. HP:0033151 (Abnormal pharynx
    morphology) is the most specific accurate ancestor available; the specific lesion is
    carried by preferred_term.
- name: Pharyngitis
  category: Respiratory
  description: >-
    Sore throat with odynophagia and tonsillar or pharyngeal inflammation, typically of
    acute onset after a short incubation period, preceding or accompanying membrane
    formation.
  phenotype_term:
    preferred_term: Pharyngitis
    term:
      id: HP:0025439
      label: Pharyngitis
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Symptoms range from the classical pseudomembranous pharyngitis and cervical
      lymphadenopathy to skin inflammatory ulceration; they develop with toxigenic or
      non-toxigenic strains.
    explanation: >-
      Names pseudomembranous pharyngitis as the classical presentation.
- name: Cervical Lymphadenopathy
  category: Lymphatic
  description: >-
    Enlarged, tender anterior cervical nodes accompanying pharyngeal disease; with
    surrounding soft-tissue oedema this produces the characteristic "bull neck" appearance
    of severe faucial diphtheria.
  phenotype_term:
    preferred_term: Cervical lymphadenopathy
    term:
      id: HP:0025289
      label: Cervical lymphadenopathy
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Symptoms range from the classical pseudomembranous pharyngitis and cervical
      lymphadenopathy to skin inflammatory ulceration; they develop with toxigenic or
      non-toxigenic strains.
    explanation: >-
      Names cervical lymphadenopathy as part of the classical respiratory presentation.
- name: Bull Neck (Anterior Cervical Swelling)
  category: Head and Neck
  description: >-
    Diffuse oedematous swelling of the anterior neck overlying enlarged cervical nodes,
    marking severe toxaemic disease. In outbreak cohorts its presence is associated with
    higher mortality, and WHO antitoxin dosing escalates to the highest tier when diffuse
    neck swelling is present.
  phenotype_term:
    preferred_term: Anterior neck swelling
    term:
      id: HP:6000176
      label: Anterior neck swelling
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mortality was high in unimmunized or partially immunized young children and those
      with bull neck, pseudomembrane, delayed (≥5 days) administration of ADS, acute kidney
      injury, thrombocytopenia and leukocytosis.
    explanation: >-
      Identifies bull neck as a recorded clinical finding associated with mortality in this
      cohort.
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A dose of 80,000 eDAT IU is recommended for any disease of more than 48 h duration,
      or diffuse swelling of the neck or severe disease (respiratory distress, shock).
    explanation: >-
      WHO dosing places diffuse neck swelling in the highest antitoxin tier, the claim made
      in this phenotype's description.
- name: Stridor
  category: Respiratory
  subtype: Laryngeal
  description: >-
    Inspiratory stridor from narrowing of the laryngeal and tracheal lumen by membrane and
    oedema; historically described as membranous croup and a harbinger of complete
    obstruction.
  phenotype_term:
    preferred_term: Stridor
    term:
      id: HP:0010307
      label: Stridor
  evidence:
  - reference: PMID:39324172
    reference_title: "Cutaneous diphtheria from 2018 to 2022: an observational, retrospective study of epidemiological, microbiological, clinical, and therapeutic characteristics in metropolitan France."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      Although the classical and most severe clinical presentation of diphtheria is
      respiratory and ear nose and throat (ENT) damages (pseudomembranous angina and
      laryngeal respiratory distress known as “croup”) which represent 10–30% of cases
      in literature, cutaneous infections are more common.
    explanation: >-
      Names laryngeal respiratory distress ("croup") as the severe respiratory presentation
      of which stridor is the cardinal sign. Graded INDIRECT because the paper names the
      syndrome rather than the individual sign.
- name: Hoarse Voice
  category: Respiratory
  subtype: Laryngeal
  description: >-
    Hoarseness from membrane involvement of the vocal folds, often the first sign that
    respiratory diphtheria has extended below the pharynx.
  phenotype_term:
    preferred_term: Hoarse voice
    term:
      id: HP:0001609
      label: Hoarse voice
  evidence:
  - reference: DOI:10.3201/eid3008.231671
    reference_title: "Retrospective Study of Infections with Corynebacterium diphtheriae Species Complex, French Guiana, 2016-2021"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      The classical clinical manifestation of diphtheria is a pseudomembrane in the upper
      respiratory airways (tonsils, pharynx, or larynx) that can cause possible fatal
      airway obstruction.
    explanation: >-
      Establishes laryngeal involvement as part of the disease. Graded INDIRECT because
      hoarseness is inferred from laryngeal membrane rather than reported as such.
- name: Upper Airway Obstruction
  category: Respiratory
  description: >-
    Progressive obstruction of the larynx and trachea by pseudomembrane and oedema. It is
    the most immediately lethal local complication, occurred in 22.6% of a 318-child
    outbreak cohort, and carries roughly thirteenfold higher odds of death in an Indonesian
    paediatric series.
  phenotype_term:
    preferred_term: Upper airway obstruction
    term:
      id: HP:0002781
      label: Upper airway obstruction
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6%
      (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12),
      thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases.
    explanation: >-
      Direct frequency measurement of airway compromise supporting the OCCASIONAL band.
  - reference: DOI:10.52225/narra.v4i2.776
    reference_title: "Determinants of mortality in relationship between clinical and laboratory characteristics with the outcomes of children with diphtheria"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patients with airway obstruction were 13 times more likely to have an increase in
      mortality compared to patients without airway obstruction.
    explanation: >-
      Quantifies the mortality associated with this phenotype.
- name: Nasal Discharge
  category: Respiratory
  subtype: Anterior nasal
  description: >-
    Serosanguineous or mucopurulent nasal discharge with excoriation of the nares and upper
    lip, the presenting feature of anterior nasal diphtheria.
  phenotype_term:
    preferred_term: Rhinorrhea
    term:
      id: HP:0031417
      label: Rhinorrhea
  evidence:
  - reference: DOI:10.3201/eid3008.231671
    reference_title: "Retrospective Study of Infections with Corynebacterium diphtheriae Species Complex, French Guiana, 2016-2021"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      The third patient (72 years of age) experienced a nasal mucosal form (superinfection
      of a chronic injury confirmed by mucus sampling).
    explanation: >-
      Documents a nasal mucosal presentation of C. diphtheriae infection. Graded INDIRECT
      because the case report establishes the nasal site and that mucus was sampled, rather
      than characterizing the discharge itself.
- name: Skin Ulcer
  category: Dermatologic
  subtype: Cutaneous
  description: >-
    A chronic, non-healing ulcer with a rolled or punched-out edge, often covered by a dirty
    grey membrane and usually polymicrobial. Lesions predominate on the lower limbs and
    constituted 82% of cutaneous presentations in a contemporary French series.
  phenotype_term:
    preferred_term: Skin ulcer
    term:
      id: HP:0200042
      label: Skin ulcer
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:39324172
    reference_title: "Cutaneous diphtheria from 2018 to 2022: an observational, retrospective study of epidemiological, microbiological, clinical, and therapeutic characteristics in metropolitan France."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Lesions involved the lower limbs (86.9%), corresponded to ulcerations in 82% of
      cases.
    explanation: >-
      Direct frequency measurement of ulceration among cutaneous cases, supporting the
      VERY_FREQUENT band within this subtype.
  notes: >-
    The frequency band applies within cutaneous diphtheria, not across all diphtheria
    presentations.
- name: Myocarditis
  category: Cardiovascular
  description: >-
    Toxin-mediated myocarditis with myocyte necrosis, mononuclear infiltration and
    interstitial fibrosis, usually presenting in the second week as acute heart failure. It
    is the most common cause of death in diphtheria and occurred in 12.9% of a 318-child
    outbreak cohort.
  phenotype_term:
    preferred_term: Myocarditis
    term:
      id: HP:0012819
      label: Myocarditis
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Cardiac involvement, in the form of myocarditis, is the most serious manifestation of
      diphtheria and is the most common cause of mortality in these patients.
    explanation: >-
      Establishes myocarditis as the dominant fatal complication.
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6%
      (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12),
      thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases.
    explanation: >-
      Direct frequency measurement of cardiac involvement supporting the OCCASIONAL band.
- name: Fever
  category: Constitutional
  description: >-
    Low-grade fever accompanying the acute respiratory illness, usually lasting a few days
    and preceding the toxin-mediated complications. It is a nonspecific finding, which is
    part of why early diphtheria is mistaken for ordinary pharyngitis.
  phenotype_term:
    preferred_term: Fever
    term:
      id: HP:0001945
      label: Fever
  evidence:
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      he accepted to have had an episode of fever that lasted for 4 days associated with
      throat pain and swelling 2 weeks before the onset of his heart failure symptoms
    explanation: >-
      Documents the febrile pharyngeal illness that opened this patient's course.
  - reference: PMID:9798043
    reference_title: "Penicillin vs. erythromycin in the treatment of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      There were no differences in times to membrane clearance or bacteriologic clearance,
      but median times to fever clearance were 27 hours (95% confidence interval [CI],
      19-30; range, 0-124 hours) for penicillin recipients and 46 hours (95% CI, 34-54;
      range, 0-148 hours) for erythromycin recipients (P = .0004).
    explanation: >-
      Fever clearance was a trial endpoint in 86 children with diphtheria, so fever was
      present at enrolment. Graded INDIRECT because the trial measures its resolution rather
      than reporting its frequency.
- name: Congestive Heart Failure
  category: Cardiovascular
  description: >-
    Acute decompensated heart failure from toxin-mediated myocardial injury, typically the
    presenting cardiac syndrome and the proximate cause of death in fatal cases. It is
    potentially reversible: with antitoxin and supportive care, ventricular function can
    return to near normal.
  phenotype_term:
    preferred_term: Congestive heart failure
    term:
      id: HP:0001635
      label: Congestive heart failure
  evidence:
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      At admission, he was in acute decompensated heart failure with elevated jugular venous
      pulse and pedal edema.
    explanation: >-
      Documents acute decompensated heart failure as the presenting cardiac syndrome of
      diphtheritic myocarditis.
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Myocardial involvement is the most serious manifestation of diphtheria which may
      present as acute heart failure with dysrhythmias.
    explanation: >-
      States that myocardial involvement presents as acute heart failure, the phenotype
      recorded here.
- name: Atrioventricular Block
  category: Cardiovascular
  description: >-
    Conduction disturbance from myocarditic involvement of the conduction system, ranging
    from junctional escape rhythm to complete heart block. About half of patients with
    diphtheritic myocarditis develop severe conduction disturbance.
  phenotype_term:
    preferred_term: Atrioventricular block
    term:
      id: HP:0001678
      label: Atrioventricular block
  evidence:
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Almost half of the patients with diphtheritic myocarditis develop severe conduction
      disturbances, the most serious being complete heart block.
    explanation: >-
      Establishes the frequency and severity of conduction block among patients with
      diphtheritic myocarditis.
- name: Palatal Palsy
  category: Neurologic
  description: >-
    Paralysis of the soft palate and posterior pharyngeal wall, the earliest and most
    characteristic neurological sign, reflecting local toxin action on adjacent nerves. It
    was the sole neurological finding in 53% of children in a diphtheritic polyneuropathy
    series.
  phenotype_term:
    preferred_term: Palatal palsy
    term:
      id: HP:0001283
      label: Bulbar palsy
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All the children presented with bulbar palsy and had h/o membranous tonsillitis.
      Isolated palatal palsy was seen in 7 children (53%). 6 (46.1%) children developed
      quadriparesis.
    explanation: >-
      Direct measurement of isolated palatal palsy frequency in a diphtheritic
      polyneuropathy cohort.
  notes: >-
    HPO has no term for palatal palsy specifically. HP:0001283 (Bulbar palsy) is the most
    specific accurate term available and is what the cited series reports; the narrower
    localization is carried by preferred_term. HP:0000220 (Velopharyngeal insufficiency)
    was considered and rejected: it names a speech-time functional deficit rather than a
    paralysis, and its manifestation is already recorded separately as Hypernasal speech.
- name: Nasal Regurgitation and Hypernasal Speech
  category: Neurologic
  description: >-
    Nasal twang to the voice and regurgitation of fluids through the nose, the functional
    consequence of palatal weakness and often the clue that leads to the diagnosis in a
    patient who presents with heart failure rather than sore throat.
  phenotype_term:
    preferred_term: Hypernasal speech
    term:
      id: HP:0001611
      label: Hypernasal speech
  evidence:
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      While awaiting biopsy result in the ward, an astute resident doctor noticed that the
      patient had a nasal twang to his voice.
    explanation: >-
      Documents the hypernasal voice quality in a patient whose diphtheria was recognized
      from it.
- name: Dysphagia
  category: Neurologic
  description: >-
    Difficulty swallowing from bulbar weakness, requiring nasogastric feeding in severe
    cases and carrying a risk of fatal aspiration.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:7477070
    reference_title: "Diphtheritic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      A 29-year-old Haitian man had a sore throat with a marked tonsillar exudate followed
      by the onset of increasingly blurred vision with swallowing difficulties and, then, a
      diffuse acute demyelinating neuropathy.
    explanation: >-
      Documents swallowing difficulty as part of the bulbar phase of diphtheritic
      neuropathy.
- name: Impaired Visual Accommodation
  category: Ophthalmologic
  description: >-
    Paralysis of accommodation from ciliary and oculomotor involvement, typically appearing
    after about three weeks and regarded as a distinctive feature of diphtheritic
    neuropathy.
  phenotype_term:
    preferred_term: Reduced visual accommodation
    term:
      id: HP:0030801
      label: Reduced visual accommodation
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Oculomotor nerve involvement in the form of accommodation paralysis was seen in 3
      children.
    explanation: >-
      Directly reports accommodation paralysis in the cohort.
- name: Peripheral Demyelination
  category: Neurologic
  description: >-
    Segmental demyelination of peripheral nerve caused by toxin-mediated blockade of myelin
    protein synthesis in Schwann cells, producing a clinically and electrophysiologically
    demyelinating neuropathy that must be distinguished from Guillain-Barre syndrome.
  phenotype_term:
    preferred_term: Peripheral demyelination
    term:
      id: HP:0011096
      label: Peripheral demyelination
  evidence:
  - reference: PMID:7477070
    reference_title: "Diphtheritic neuropathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diphtheritic neuropathy should be considered in the differential diagnosis of
      Guillain-Barré syndrome in nonvaccinated patients.
    explanation: >-
      Frames diphtheritic neuropathy as a demyelinating differential of Guillain-Barre
      syndrome in unvaccinated patients.
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diptheritic toxin penetrates into Schwann cells and it inhibits the synthesis of
      myelin proteolipid and basic protein.
    explanation: >-
      States the Schwann cell mechanism that produces this demyelinating phenotype.
- name: Polyneuropathy
  category: Neurologic
  description: >-
    A descending, symmetric polyneuropathy following bulbar involvement, appearing 10 days
    to 3 months after the primary infection. It is reported in roughly 20% of mild and 75%
    of severe respiratory cases, and recovery is usually complete because axons are spared.
  phenotype_term:
    preferred_term: Polyneuropathy
    term:
      id: HP:0001271
      label: Polyneuropathy
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DP is seen in 20% and 75% of patients with mild and severe infection, respectively.
    explanation: >-
      Provides the severity-stratified frequency of diphtheritic polyneuropathy recorded in
      this description.
  - reference: PMID:24365424
    reference_title: "Neurologic manifestations of diphtheria and pertussis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Diphtheritic polyneuropathy can be a serious complication in patients who have a
      severe infection.
    explanation: >-
      Independent confirmation that polyneuropathy is a recognized serious complication of
      severe disease.
- name: Tetraparesis
  category: Neurologic
  description: >-
    Symmetric four-limb weakness following palatal and bulbar involvement in severe
    diphtheritic polyneuropathy, occurring in 46% of a paediatric case series and recovering
    over five to six weeks.
  phenotype_term:
    preferred_term: Tetraparesis
    term:
      id: HP:0002273
      label: Tetraparesis
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      All the children presented with bulbar palsy and had h/o membranous tonsillitis.
      Isolated palatal palsy was seen in 7 children (53%). 6 (46.1%) children developed
      quadriparesis.
    explanation: >-
      Direct measurement of quadriparesis frequency in the cohort.
- name: Acute Kidney Injury
  category: Renal
  description: >-
    Toxin-mediated renal injury reported in a minority of severe cases and independently
    associated with mortality in outbreak cohorts.
  phenotype_term:
    preferred_term: Acute kidney injury
    term:
      id: HP:0001919
      label: Acute kidney injury
  frequency: VERY_RARE
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6%
      (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12),
      thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases.
    explanation: >-
      Direct frequency measurement of acute kidney injury supporting the VERY_RARE band.
- name: Thrombocytopenia
  category: Hematologic
  description: >-
    Low platelet count in severe disease, reported in 8.5% of a paediatric outbreak cohort
    and significantly associated with mortality in an independent Indonesian series.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Complications developed in 48.4% (n=154) cases and included: airway compromise 22.6%
      (n=72), diphtheritic cardiomyopathy 12.9% (n=41), acute kidney injury 3.7% (n=12),
      thrombocytopenia 8.5% (n=27) and hepatitis 0.6% (n=2) cases.
    explanation: >-
      Direct frequency measurement of thrombocytopenia supporting the OCCASIONAL band.
  - reference: DOI:10.52225/narra.v4i2.776
    reference_title: "Determinants of mortality in relationship between clinical and laboratory characteristics with the outcomes of children with diphtheria"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      There was also a significant association between thrombocytopenia (p=0.020) and
      mortality in diphtheria patients.
    explanation: >-
      Independent cohort linking thrombocytopenia to mortality.
clinical_burden:
  burden_level: HIGH
  rationale: >-
    Untreated toxin-mediated diphtheria kills. Contemporary outbreak cohorts report case
    fatality of 17.9% in a 318-child Indian series and 330 deaths among 5701 probable cases
    in Yemen, with cardiac involvement the leading cause of death and airway obstruction
    carrying roughly thirteenfold higher odds of dying. Survivors of severe disease face
    weeks of bulbar and limb weakness before recovery. The burden is almost entirely
    preventable by toxoid vaccination, which is what makes it a burden of programme failure
    rather than of the organism.
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tracheostomy was done in (n=57) (17.9%) children. Case fatality rate was 17.9%.
    explanation: >-
      Contemporary paediatric outbreak case fatality supporting the HIGH burden level.
  - reference: PMID:35544196
    reference_title: "Ongoing diphtheria outbreak in Yemen: a cross-sectional and genomic epidemiology study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The Yemen diphtheria outbreak affected almost all governorates (provinces), with
      5701 probable cases and 330 deaths recorded up to April 26, 2020.
    explanation: >-
      Independent outbreak mortality figures corroborating the burden assessment.
environmental:
- name: Person-to-person respiratory transmission of toxigenic Corynebacterium diphtheriae
  description: >-
    Classical diphtheria is a human-to-human respiratory infection: humans are the only
    reservoir of C. diphtheriae, and it spreads by respiratory secretions and by contact
    with skin lesions. Crowding, displacement and collapsed immunization programmes are the
    conditions under which it propagates, which is why outbreaks track conflict and
    humanitarian crisis rather than any change in the organism.
  exposure_term:
    preferred_term: exposure to toxigenic Corynebacterium diphtheriae via respiratory
      secretions
    term:
      id: ECTO:3000000
      label: exposure to organism
  notes: >-
    Bound to ECTO:3000000 exposure to organism, the most specific applicable ECTO term:
    ECTO has no Corynebacterium class and no class for a bacterial pathogen acquired by
    respiratory droplet, so the organism and the route are carried by preferred_term. Same
    general-but-accurate-ancestor pattern as the Brucellosis livestock exposure and as the
    HP:0033151 binding on the pseudomembrane phenotype in this entry.
  influences_mechanisms:
  - target: Mucosal Colonization and Adherence
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Acquisition of the organism from another person is the route by which the pharyngeal
      or cutaneous surface becomes colonized, the first step of the pathograph.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        However, the exclusively zoonotic transmission of C. ulcerans, which is typically
        transmitted to humans through domestic dogs and cats, implies its exclusion as an
        agent of classical diphtheria, defined as the toxigenic C. diphtheriae respiratory
        infection transmitted among humans.
      explanation: >-
        Defines classical diphtheria as a respiratory infection transmitted between humans,
        the exposure route this link encodes.
  evidence:
  - reference: DOI:10.4314/ajcem.v24i2.2
    reference_title: "A review of the current diphtheria outbreaks"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Humans are the only hosts of the organism and is present in the upper respiratory
      tract.
    explanation: >-
      Establishes humans as the sole reservoir of C. diphtheriae, which is what makes
      person-to-person spread the transmission route for classical diphtheria.
  - reference: DOI:10.4314/ajcem.v24i2.2
    reference_title: "A review of the current diphtheria outbreaks"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The predisposing factor for this disease is the failure to immunize
    explanation: >-
      Identifies failure of immunization as the predisposing condition under which this
      exposure produces disease.
- name: Contact with companion or farm animals carrying toxigenic Corynebacterium ulcerans
  description: >-
    C. ulcerans is acquired from animals rather than from other people; dogs, cats and farm
    livestock are the documented reservoirs. This is the route by which diphtheria still
    reaches well-vaccinated populations, and it is why C. ulcerans is now the species most
    often reported in high-income countries.
  exposure_term:
    preferred_term: exposure to toxigenic Corynebacterium ulcerans via animal contact
    term:
      id: ECTO:3000000
      label: exposure to organism
  notes: >-
    Bound to ECTO:3000000 for the same reason as the respiratory exposure above: ECTO has
    no Corynebacterium class and no animal-contact class for a bacterial pathogen, so the
    organism and the route stay in preferred_term.
  influences_mechanisms:
  - target: Mucosal Colonization and Adherence
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: >-
      Animal contact delivers toxigenic C. ulcerans to the human respiratory or cutaneous
      surface, where it colonizes and, if toxigenic, initiates the same toxin cascade.
    evidence:
    - reference: PMID:37957801
      reference_title: "Zoonotic transmission of diphtheria toxin-producing Corynebacterium ulcerans."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        We successfully identified companion canines as probable sources for the human
        case, with WGS confirming the link.
      explanation: >-
        Genomically confirmed animal-to-human acquisition, the exposure route this link
        encodes.
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      However, the exclusively zoonotic transmission of C. ulcerans, which is typically
      transmitted to humans through domestic dogs and cats, implies its exclusion as an
      agent of classical diphtheria, defined as the toxigenic C. diphtheriae respiratory
      infection transmitted among humans.
    explanation: >-
      States the zoonotic route and names dogs and cats as the usual sources.
biochemical:
- name: Serum diphtheria antitoxin titre
  presence: PRESENT
  context: Population serosurveillance and individual susceptibility assessment
  notes: >-
    Measured by toxin neutralization test (TNT), the reference method, or by anti-toxoid
    ELISA, which is cheaper but correlates poorly with TNT at low titres and therefore
    understates the susceptible fraction of a population unless its threshold is
    recalibrated against TNT. Dried blood spots perform well against TNT and are a viable
    low-cost alternative to serum in low- and middle-income settings.
  reference_ranges:
  - unit: IU/mL
    population: General population, toxin neutralization test
    notes: >-
      The source establishes 0.01 and 0.1 IU/mL as the two reference cut-offs used in TNT
      and identifies titres below 0.01 IU/mL as the susceptible fraction. It does not label
      the 0.01-0.1 IU/mL interval, so no protective category is asserted for it here.
    evidence:
    - reference: DOI:10.1099/jmm.0.001721
      reference_title: "Evaluation and validation of a commercial ELISA versus the in vitro toxin neutralization assay for determination of diphtheria anti-toxin in human serum"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        The cut-off values for ELISA measurement corresponding to the TNT cut-off values of
        0.01 IU ml−1 were 0.060 IU ml−1 in serum samples, and 0.044 IU ml−1 in DBS samples.
      explanation: >-
        Establishes 0.01 IU/mL as a TNT reference cut-off and gives the ELISA values that
        correspond to it.
    interpretation_bands:
    - name: Susceptible
      upper_bound: 0.01
      unit: IU/mL
      abnormal_flag: LOW
      interpretation: >-
        Titres below 0.01 IU/mL identify the susceptible fraction of a population.
    - name: Above the lower reference cut-off
      lower_bound: 0.01
      unit: IU/mL
      abnormal_flag: NORMAL
      interpretation: >-
        At or above the lower TNT cut-off. The source names 0.1 IU/mL as a second reference
        cut-off without defining a category for it, so no finer band is asserted.
  evidence:
  - reference: DOI:10.1099/jmm.0.001721
    reference_title: "Evaluation and validation of a commercial ELISA versus the in vitro toxin neutralization assay for determination of diphtheria anti-toxin in human serum"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The correlation between the ELISA results against diphtheria toxoid and the gold
      standard diphtheria toxin neutralization test (TNT) values is poor when ELISA values
      are <0.1 IU ml−1, which results in inaccurate estimates of susceptibility in
      populations when ELISA is used for measuring antibody levels.
    explanation: >-
      Identifies TNT as the reference method and states the ELISA limitation recorded in
      this marker's notes.
  - reference: DOI:10.1099/jmm.0.001721
    reference_title: "Evaluation and validation of a commercial ELISA versus the in vitro toxin neutralization assay for determination of diphtheria anti-toxin in human serum"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      DBS is an effective low-cost alternative to serum for future serological studies for
      diphtheria.
    explanation: >-
      Source for the dried-blood-spot recommendation recorded here.
- name: Brain natriuretic peptide and creatine kinase MB
  presence: INCREASED
  context: Cardiac involvement in respiratory diphtheria
  notes: >-
    Cardiac biomarkers are elevated when diphtheritic myocarditis is present. They are
    monitoring markers rather than diagnostic ones: diphtheria is diagnosed clinically and
    microbiologically, and endomyocardial biopsy or cardiac MRI is not required.
  evidence:
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The brain-type natriuretic peptide level at presentation was 1200 pg/mL, and the
      creatine kinase myocardial band was 35 U/L, both of which were elevated.
    explanation: >-
      Reports both cardiac markers as elevated at presentation in diphtheritic myocarditis.
  - reference: PMID:36589640
    reference_title: "Diphtheritic myocarditis: An unusual and reversible cause of heart failure."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      EMB or cardiac MRI is not necessary for its diagnosis.
    explanation: >-
      Supports treating cardiac imaging and biopsy as monitoring rather than diagnostic
      steps, as recorded in this marker's notes.
progression:
- phase: Bulbar phase
  duration: First 2 weeks after the onset of oropharyngeal disease
  notes: >-
    Palatal and posterior pharyngeal weakness is the first neurological
    manifestation and reflects local toxin action on adjacent nerves rather than
    haematogenous spread.
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Bulbar dysfunction typically develops during the first 2 weeks.
    explanation: >-
      Directly dates the bulbar phase recorded here.
- phase: Oculomotor and ciliary phase
  duration: After about 3 weeks
  notes: >-
    Accommodation paralysis and other oculomotor findings appear later than the
    bulbar signs and are regarded as distinctive for diphtheritic neuropathy.
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Oculomotor and ciliary paralyses seen after 3 weeks are common and
      distinctive features of DP.
    explanation: >-
      Dates the oculomotor phase and identifies it as characteristic.
- phase: Generalized peripheral neuritis
  duration: 10 days to 3 months after the onset of oropharyngeal disease
  notes: >-
    The descending symmetric polyneuropathy that follows haematogenous toxin
    dissemination. Its long and variable latency is why patients need
    neurological follow-up for months after the acute illness resolves.
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Peripheral neuritis develops later, from 10 days to 3 months after the onset
      of oropharyngeal disease.
    explanation: >-
      Source for the latency window recorded on this phase.
- phase: Neurological recovery
  duration: 2 to 6 weeks from the onset of neurological symptoms
  notes: >-
    Recovery is usually complete because the lesion is demyelinating and axons are
    preserved; children with isolated bulbar palsy recover faster than those who
    progress to quadriparesis.
  evidence:
  - reference: PMID:26962337
    reference_title: "Diphtheritic polyneuropathy in the wake of resurgence of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Children with isolated bulbar palsy recovered within 2 to 4 weeks while
      children with quadriparesis recovered within 5-6 wks.
    explanation: >-
      Source for the recovery intervals and their dependence on severity.
diagnosis:
- name: Culture and toxigenicity testing
  description: >-
    Diagnosis is clinical and is confirmed by isolating a member of the C. diphtheriae
    species complex and then demonstrating toxin production. Species identification alone
    is insufficient, because tox-bearing isolates may still fail to express toxin: in the
    French Guiana series five isolates were tox-positive by PCR yet all were negative by
    Elek test. Phenotypic toxigenicity testing therefore governs whether antitoxin is
    indicated.
  evidence:
  - reference: DOI:10.3390/pathogens11111264
    reference_title: "New Corynebacterium Species with the Potential to Produce Diphtheria Toxin"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      However, ‘nontoxigenic tox gene-bearing’ (NTTB) strains, which are genotypically
      tox-positive but do not express the protein, have been described.
    explanation: >-
      Names the NTTB phenomenon that makes phenotypic toxigenicity testing, rather than tox
      PCR alone, the step that governs treatment.
  - reference: PMID:31804499
    reference_title: "Diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Clinical diagnosis is confirmed by the isolation and identification of the causative
      Corynebacterium spp., usually by bacterial culture followed by enzymatic and toxin
      detection tests.
    explanation: >-
      Describes the culture-then-toxin-detection sequence this diagnostic entry represents.
  - reference: DOI:10.3201/eid3008.231671
    reference_title: "Retrospective Study of Infections with Corynebacterium diphtheriae Species Complex, French Guiana, 2016-2021"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      5 tested positive for the diphtheria toxin gene, and all results were negative by
      Elek test
    explanation: >-
      Demonstrates the gap between tox gene carriage and toxin expression that makes
      phenotypic testing necessary.
treatments:
- name: Diphtheria Antitoxin
  description: >-
    Equine hyperimmune serum containing polyclonal antibody against diphtheria toxin. It is
    the only treatment that addresses the toxin itself and it neutralizes only toxin that
    has not yet entered cells, so benefit falls sharply with delay; administration five or
    more days after onset is associated with higher mortality. Adverse reactions to horse
    protein are frequent, and global supply has been constrained for years, which is itself
    a recognized contributor to outbreak mortality.
  treatment_term:
    preferred_term: immunoglobulin therapy
    term:
      id: NCIT:C62710
      label: Immunoglobulin Therapy
  therapeutic_modality: OTHER
  target_mechanisms:
  - target: Diphtheria Toxin Binding to the proHB-EGF Receptor
    description: >-
      Circulating antibody binds free toxin and prevents it engaging proHB-EGF, which is why
      antitoxin cannot help once toxin has been internalized.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        The pathological effects caused by its main virulence factor, diphtheria toxin, can
        be diminished by passive transfer of antibodies.
      explanation: >-
        States that passively transferred antibody diminishes the toxin's pathological
        effects, the neutralization step this link targets.
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Equine diphtheria antitoxin (eDAT), the cornerstone of treatment against toxinic
      complications of diphtheria, was invented more than 130 years ago, in 1890, and is
      still in use today.
    explanation: >-
      Establishes equine antitoxin as the cornerstone treatment for the toxin-mediated
      complications.
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      But eDAT, being produced from horse serum, has frequent adverse effects, including
      anaphylactic reactions to horse proteins, fever and serum sickness.
    explanation: >-
      Source for the adverse-effect burden recorded in this treatment description.
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Mortality was high in unimmunized or partially immunized young children and those
      with bull neck, pseudomembrane, delayed (≥5 days) administration of ADS, acute kidney
      injury, thrombocytopenia and leukocytosis.
    explanation: >-
      Supports the time-dependence of antitoxin benefit: delayed administration is
      associated with higher mortality.
  notes: >-
    therapeutic_modality is recorded as OTHER because equine polyclonal hyperimmune serum is
    neither a monoclonal antibody nor any other listed platform. A human monoclonal
    replacement (S315) has completed phase I but is not licensed.
- name: Macrolide Antibiotic Therapy
  description: >-
    Azithromycin, erythromycin or clarithromycin, recommended by WHO in 2024 as first-line
    antimicrobial therapy in preference to penicillin. Antibiotics eradicate the organism,
    stop further toxin production and end transmissibility, but they do not neutralize toxin
    already released and are never a substitute for antitoxin. Macrolide resistance is
    documented and susceptibility testing should guide therapy where available.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: azithromycin
      term:
        id: CHEBI:2955
        label: azithromycin
    - preferred_term: erythromycin
      term:
        id: CHEBI:48923
        label: erythromycin
    - preferred_term: clarithromycin
      term:
        id: CHEBI:3732
        label: clarithromycin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Bacterial mRNA Translation by the Ribosome (Macrolide Target)
    description: >-
      Macrolides bind the 50S ribosomal subunit and arrest bacterial protein synthesis,
      killing or suppressing the organism and cutting off further toxin production.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        In February 2024, in the context of the 2023 West African diphtheria outbreak, WHO
        published a new guideline for the clinical management of diphtheria, where the
        first-line use of macrolide antibiotics (azithromycin, erythromycin) is recommended
        in preference to penicillin.
      explanation: >-
        Identifies the macrolides that act on this ribosomal target as WHO first-line
        therapy.
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Antibiotics should be administered alongside eDAT, and should not be delayed.
      Penicillin (penicillin G intravenous or intramuscular; penicillin V oral) or
      macrolides (azithromycin, erythromycin) have been recommended as first line
      antimicrobial therapies.
    explanation: >-
      Establishes macrolides as recommended first-line antimicrobial therapy given alongside
      antitoxin.
  - reference: PMID:9798043
    reference_title: "Penicillin vs. erythromycin in the treatment of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: DIRECT
    snippet: >-
      All isolates were susceptible to penicillin, but for isolates (27%), all of which were
      from patients who received penicillin treatment, were resistant to erythromycin
      (minimum inhibitory concentrations, > 64 mg/L).
    explanation: >-
      Documents erythromycin resistance among clinical isolates, which is the caveat this
      treatment's description records: susceptibility testing should guide macrolide use
      where it is available. Graded DIRECT because the trial reports the resistance itself
      rather than something the caveat is inferred from.
- name: Benzylpenicillin
  description: >-
    Intravenous or intramuscular benzylpenicillin, used as an alternative to a macrolide and
    combined with one in severe disease under UK guidance. In the only randomized comparison
    in diphtheria, penicillin cleared fever significantly faster than erythromycin with no
    difference in membrane or bacteriological clearance, and all isolates in that trial
    remained penicillin-susceptible.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: benzylpenicillin
      term:
        id: CHEBI:18208
        label: benzylpenicillin
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Bacterial Peptidoglycan Cross-Linking (Beta-Lactam Target)
    description: >-
      Benzylpenicillin acylates the penicillin-binding protein transpeptidase and halts
      peptidoglycan cross-linking.
    evidence:
    - reference: PMID:9798043
      reference_title: "Penicillin vs. erythromycin in the treatment of diphtheria."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      directness: INDIRECT
      snippet: >-
        All isolates were susceptible to penicillin, but for isolates (27%), all of which
        were from patients who received penicillin treatment, were resistant to erythromycin
        (minimum inhibitory concentrations, > 64 mg/L).
      explanation: >-
        Documents retained penicillin susceptibility of the isolates, establishing that this
        drug target is intact. Graded INDIRECT because susceptibility is reported rather than
        the transpeptidase mechanism, which is carried on the target node.
  evidence:
  - reference: PMID:9798043
    reference_title: "Penicillin vs. erythromycin in the treatment of diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Penicillin is recommended as first-line treatment for diphtheria in Vietnam.
    explanation: >-
      Trial conclusion recommending penicillin as first-line therapy in that setting.
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      For severe disease, intravenous benzylpenicillin should be combined with a macrolide;
      in patients who are both extremely and systemically unwell, a third agent such as IV
      vancomycin or linezolid is considered until local susceptibility results are available.
    explanation: >-
      Source for the combination use of benzylpenicillin with a macrolide in severe disease.
- name: Diphtheria Toxoid Vaccination
  description: >-
    Formaldehyde-inactivated diphtheria toxin, given in combination vaccines through
    childhood with life-course boosters. It induces neutralizing antitoxin and prevents
    toxin-mediated disease rather than colonization, and the antibody it raises also
    recognizes the toxin of C. ulcerans. It is the intervention that turned diphtheria from
    a leading cause of childhood death into a disease of immunization-programme failure.
  treatment_term:
    preferred_term: vaccination
    term:
      id: NCIT:C15346
      label: Vaccination
    therapeutic_agent:
    - preferred_term: diphtheria and tetanus toxoids vaccine
      term:
        id: NCIT:C91718
        label: Diphtheria Toxoid/Tetanus Toxoid Vaccine Adsorbed
  therapeutic_modality: VACCINE
  target_mechanisms:
  - target: Absent or Waning Antitoxin Immunity
    description: >-
      Toxoid immunization converts the susceptible, antitoxin-negative host state into a
      protected one by raising neutralizing antibody.
    evidence:
    - reference: PMID:39841756
      reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Diphtheria toxoid vaccination, which is prepared from detoxified DT of C.
        diphtheriae strain Park-Williams 8, raises antibodies that recognise DT from C.
        ulcerans.
      explanation: >-
        States that toxoid vaccination raises anti-toxin antibody, the host state this
        treatment restores.
  evidence:
  - reference: PMID:31804499
    reference_title: "Diphtheria."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although effective vaccines are available, this disease has the potential to re-emerge
      in countries where the recommended vaccination programmes are not sustained, and
      increasing proportions of adults are becoming susceptible to diphtheria.
    explanation: >-
      Establishes vaccine effectiveness and identifies programme failure and waning adult
      immunity as the conditions for re-emergence.
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    directness: INDIRECT
    snippet: >-
      none of 39 fully vaccinated cases presented with classic respiratory diphtheria with
      pseudomembrane, whereas 14 out of 43 unvaccinated or incompletely vaccinated cases
      presented with these symptoms (p < 0.001).
    explanation: >-
      Comparative evidence that vaccination prevents the defining toxin-mediated lesion.
      Graded INDIRECT because the comparison is restricted to Corynebacterium ulcerans
      cases, so reading it as evidence about diphtheria toxoid generally takes an inference
      step. Separately from directness, it is an uncontrolled observational comparison, and
      the review reporting it states there is no randomised trial of vaccine efficacy for
      that species.
  - reference: PMID:24365424
    reference_title: "Neurologic manifestations of diphtheria and pertussis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Vaccination against diphtheria and pertussis in children and booster vaccination in
      adults is recommended.
    explanation: >-
      Supports the childhood-plus-booster schedule described here.
- name: Tracheotomy
  description: >-
    Surgical airway control for laryngeal obstruction by membrane and oedema, required in
    17.9% of children in a large outbreak cohort. It treats the mechanical consequence of
    the local lesion, not the toxin. Endotracheal intubation serves the same purpose where
    it is feasible, but it is a separate, non-surgical intervention and is not covered by
    this entry's NCIT binding or modality.
  treatment_term:
    preferred_term: tracheotomy
    term:
      id: NCIT:C15341
      label: Tracheotomy
  therapeutic_modality: SURGERY
  target_mechanisms:
  - target: Upper Airway Obstruction
    description: >-
      Bypassing the obstructed larynx relieves the airway compromise caused by the membrane
      without affecting the underlying toxin-mediated process.
    evidence:
    - reference: PMID:36633113
      reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: >-
        Tracheostomy was done in (n=57) (17.9%) children. Case fatality rate was 17.9%.
      explanation: >-
        Quantifies how often surgical airway control was required in an outbreak cohort with
        22.6% airway compromise.
  evidence:
  - reference: PMID:36633113
    reference_title: "Clinico-Epidemiological Profile and Predictors of Poor Outcome Among Children During a Diphtheria Outbreak in Haryana."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Tracheostomy was done in (n=57) (17.9%) children. Case fatality rate was 17.9%.
    explanation: >-
      Documents the use of surgical airway control in the management of this outbreak.
animal_models:
- name: Guinea pig diphtheria toxin intoxication and lethality model
  species: Guinea pig
  category: Toxin challenge model
  publication: PMID:23940209
  description: >-
    Subcutaneous challenge with a calibrated dose of purified diphtheria toxin in
    Hartley guinea pigs, monitored for 30 days for dehydration, hind-limb weakness,
    lethargy and death. It is the accepted in vivo system for diphtheria
    intoxication and the standardized assay by which antitoxin potency is measured
    in international units. Guinea pigs are used because mice and rats are
    naturally resistant, a difference that traces to the toxin receptor itself.
  evidence:
  - reference: PMID:23940209
    reference_title: "Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of diphtheria intoxication."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      The guinea pig is the accepted model system for the study of diphtheria
      intoxication due to its sensitivity to the toxin compared to the highly
      resistant mouse and rat.
    explanation: >-
      Establishes the guinea pig as the accepted in vivo model and names the rodent
      resistance that excludes mice and rats.
  modeled_mechanisms:
  - target: Translational Arrest and Host Cell Death
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Parenteral toxin challenge reproduces the systemic toxin-mediated illness and
      death that follow translational arrest in host tissues, and it is sensitive
      enough to grade antitoxin potency quantitatively.
    limitations: >-
      This is an intoxication model, not an infection model. Toxin is injected
      rather than elaborated by an adherent organism, so it bypasses mucosal
      colonization, pseudomembrane formation and the local-versus-haematogenous
      distinction that governs the clinical sequence in humans. It therefore
      speaks to what the toxin does, not to how much toxin a colonized patient
      actually absorbs.
    readouts:
    - name: 30-day survival after calibrated toxin challenge
      target: Translational Arrest and Host Cell Death
      description: >-
        Survival and symptom-free status at day 30 after subcutaneous challenge,
        with and without neutralizing antibody.
      direction: RESTORED
      interpretation: >-
        Complete protection by a neutralizing antibody establishes that lethality
        in this model is attributable to the toxin acting on this node.
      evidence:
      - reference: PMID:23940209
        reference_title: "Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of diphtheria intoxication."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          In addition, 25 μg of 315C4 completely protected guinea pigs from
          intoxication in an in vivo lethality model, yielding an estimated relative
          potency of 64 IU/mg.
        explanation: >-
          Reports the survival readout and its quantification in potency units.
    - name: Symptoms of diphtheria intoxication
      target: Translational Arrest and Host Cell Death
      description: >-
        Dehydration, hind-limb weakness and lethargy scored over 30 days of
        observation.
      direction: INCREASED
      interpretation: >-
        Hind-limb weakness in the challenged animal is the model counterpart of the
        toxin-mediated neuropathy seen in patients.
      evidence:
      - reference: PMID:23940209
        reference_title: "Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of diphtheria intoxication."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Animals were closely monitored over 30 days for symptoms of diphtheria
          intoxication which includes symptoms such as dehydration, hind-limb
          weakness, and lethargy.
        explanation: >-
          Names the clinical signs scored as the symptomatic readout in this model.
    evidence:
    - reference: PMID:23940209
      reference_title: "Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of diphtheria intoxication."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        A guinea pig lethality model has been well established and standardized for
        the measurement of DAT potency of neutralizing diphtheria toxin and
        subsequently preventing mortality
      explanation: >-
        Establishes this model as the standardized in vivo system for measuring toxin
        neutralization, which is what makes it informative for the translational-arrest
        and cell-death node.
  - target: Diphtheria Toxin Binding to the proHB-EGF Receptor
    relationship: MEASURES
    fidelity: HIGH
    description: >-
      Because protection in this model tracks the ability of an antibody to keep
      toxin off its receptor, the assay is a functional readout of the
      receptor-binding step. The lead human monoclonal was shown to act precisely
      there, blocking toxin binding to HB-EGF.
    limitations: >-
      The model reports the net consequence of blocking receptor engagement rather
      than measuring binding directly; the receptor-blockade mechanism was
      established in a separate in vitro assay.
    readouts:
    - name: Blockade of toxin binding to HB-EGF
      target: Diphtheria Toxin Binding to the proHB-EGF Receptor
      description: >-
        Antibody-mediated inhibition of diphtheria toxin binding to recombinant
        human HB-EGF, mapped to the toxin receptor-binding domain.
      direction: ABOLISHED
      interpretation: >-
        Confirms that neutralization acts at the receptor-binding step modelled by
        this node.
      evidence:
      - reference: PMID:23940209
        reference_title: "Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of diphtheria intoxication."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          We further established that our lead candidate hMAb binds to the
          receptor-binding domain of diphtheria toxin and physically blocks the
          toxin from binding to the putative receptor, heparin-binding epidermal
          growth factor-like growth factor.
        explanation: >-
          Demonstrates that the neutralizing antibody acts by blocking the
          toxin-receptor interaction this node represents.
    evidence:
    - reference: PMID:23940209
      reference_title: "Identification of a human monoclonal antibody to replace equine diphtheria antitoxin for treatment of diphtheria intoxication."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        In addition, 25 μg of 315C4 completely protected guinea pigs from intoxication
        in an in vivo lethality model, yielding an estimated relative potency of 64
        IU/mg.
      explanation: >-
        In-animal protection by an antibody whose only established action is blocking
        toxin binding to HB-EGF is what makes this model informative for the
        receptor-binding node.
clinical_trials:
- name: NCT04075175
  phase: PHASE_I
  status: COMPLETED
  description: >-
    First-in-human, randomized, triple-masked, dose-escalating study of S315, a fully human
    monoclonal antibody against diphtheria toxin, in 41 healthy adults. It evaluates safety
    and pharmacokinetics only, not efficacy in patients, but it is the lead candidate to
    replace the equine antitoxin whose supply and adverse-effect profile currently limit
    diphtheria care.
  evidence:
  - reference: clinicaltrials:NCT04075175
    reference_title: "A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (mAb) S315 Against Diphtheria Toxin"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      S315 is a monoclonal antibody that is being developed for treatment of diphtheria.
    explanation: >-
      Registry record establishing S315 as a monoclonal antitoxin in clinical development
      for diphtheria.
discussions:
- discussion_id: human_monoclonal_antitoxin_replacement
  kind: KNOWLEDGE_GAP
  prompt: >-
    Can a human monoclonal antitoxin replace equine diphtheria antitoxin, and does earlier
    availability translate into lower mortality?
  attaches_to:
  - treatments#Diphtheria Antitoxin
  - pathophysiology#Systemic Toxin Dissemination
  rationale: >-
    Equine antitoxin is a 130-year-old product with frequent hypersensitivity reactions and
    a chronically constrained global supply, and antitoxin shortage is repeatedly identified
    as a contributor to outbreak mortality. A recombinant human replacement would remove both
    the adverse-effect burden and the animal-dependent manufacturing bottleneck. S315 has
    completed phase I in healthy volunteers, but no efficacy trial in patients exists, and
    because the mechanism is time-critical neutralization of extracellular toxin, an efficacy
    trial has to measure time-to-administration as well as the agent itself.
  evidence:
  - reference: PMID:39841756
    reference_title: "Diphtheria antitoxin treatment: from pioneer to neglected."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The resurgence of diphtheria cases, associated with poor vaccination coverage in
      multiple settings and shortage of existing eDAT products, underlines the urgent need
      for alternative DAT strategies.
    explanation: >-
      States the supply-driven need for an antitoxin alternative that this gap describes.
  - reference: DOI:10.1038/s41598-019-57103-5
    reference_title: "Human antibodies neutralizing diphtheria toxin in vitro and in vivo"
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      These recombinant antibody combinations are candidates for further clinical and
      regulatory development to replace equine DAT.
    explanation: >-
      Preclinical recombinant-antibody work proposing replacement of equine antitoxin, the
      line of development this gap asks about.
- discussion_id: rodent_hbegf_species_barrier
  kind: HUMAN_MODEL_MISMATCH
  prompt: >-
    Mice and rats are naturally resistant to diphtheria toxin because their proHB-EGF binds
    it poorly; how far can rodent work be trusted to describe human diphtheria?
  attaches_to:
  - pathophysiology#Diphtheria Toxin Binding to the proHB-EGF Receptor
  rationale: >-
    The species barrier sits at the very first step of the toxin cascade. Wild-type rodents
    cannot be intoxicated at physiological doses, so rodent studies either use transgenic
    animals expressing a toxin-sensitive receptor or bypass the receptor entirely, and
    neither reproduces the natural respiratory colonization that precedes intoxication.
    Guinea pigs are toxin-sensitive and remain the potency and neutralization model, but they
    are intoxication models rather than infection models. Claims about tissue tropism and the
    relative vulnerability of cardiomyocytes and Schwann cells therefore rest largely on human
    autopsy and biopsy material rather than on a faithful animal model.
  evidence:
  - reference: PMID:1606612
    reference_title: "Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Mouse cells are naturally resistant to DT, because they lack functional cell surface
      receptors for the toxin.
    explanation: >-
      Establishes the receptor-level species difference that limits rodent modelling of this
      disease.
notes: >-
  Concept decision: diphtheria is curated as a single Disease entry with anatomical
  has_subtypes rather than as a grouping, because every presentation shares one conserved
  pathograph - phage-encoded toxin, proHB-EGF binding, eEF2 diphthamide ADP-ribosylation,
  translational arrest - and differs only in where colonization occurs and how much toxin is
  absorbed. The systemic complications (myocarditis, neuropathy, acute kidney injury) are
  modelled as downstream pathophysiology and phenotypes rather than as subtypes, since they
  are consequences of the same mechanism reaching distant organs. MONDO:0041259 (diphtheritic
  myocarditis) is therefore represented by the Diphtheritic Myocarditis pathophysiology node
  and the Myocarditis phenotype, not by a has_subtypes entry.


  No `datasets:` block is curated. `just discover-datasets Diphtheria` returns 12 GEO
  candidates and every one of them is a diphtheria-toxin-receptor cell-ablation experiment
  (the iDTR/DTR-transgene system), in which diphtheria toxin is a laboratory tool for killing
  a targeted cell population and the study has nothing to do with diphtheria the disease.
  This is Named Entity Confusion reached through dataset search, and the correct outcome is
  an empty section rather than a plausible-looking but irrelevant accession.


  No prevalence record is curated for the French Guiana incidence series
  (DOI:10.3201/eid3008.231671), although the paper is cited elsewhere in this entry. Its
  rise from 0.7 to 7.7 cases per 100,000 per year is an occurrence rate for
  Corynebacterium diphtheriae species complex *infection*: 95% of those cases were
  cutaneous and every isolate was negative by Elek test, so none of them was toxin-mediated
  diphtheria. Recording it under `prevalence:` would put the entry's only quantitative
  population rate on a quantity that is not this disease. The paper's clinical content is
  used where it does apply, on the pseudomembrane and airway nodes and in the diagnosis
  entry.


  Corynebacterium pseudotuberculosis is named in several of the cited reviews as an
  occasional carrier of the tox gene but is deliberately not listed under
  `infectious_agent`. It causes a different disease spectrum in humans (granulomatous
  lymphadenitis), is acquired from goats and sheep, and only an exceptional subset of
  isolates has ever been found to carry tox. C. ulcerans is included because it produces a
  toxin neutralized by the same antitoxin and causes a clinically similar respiratory or
  cutaneous illness.

📚

References & Deep Research

References

2

PMID:31804499

Diphtheria.

No top-level findings curated for this source.

PMID:39841756

Diphtheria antitoxin treatment: from pioneer to neglected.

No top-level findings curated for this source.

Deep Research

1

Falcon ▸

Disease Characteristics Research Template

Edison Scientific Literature 37 citations 2026-08-28T15:17:15.099605

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

Disease Name: Diphtheria
MONDO ID: (if available)
Category: Infectious Disease

Research Objectives

Please provide a comprehensive research report on Diphtheria covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

What is the disease? Provide a concise overview.
What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
What are the common synonyms and alternative names?
Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
Risk Factors:

Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Genetic risk factors (causal variants, susceptibility loci, modifier genes)
Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
Protective Factors:

Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Genetic protective factors (protective variants, modifier alleles)
Environmental protective factors (diet, lifestyle, exposures that reduce risk)
Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Pathogenic Variants:
Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
Variant type/class (missense, frameshift, nonsense, splice-site, structural)
Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
Functional consequences (loss of function, gain of function, dominant negative)
Modifier Genes: Genes that modify disease severity or expression
Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

Search first: CDC databases, WHO, PubMed, NHANES
Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

Search first: PubMed, Gene Ontology, Reactome
Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Molecular Profiling (if available):
Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
Advanced Technologies (if applicable):
Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

Organ Level:
Primary organs directly affected
Secondary organ involvement (complications, secondary effects)
Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Tissue and Cell Level:
Specific tissue types affected (epithelial, connective, muscle, nervous)
Specific cell populations targeted (with Cell Ontology terms)

Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Subcellular Level:
Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Localization:
Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

Onset:
Typical age of onset (congenital, pediatric, adult, geriatric)
Onset pattern (acute, subacute, chronic, insidious)

Search first: OMIM, Orphanet, HPO, PubMed
Progression:
Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
Progression rate (rapid, slow, variable)
Disease course pattern (episodic, relapsing-remitting, progressive, stable)
Disease duration (self-limited, chronic lifelong)

Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Patterns:
Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

Epidemiology:
Prevalence (cases per 100,000 at given time)
Incidence (new cases per 100,000 per year)

Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
For Genetic Etiology:
Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
Population Demographics:
Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
Geographic distribution of specific variants
Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

Clinical Tests:
Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
Genetic Testing:

Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
Overview of recommended genetic testing approach
Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
FISH > Search first: ClinVar, cytogenetics databases, PubMed
Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
Omics-Based Diagnostics (if applicable):
RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
Clinical Criteria:
Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
Screening:
Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

Survival and Mortality:
Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
Morbidity and Function:
Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
Disease Course:
Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
Prediction:
Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

Pharmacotherapy:
Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
Advanced Therapeutics:
Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
Surgical and Interventional:
Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
Supportive and Rehabilitative:
Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
Experimental:
Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
Treatment Outcomes:
Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
Treatment Strategy:
Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

Prevention Levels:
Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
Immunization: Vaccine strategies (if applicable)

Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Screening and Early Detection:
Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
Behavioral Interventions: Lifestyle modifications to reduce risk

Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Counseling: Genetic counseling (risk assessment, family planning guidance)

Search first: NSGC resources, ACMG guidelines, GeneReviews
Public Health:
Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
Prophylaxis: Preventive medications or procedures

Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

Taxonomy: Species affected (with NCBI Taxon identifiers)

Search first: NCBI Taxonomy
Breed: Specific breeds affected (with VBO identifiers if applicable)

Search first: VBO (Vertebrate Breed Ontology)
Gene: Orthologous genes in other species (with NCBI Gene IDs)

Search first: NCBI Gene
Natural Disease:
Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
Comparative Biology:
Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
Transmission (if applicable):
Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

Model Types:
Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
Genetic Models:
Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
Model Characteristics:
Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
Applications:
Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
Resources:
Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

Cite primary literature (PMID preferred) for all mechanistic and clinical claims
Prioritize recent reviews and landmark papers
Include direct quotes from abstracts where possible to support key statements
Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

Diphtheria: comprehensive disease-characteristics report

Scope and evidence note. Diphtheria is an infectious, toxin-mediated disease rather than a Mendelian disorder. Accordingly, pathogen genetics, toxigenicity, immunity, exposure, and health-system factors are much more relevant than human causal variants. Evidence below is labeled where useful as human clinical, laboratory/in-vitro, animal, or surveillance/review. Publication dates and DOI URLs are supplied for the major retrieved sources; several requested ontology mappings are curator suggestions and should be validated against the current ontology release.

Domain	Key facts	Quantitative/current evidence	Suggested ontology terms
Etiology / transmission	Acute toxin-mediated bacterial infection classically caused by toxigenic Corynebacterium diphtheriae; other CdSC species, especially C. ulcerans and rarely C. pseudotuberculosis, can produce diphtheria toxin. Transmission is mainly respiratory droplets for respiratory disease and direct/indirect contact for cutaneous disease; zoonotic transmission is important for C. ulcerans. Incubation usually 2–5 days. (osarenren2024globalstrategiesfor pages 2-4, prygiel2022newcorynebacteriumspecies pages 1-2, chene2024cutaneousdiphtheriafrom pages 1-2, museux2023corynebacteriaofthe pages 1-2)	2024 review reported 27,991 suspected cases and 828 deaths across 5 African countries; untreated contagious period 2–3 weeks vs ~1 day after antibiotics in cited review synthesis. In French cutaneous cohort, 39% of isolates were toxigenic; species were C. diphtheriae 77% and C. ulcerans 23%. (osarenren2024globalstrategiesfor pages 2-4, chene2024cutaneousdiphtheriafrom pages 1-2)	MONDO: diphtheria; MeSH: Diphtheria; NCIT: Infectious Process; NCBITaxon: C. diphtheriae, C. ulcerans
Phenotypes	Core respiratory phenotype: sore throat/pharyngitis, low-grade fever, adherent gray-white pseudomembrane, cervical lymphadenopathy, “bull neck,” dysphagia, airway obstruction. Cutaneous phenotype: chronic ulcer or nonhealing wound, often on limbs, sometimes with gray membrane. Major complications: myocarditis, neuritis/polyneuropathy, respiratory failure. (muhammed2018diphtheriathestrangling pages 2-3, chene2024cutaneousdiphtheriafrom pages 1-2, museux2023corynebacteriaofthe pages 1-2, dinanti2024determinantsofmortality pages 1-2)	In French cutaneous cohort: lower limbs 86.9%, ulcerations 82%, polymicrobial lesions 88.9%. In a 2024 pediatric mortality study, myocarditis and airway obstruction were significantly associated with death; airway obstruction carried ~13-fold higher mortality odds. (chene2024cutaneousdiphtheriafrom pages 1-2, dinanti2024determinantsofmortality pages 1-2)	HPO: HP:0030247 Pseudomembranous pharyngitis; HP:0002039 Dysphagia; HP:0001644 Dilated cardiomyopathy / myocarditis-related cardiac dysfunction; HP:0001257 Spasticity not appropriate—prefer HP:0009830 Peripheral neuropathy; HP:0012735 Cutaneous ulcer; HP:0000456 Neck swelling
Mechanism / pathophysiology	Disease has two linked layers: local mucosal/skin infection and systemic toxemia. Diphtheria toxin is phage-encoded, secreted by lysogenized strains; receptor-binding domain binds HB-EGF/proHB-EGF, toxin enters via receptor-mediated endocytosis, acidic endosome enables translocation, catalytic domain ADP-ribosylates EF-2, blocking protein synthesis and causing cell death. Toxin expression is regulated in part by DtxR and iron availability. (wenzel2020humanantibodiesneutralizing pages 1-2, prygiel2022newcorynebacteriumspecies pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)	DT is a 535-aa, ~58 kDa polypeptide with catalytic, transmembrane, and receptor-binding domains. Genome studies show acquisition of tox plus iron-uptake, adhesin, and fimbrial determinants. NTTB strains exist and may be tox-positive but non-expressing. (wenzel2020humanantibodiesneutralizing pages 1-2, prygiel2022newcorynebacteriumspecies pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)	GO:0006412 translation; GO:0042776 mitochondrial ATP synthesis not central—prefer GO:0017148 negative regulation of translation by toxin not standard; GO:0009405 pathogenesis; GO:0019219 regulation of nucleobase-containing compound metabolic process; GO:0006886 intracellular protein transport
Anatomy / cells	Primary sites are upper respiratory tract mucosa (tonsils, pharynx, larynx, trachea) and skin. Secondary systemic injury affects myocardium and peripheral nerves; kidneys can also be affected. Cell-level involvement includes mucosal epithelial cells, keratinocytes, cardiomyocytes, and peripheral neurons/Schwann-cell-associated tissues. (osarenren2024globalstrategiesfor pages 2-4, wenzel2020humanantibodiesneutralizing pages 1-2, museux2023corynebacteriaofthe pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)	Respiratory obstruction from pseudomembrane can cause fatal asphyxia; in cutaneous French series, lower limbs predominated. Human toxin complications reflect hematogenous spread to distant organs. (chene2024cutaneousdiphtheriafrom pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)	UBERON: pharynx, palatine tonsil, larynx, trachea, skin, heart, peripheral nerve; CL: epithelial cell, keratinocyte, cardiomyocyte, neuron, Schwann cell
Diagnostics	Diagnosis is clinical first when compatible membrane/airway disease is present; confirm with culture, species identification, and toxigenicity testing. Culture may use tellurite media; current workflows commonly add tox PCR and reference-lab confirmation; Elek test remains classical phenotypic toxin-expression assay. Serology is useful for population immunity studies, not acute diagnosis. (gaillet2024retrospectivestudyof pages 1-2, muhammed2018diphtheriathestrangling pages 2-3, chene2024cutaneousdiphtheriafrom pages 1-2)	In French Guiana, 61 C. diphtheriae isolates included 5 tox-gene positive, all Elek-negative. In Kitamura 2023, ELISA cutoffs corresponding to TNT 0.01 IU/mL were 0.060 IU/mL (serum) and 0.044 IU/mL (DBS); applying 0.06 IU/mL to a Vietnam serosurvey classified 54% as susceptible, while multiple-imputation estimate was 35%. (gaillet2024retrospectivestudyof pages 1-2, kitamura2023evaluationandvalidation pages 1-2, kitamura2023evaluationandvalidation pages 6-9, kitamura2023evaluationandvalidation pages 3-6)	NCIT: Polymerase Chain Reaction; LOINC concepts for bacterial culture and antitoxin serology; MeSH: Elek Test
Treatment	Immediate therapy should not await lab confirmation when respiratory diphtheria is suspected. Mainstays: diphtheria antitoxin/antiserum to neutralize circulating toxin, antibiotics (classically penicillin or erythromycin), isolation, airway management, cardiac monitoring, and update of immunization after recovery. (osarenren2024globalstrategiesfor pages 1-2, muhammed2018diphtheriathestrangling pages 1-2, dinanti2024determinantsofmortality pages 1-2)	Historical/modern reviews report overall fatality commonly 5–10%, higher in young children; untreated/unvaccinated severe cases may approach ~29% in review synthesis. 2024 pediatric cohorts identify airway obstruction and myocarditis as major mortality drivers. (osarenren2024globalstrategiesfor pages 1-2, wenzel2020humanantibodiesneutralizing pages 1-2, dinanti2024determinantsofmortality pages 1-2)	NCIT: Antitoxin Therapy; Penicillin; Erythromycin; Anti-Bacterial Agent; Airway Management; Cardiac Monitoring
Prevention / public health	Prevention is dominated by diphtheria toxoid-containing vaccination, booster maintenance, rapid case recognition, isolation, prophylaxis and vaccination of close contacts, and surveillance. Cutaneous disease also requires wound/contact control; zoonotic C. ulcerans requires animal-human interface management. (osarenren2024globalstrategiesfor pages 1-2, osarenren2024globalstrategiesfor pages 2-4, chene2024cutaneousdiphtheriafrom pages 1-2, museux2023corynebacteriaofthe pages 1-2)	Vaccination gaps and disrupted immunization services are repeatedly linked to resurgence. In the French cutaneous cohort, immunization rate was 44%; in companion-animal work, authors emphasized tox-gene testing and management of animal contacts. (chene2024cutaneousdiphtheriafrom pages 1-2, museux2023corynebacteriaofthe pages 1-2, dinanti2024determinantsofmortality pages 1-2)	NCIT: Vaccination; Diphtheria Toxoid Vaccine; Contact Tracing; Chemoprophylaxis; Isolation Precaution
Epidemiology / prognosis	Disease burden is now concentrated in under-immunized populations and humanitarian/health-system-fragile settings. Respiratory disease remains the classic severe form, while cutaneous disease is increasingly recognized and epidemiologically important. Prognosis worsens with delayed antitoxin, airway obstruction, myocarditis, incomplete immunization, and young age. (osarenren2024globalstrategiesfor pages 1-2, gaillet2024retrospectivestudyof pages 1-2, osarenren2024globalstrategiesfor pages 2-4, chene2024cutaneousdiphtheriafrom pages 1-2, dinanti2024determinantsofmortality pages 1-2)	French Guiana incidence rose from 0.7/100,000 in 2016 to 7.7/100,000 in 2021; mean age 30.4 years; male:female 1.7:1; 95% of cases were cutaneous. Nigeria early 2023 review cited 733 suspected cases and 89 deaths Jan–Mar 2023. In recent French cutaneous series, 68.3% were men and 56.7% had traveled outside mainland France. (gaillet2024retrospectivestudyof pages 1-2, medugu2023areviewof pages 1-2, chene2024cutaneousdiphtheriafrom pages 1-2)	MeSH: Incidence; Prevalence; Mortality; UBERON/HPO terms for complications
Veterinary reservoirs / models	C. ulcerans is a major zoonotic reservoir species in companion animals and other mammals; horses can carry tox-positive C. diphtheriae. Animal and experimental systems have been central to toxin biology and antitoxin development. Classical toxin-neutralization and intoxication studies use guinea pigs; rodents are naturally resistant unless engineered to express the receptor. (museux2023corynebacteriaofthe pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2, wenzel2020humanantibodiesneutralizing pages 1-2)	Companion-animal survey screened 18,308 animals and found 51 C. ulcerans cases (24 toxigenic), plus 2 horses with tox-positive C. diphtheriae and 11 C. rouxii infections. Phase 1 monoclonal antitoxin program cites prior guinea-pig potency work. (museux2023corynebacteriaofthe pages 1-2, NCT04075175 chunk 1)	NCBITaxon: dog, cat, horse, rat, C. ulcerans; NCIT: Animal Model; UBERON: skin, nasal cavity
Human genetics / omics applicability notes	Diphtheria is not primarily a Mendelian human genetic disease; there are no established causal human germline genes or inheritance patterns for “having diphtheria.” Relevant genetics are mostly pathogen-side (tox, phage carriage, DtxR-regulated virulence programs) and host receptor biology used mechanistically. Human omics for routine diagnosis are limited; serology and pathogen genomics are more actionable than host genomics. (wenzel2020humanantibodiesneutralizing pages 1-2, prygiel2022newcorynebacteriumspecies pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)	Recent practical advances center on pathogen genomic surveillance, tox-gene detection, and serosurveys rather than WES/WGS for host diagnosis. Clinical trials include anti-toxin mAb S315 (NCT04075175; completed, n=41) and new DTaP-containing vaccine studies such as NCT06184542 (recruiting, target n=460). (NCT04075175 chunk 1, NCT06184542 chunk 1)	SO/NCIT not applicable for causal human variant annotation; NCIT: Whole Genome Sequencing (pathogen surveillance context), Serologic Test, Monoclonal Antibody Therapy

Table: This compact table summarizes the most actionable disease-knowledge-base facts for diphtheria across clinical, mechanistic, epidemiologic, veterinary, and implementation domains. It is designed to support structured curation with recent evidence and ontology term suggestions.

1. Disease information

Diphtheria is an acute communicable bacterial infection, classically of the upper respiratory tract, in which toxigenic Corynebacterium colonizes mucosa and secretes diphtheria toxin (DT). Local epithelial injury produces an adherent pseudomembrane and possible airway obstruction; absorbed toxin can injure myocardium, peripheral nerves, and other organs. Cutaneous disease presents primarily as chronic ulcers and is an important reservoir for transmission. Modern definitions vary: the strict definition requires toxin-producing C. diphtheriae or C. ulcerans, whereas some surveillance systems include non-toxigenic infections by the C. diphtheriae species complex (CdSC). (gaillet2024retrospectivestudyof pages 1-2, prygiel2022newcorynebacteriumspecies pages 1-2, chene2024cutaneousdiphtheriafrom pages 1-2, museux2023corynebacteriaofthe pages 1-2)

Identifiers and synonyms

MONDO: MONDO:0005015 (diphtheria; verify against the current MONDO release).
MeSH: D004165, Diphtheria, confirmed in the ClinicalTrials.gov-derived MeSH record. (NCT04075175 chunk 1)
ICD-10: A36, with A36.0 pharyngeal, A36.1 nasopharyngeal, A36.2 laryngeal, A36.3 cutaneous, A36.8 other, and A36.9 unspecified diphtheria.
ICD-11: 1C1A, diphtheria; extension/subcategory codes should be checked in the current ICD-11 browser.
OMIM/Orphanet: no appropriate Mendelian OMIM disease entry or rare-genetic Orphanet disease entity is expected; this is an acquired infection.
Synonyms: respiratory diphtheria, pharyngeal/faucial diphtheria, laryngeal diphtheria or diphtheritic croup, nasal diphtheria, cutaneous diphtheria, diphtheritic angina, and historically “the strangling angel.”
Data provenance: the entry is aggregated disease-level knowledge based on surveillance, cohorts, microbiology, and mechanistic studies. It is not derived from one patient's EHR, although some source cohorts used retrospective medical records. (gaillet2024retrospectivestudyof pages 1-2, dinanti2024determinantsofmortality pages 1-2)

2. Etiology, risks, and protective factors

Causal factors

The primary cause is infection with a toxigenic strain of C. diphtheriae. C. ulcerans and, very rarely, C. pseudotuberculosis can also produce DT. The bacterial tox structural gene is carried by related corynebacteriophages and ordinarily requires lysogenic insertion into the bacterial chromosome. Genotype does not perfectly predict phenotype: “nontoxigenic tox-gene-bearing” strains carry tox but fail to express active toxin. (prygiel2022newcorynebacteriumspecies pages 1-2, museux2023corynebacteriaofthe pages 1-2)

Respiratory disease spreads predominantly through droplets or close contact with respiratory secretions. Cutaneous organisms spread through direct skin contact and, less often, contaminated objects. C. ulcerans is zoonotic and associated with contact with cats, dogs, livestock, and diverse wild mammals; unpasteurized milk is an uncommon exposure. Humans are the principal reservoir for C. diphtheriae. (osarenren2024globalstrategiesfor pages 2-4, medugu2023areviewof pages 1-2, chene2024cutaneousdiphtheriafrom pages 1-2, museux2023corynebacteriaofthe pages 1-2)

Risk factors

The dominant risk is absent, incomplete, or waned diphtheria-toxoid immunity. Other risks include overcrowding, close contact with a case or carrier, poverty, homelessness, migration or displacement, disrupted vaccination services, civil unrest, limited laboratory/antitoxin access, poor wound hygiene, and travel to endemic regions. Immunocompromise and socioeconomic disadvantage are prominent in cutaneous cohorts. Pandemic-related interruptions in immunization and surveillance contributed to recent resurgence. (osarenren2024globalstrategiesfor pages 1-2, gaillet2024retrospectivestudyof pages 1-2, osarenren2024globalstrategiesfor pages 2-4, medugu2023areviewof pages 1-2, dinanti2024determinantsofmortality pages 1-2)

Age is not intrinsically protective: in well-vaccinated settings, waning antibody can shift cases to adolescents and adults. In the Nigerian outbreak reviewed in 2023, many cases occurred at 5–18 years; historical Indian data likewise showed substantial disease after age five. (medugu2023areviewof pages 1-2, muhammed2018diphtheriathestrangling pages 1-2)

Protective factors and gene–environment interaction

Primary vaccination and age-appropriate boosters are the strongest protective factors. Rapid identification and antibiotics shorten carriage; isolation, contact tracing, prophylactic antibiotics, and vaccination of contacts interrupt spread. No reproducible human “protective variant,” susceptibility locus, modifier gene, or clinically actionable host pharmacogenomic marker is established. Mechanistically, host expression and species structure of HBEGF/proHB-EGF, the toxin receptor, influence cellular/species susceptibility, but this is not a validated human risk-stratification test. Protection is therefore best modeled as the interaction of exposure intensity and pathogen toxigenicity with vaccine-derived neutralizing antibody, not as classical host G×E inheritance. (osarenren2024globalstrategiesfor pages 1-2, wenzel2020humanantibodiesneutralizing pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)

3. Phenotypes

Respiratory symptoms usually begin acutely after a short incubation. Common manifestations include malaise, low-grade fever, sore throat, odynophagia/dysphagia, tonsillitis or pharyngitis, cervical lymphadenopathy and edema, and an adherent gray-white membrane that bleeds if forcibly removed. Extensive edema produces “bull neck.” Nasal disease can cause serosanguineous discharge; laryngeal/tracheal extension causes hoarseness, stridor, croup, and potentially fatal airway obstruction. Suggested HPO terms include Fever HP:0001945, Sore throat HP:0025439, Dysphagia HP:0002015, Cervical lymphadenopathy HP:0025289, Neck swelling HP:0000464, Stridor HP:0010307, Dyspnea HP:0002094, and Upper-airway obstruction HP:0002781; “diphtheritic pseudomembrane” may require a disease-specific annotation because exact HPO coverage should be verified. (osarenren2024globalstrategiesfor pages 2-4, muhammed2018diphtheriathestrangling pages 2-3, museux2023corynebacteriaofthe pages 1-2, dinanti2024determinantsofmortality pages 1-2)

The pseudomembrane generally forms within two to three days. It reflects fibrin, inflammatory cells, bacteria, and necrotic epithelium. Severity ranges from asymptomatic carriage or localized disease to rapidly progressive obstruction and systemic toxemia; severe cases may die within 6–10 days. (osarenren2024globalstrategiesfor pages 2-4, muhammed2018diphtheriathestrangling pages 2-3)

Cutaneous diphtheria commonly causes a chronic, nonhealing, “punched-out” or rolled-edge ulcer, often with dirty-gray membrane. Suggested HPO terms are Skin ulcer HP:0200042, Impaired wound healing HP:0001058, and Abnormality of the lower limb HP:0002814. In a 2024 French series of 63 adults, 86.9% of lesions involved lower limbs, 82% were ulcers, and 88.9% were polymicrobial; mean age was 53.8 years, 68.3% were men, 56.7% had traveled outside mainland France, and only 44% were appropriately immunized. These figures describe a selected metropolitan-French cohort, not universal phenotype frequencies. (chene2024cutaneousdiphtheriafrom pages 1-2)

Systemic complications include myocarditis/cardiomyopathy, conduction disturbances and arrhythmia, heart failure, peripheral or cranial neuropathy, palatal paralysis, descending weakness, respiratory-muscle paralysis, acute kidney injury, and thrombocytopenia in severe disease. Suggested HPO terms include Myocarditis HP:0012819, Cardiac arrhythmia HP:0011675, Heart failure HP:0001635, Peripheral neuropathy HP:0009830, Muscle weakness HP:0001324, Acute kidney injury HP:0001919, and Thrombocytopenia HP:0001873. Myocarditis often appears in the second week and neuropathy later, sometimes after apparent respiratory improvement. A 2024 Indonesian pediatric cohort found myocarditis and airway obstruction significantly associated with mortality; airway obstruction was associated with approximately 13-fold higher odds of death. (muhammed2018diphtheriathestrangling pages 2-3, dinanti2024determinantsofmortality pages 1-2)

Diphtheritic myocarditis may present with no echocardiographic dysfunction or mild-to-severe dysfunction. In a 2024 Pakistani series restricted to 73 children already diagnosed with diphtheritic myocarditis, 27.4% had rhythm abnormalities, 20% conduction abnormalities, and 30.1% severe echocardiographic dysfunction; those percentages must not be generalized to all diphtheria cases.

Disease-specific validated quality-of-life instruments are scarce. Acute respiratory disease profoundly impairs swallowing, breathing, mobility, schooling/work, and self-care; neuropathy and cardiomyopathy can prolong rehabilitation. Published cohorts focus on survival and organ complications rather than EQ-5D, SF-36, or PROMIS scores.

4. Genetic and molecular information

Human genetics

There are no established human causal genes, pathogenic germline variants, chromosomal abnormalities, inheritance pattern, penetrance estimates, anticipation, founder variants, or carrier frequency for diphtheria. ClinVar/HGMD-style ACMG classification, WES/WGS, CMA, karyotyping, FISH, mitochondrial sequencing, and repeat-expansion testing are not indicated for routine diagnosis. HBEGF (HGNC:3059) and EEF2 (HGNC:3214) are mechanistically relevant host genes, not diphtheria-causative genes. No clinically established host modifier or disease-specific epigenetic signature is available.

Pathogen genetics

The key virulence determinant is phage-borne tox, a 1,683-bp gene encoding a 535-amino-acid toxin. dtxR, encoding the iron-dependent diphtheria-toxin repressor, coordinates toxin/iron-homeostasis programs; low available iron relieves repression and favors toxin transcription. Adhesins, pili/fimbriae, iron-uptake systems, biofilm-related factors, and other horizontally acquired loci contribute to colonization and virulence. The landmark NCTC13129 genome is a single 2,488,635-bp chromosome with 53.48% GC and 2,320 predicted coding sequences; the analysis identified recent acquisition of toxin, iron-uptake, adhesion, and fimbrial determinants. (prygiel2022newcorynebacteriumspecies pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)

The clinically meaningful “variant classification” is therefore pathogen-side: tox-positive/toxin-expressing, tox-negative, or NTTB, rather than human ACMG pathogenicity. In one contemporary synthesis, approximately 10–15% of tox-bearing CdSC strains were NTTB because of disruptive changes. Whole-genome sequencing, MLST, and resistance-gene analysis support outbreak linkage and antimicrobial-resistance surveillance but are not replacements for phenotypic toxigenicity testing. (prygiel2022newcorynebacteriumspecies pages 1-2, museux2023corynebacteriaofthe pages 1-2)

5. Environmental, lifestyle, and infectious-agent information

The infectious agents are gram-positive, non-spore-forming, nonmotile pleomorphic bacilli in the CdSC. Suggested NCBI Taxonomy mappings include C. diphtheriae TaxID 1717, C. ulcerans TaxID 65058, and C. pseudotuberculosis TaxID 1719; identifiers should be release-validated before ingestion.

Relevant environmental/social exposures are crowding, household or institutional contact, displacement camps, weak sanitation and health infrastructure, interrupted immunization, contact with infected wounds/fomites, and animal contact for C. ulcerans. Smoking, diet, alcohol, and exercise are not established direct causal factors, although alcohol-use disorder, homelessness, poor nutrition, and chronic wounds can cluster with cutaneous-disease risk. No radiation, pollution, or occupational toxin is causal. Veterinary, farm, and laboratory work may increase exposure to zoonotic CdSC organisms. (osarenren2024globalstrategiesfor pages 1-2, gaillet2024retrospectivestudyof pages 1-2, prygiel2022newcorynebacteriumspecies pages 1-2, chene2024cutaneousdiphtheriafrom pages 1-2)

6. Mechanism and pathophysiology

Causal chain

Upstream exposure and colonization: droplets or contact introduce organisms to pharyngeal/laryngeal epithelium or damaged skin. Bacterial adhesins and pili support attachment; local replication initiates inflammation.
Toxigenesis: a lysogenized strain expresses and secretes DT. Iron availability regulates expression through DtxR.
Local tissue injury: DT kills epithelial cells, producing necrosis, fibrin-rich exudate, and the tightly adherent pseudomembrane. Membrane extension and edema narrow the airway.
Cell entry: the toxin receptor-binding domain binds membrane proHB-EGF/HB-EGF; receptor-mediated endocytosis follows. Endosomal acidification changes toxin conformation, and its translocation domain delivers the catalytic domain into cytosol.
Biochemical lesion: the catalytic domain transfers ADP-ribose from NAD⁺ to diphthamide on eukaryotic elongation factor 2, halting translation and causing cell dysfunction/death.
Downstream toxemia: hematogenous toxin reaches cardiomyocytes and peripheral nervous tissue, producing myocarditis, conduction failure, demyelinating/axonal neuropathy, weakness, and possible respiratory failure. Renal and hematologic abnormalities can accompany severe systemic illness. (osarenren2024globalstrategiesfor pages 2-4, wenzel2020humanantibodiesneutralizing pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)

DT is approximately 58 kDa and has catalytic, translocation, and receptor-binding domains. The retrieved mechanistic study generated 400 recombinant human antibodies; 35 were produced as human IgG1. The best individual antibody had estimated in-vitro potency of 454 IU/mg, while combinations retained activity at higher toxin loads and reached 79.4 IU/mg in an in-vivo intradermal assay. This supports multi-epitope human-antibody replacement of equine antitoxin, but it was preclinical evidence rather than demonstrated patient efficacy. (wenzel2020humanantibodiesneutralizing pages 1-2)

Suggested GO biological-process terms: pathogenesis (GO:0009405), receptor-mediated endocytosis (GO:0006898), protein ADP-ribosylation (GO:0006471), cytoplasmic translation (GO:0002181), negative regulation of translation (GO:0017148), apoptotic process (GO:0006915), inflammatory response (GO:0006954), and response to iron ion (GO:0010039). Relevant compartments include extracellular region (GO:0005576), plasma membrane (GO:0005886), endosome (GO:0005768), endosomal membrane (GO:0010008), and cytosol (GO:0005829).

Suggested CL terms: epithelial cell (CL:0000066), keratinocyte (CL:0000312), cardiomyocyte (CL:0000746), neuron (CL:0000540), Schwann cell (CL:0000218), macrophage (CL:0000235), and neutrophil (CL:0000775).

Molecular profiling and advanced technologies

Pathogen genomics and transcriptomics have identified phage cargo, iron-acquisition systems, adhesins/pili, and regulatory networks. These data are primarily microbial, not host clinical omics. No validated human transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or epigenomic diagnostic signature is in routine use. Single-cell and CRISPR methods are research opportunities rather than established diphtheria knowledge-base associations.

7. Anatomical structures affected

The principal sites are the posterior mouth, palatine tonsils, nasopharynx, oropharynx, larynx, and proximal trachea; skin, especially lower-limb skin, is the other major site. Less common local sites include eye, ear, and genital mucosa. Secondary toxin targets include myocardium, cardiac conduction tissue, peripheral nerves, cranial nerves, and kidneys. Disease is not characteristically lateralized. (prygiel2022newcorynebacteriumspecies pages 1-2, chene2024cutaneousdiphtheriafrom pages 1-2, cerdenotarraga2003thecompletegenome pages 1-2)

Suggested UBERON mappings are pharynx UBERON:0001042, palatine tonsil UBERON:0002373, larynx UBERON:0001737, trachea UBERON:0003126, skin UBERON:0002097, heart UBERON:0000948, myocardium UBERON:0002349, kidney UBERON:0002113, and peripheral nervous system UBERON:0000010. At the tissue level, respiratory stratified/squamous epithelium, skin epithelium, cardiac muscle, and peripheral nerve are involved. Relevant subcellular compartments are cell surface, endosome, cytosol, and translational machinery.

8. Temporal development

Incubation is usually 2–5 days, with reported ranges around 1–6 days. Onset is acute. Membrane formation commonly occurs by day 2–3. Early disease comprises colonization, pharyngitis, low fever, and membrane expansion; intermediate disease includes airway compromise and cervical edema; advanced disease includes systemic toxemia, myocarditis, neuritis, renal injury, and respiratory failure. (osarenren2024globalstrategiesfor pages 2-4, muhammed2018diphtheriathestrangling pages 2-3, muhammed2018diphtheriathestrangling pages 1-2)

Untreated persons may remain infectious for 2–3 weeks; effective antibiotics markedly shorten contagiousness, reported as about one day in a 2024 review synthesis. Myocarditis often emerges during the first or second week; neuropathy may appear in weeks 2–6 and recover slowly over weeks to months. Respiratory disease is generally acute and nonrelapsing after eradication, although neurologic deficits can persist. The decisive intervention window is immediately when respiratory diphtheria is suspected, before toxin binds cells; antitoxin cannot reverse already internalized toxin. (osarenren2024globalstrategiesfor pages 2-4, muhammed2018diphtheriathestrangling pages 2-3)

9. Inheritance and population epidemiology

There is no Mendelian inheritance, penetrance, anticipation, germline mosaicism, consanguinity effect, or human carrier frequency. “Carrier” in this disease means asymptomatic bacterial carriage, not heterozygosity.

Vaccination reduced diphtheria dramatically in high-income countries, but outbreaks persist or recur in under-immunized populations, especially in parts of Africa and Asia and in humanitarian settings. A December 2024 review reported 27,991 suspected cases and 828 deaths across five African countries in 2024. A 2023 review of Nigeria reported 733 suspected cases and 89 deaths (12.3% case-fatality) during January–March 2023, mainly in children aged 5–18 years. These counts are time- and definition-dependent and should not be interpreted as stable incidence estimates. (osarenren2024globalstrategiesfor pages 2-4, medugu2023areviewof pages 1-2)

In French Guiana, a 2016–2021 multicenter study found 64 infection episodes in 60 patients; incidence increased from 0.7/100,000 in 2016 to 7.7/100,000 in 2021. Mean age was 30.4 years, male:female ratio 1.7:1, and 95% of episodes were cutaneous. Only five of 61 C. diphtheriae isolates carried tox, and all were Elek-negative, demonstrating that CdSC infection counts are not equivalent to toxin-mediated classical diphtheria. (gaillet2024retrospectivestudyof pages 1-2)

Sex effects are inconsistent and probably exposure-dependent rather than biological. Male predominance occurred in French Guiana and metropolitan-French cutaneous cohorts, while a Pakistani myocarditis cohort was nearly sex-balanced. Age distribution depends strongly on vaccine history, booster policies, and outbreak setting.

10. Diagnostics

Clinical and laboratory diagnosis

Suspected respiratory diphtheria is a clinical emergency: acute pharyngitis/tonsillitis/laryngitis with low fever and an adherent gray pseudomembrane, especially with bull neck, bleeding on attempted removal, incomplete vaccination, or epidemiologic exposure. Treatment and public-health notification should not await confirmation. (osarenren2024globalstrategiesfor pages 1-2, dinanti2024determinantsofmortality pages 1-2)

Before antibiotics where feasible, obtain throat and nasal swabs from beneath/around the membrane, or swab/tissue from a skin lesion. Microscopy may show pleomorphic gram-positive rods in “Chinese-letter” arrangements. Culture uses selective tellurite-containing media, on which colonies can appear gray/black. Modern reference workflows combine species identification with PCR for tox. Because PCR establishes gene carriage rather than active toxin production, a phenotypic assay—classically the Elek immunoprecipitation test—is required for expression. MALDI-TOF can aid species identification but may need updated databases/reference-laboratory confirmation for closely related CdSC species. (gaillet2024retrospectivestudyof pages 1-2, muhammed2018diphtheriathestrangling pages 2-3, chene2024cutaneousdiphtheriafrom pages 1-2)

A negative culture after antibiotics does not reliably exclude disease. Routine imaging is not diagnostic. ECG, troponin/CK and other cardiac enzymes, echocardiography, renal function, CBC/platelets, and neurologic examinations assess complications. Electromyography and nerve-conduction studies can characterize delayed neuropathy. Airway imaging/endoscopy should be used cautiously and only when clinically necessary because manipulation may worsen obstruction.

Serology and omics

Antitoxin titers assess immunity, not acute infection. Conventionally, <0.01 IU/mL suggests susceptibility, 0.01–0.1 IU/mL partial/basic protection, and ≥0.1 IU/mL more durable protection, although assay-specific calibration matters. In a 2023 Vietnamese validation study, serum/DBS ELISA values corresponding to a TNT threshold of 0.01 IU/mL were 0.060 and 0.044 IU/mL. In a 510-person serosurvey, a corrected cutoff classified 54% as susceptible, whereas multiple imputation estimated 35%, showing that uncorrected ELISA can substantially misclassify population immunity. At the 0.1-IU/mL threshold, AUC was 0.82 for serum and 0.89 for DBS. (kitamura2023evaluationandvalidation pages 9-11, kitamura2023evaluationandvalidation pages 1-2, kitamura2023evaluationandvalidation pages 6-9, kitamura2023evaluationandvalidation pages 3-6)

Pathogen WGS is valuable for outbreak reconstruction, strain taxonomy, and resistance surveillance. Host WES/WGS, RNA-seq, proteomics, metabolomics, epigenomics, and liquid biopsy have no routine diagnostic role.

Differential diagnosis and screening

Differentials include streptococcal pharyngitis/scarlet fever, infectious mononucleosis, peritonsillar or retropharyngeal abscess, epiglottitis, bacterial tracheitis, candidiasis, Vincent angina, agranulocytosis-related necrotic pharyngitis, and caustic injury. An adherent bleeding membrane, bull neck, low-grade rather than high fever, incomplete vaccination, toxin complications, and isolation of a toxigenic CdSC organism favor diphtheria.

There is no newborn or genetic screening. Outbreak screening consists of clinical assessment and nasal/throat culture/PCR of close contacts; population serosurveys identify immunity gaps.

11. Outcome and prognosis

Overall case-fatality is commonly cited around 5–10%, rising toward 20% in young children in some settings; untreated, unvaccinated severe disease may approach 29% in review syntheses. Values vary markedly with case definition, antitoxin availability, vaccination, referral bias, and outbreak setting. Severe disease can cause death within 6–10 days from asphyxia, cardiogenic shock, or malignant arrhythmia. (osarenren2024globalstrategiesfor pages 1-2, osarenren2024globalstrategiesfor pages 2-4, wenzel2020humanantibodiesneutralizing pages 1-2)

Poor prognostic factors include delayed antitoxin, extensive membrane/bull neck, airway obstruction, myocarditis or arrhythmia, shock, renal injury, thrombocytopenia/leukocytosis in severe disease, young age, absent/incomplete immunization, and limited critical-care access. In the Indonesian 2020–2023 pediatric cohort, myocarditis, airway obstruction, and thrombocytopenia were statistically associated with mortality, and obstruction conferred approximately 13-fold higher death odds. (dinanti2024determinantsofmortality pages 1-2)

Localized cutaneous disease is usually less systemically severe but sustains transmission and may still cause toxemia if the isolate is toxigenic. In French Guiana, 95% of cases were cutaneous and all five tox-PCR-positive isolates were Elek-negative, helping explain the cohort’s different clinical profile from classic respiratory outbreaks. (gaillet2024retrospectivestudyof pages 1-2)

Survivors of uncomplicated disease may recover fully. Neuropathy can require prolonged physical, occupational, respiratory, and swallowing rehabilitation. No meaningful 5- or 10-year survival statistic is used for this acute infection, and formal long-term quality-of-life datasets are limited.

12. Treatment

Immediate algorithm

Isolate suspected respiratory cases with droplet precautions; add contact precautions for wounds.
Collect cultures/PCR specimens without delaying therapy.
Administer diphtheria antitoxin (DAT) promptly for suspected respiratory/toxin-mediated disease after appropriate hypersensitivity precautions. DAT neutralizes circulating toxin but not toxin already bound/internalized.
Give an effective antibiotic—traditionally erythromycin or penicillin—to eradicate organisms and stop transmission; follow national guidance, susceptibility results, age, allergy, pregnancy, and local resistance patterns. Macrolide alternatives may be used according to guidelines.
Secure and monitor the airway; avoid traumatic membrane removal. Provide ICU care, telemetry/serial ECG, cardiac biomarkers and echocardiography when severe disease is present.
Confirm eradication with post-treatment cultures as required; repeat treatment if carriage persists.
Vaccinate during convalescence because infection does not reliably confer immunity. (osarenren2024globalstrategiesfor pages 1-2, muhammed2018diphtheriathestrangling pages 1-2, dinanti2024determinantsofmortality pages 1-2)

Suggested NCIT intervention mappings include Diphtheria Antitoxin, Antibiotic Therapy, Penicillin, Erythromycin, Airway Management, Mechanical Ventilation, Cardiac Monitoring, Temporary Cardiac Pacing, Vaccination, and Rehabilitation Therapy; exact NCIT concept codes should be release-validated. Equine DAT can cause immediate hypersensitivity/anaphylaxis and delayed serum sickness. Macrolides commonly cause gastrointestinal intolerance and can prolong QT; penicillins can cause allergy.

There is no routine surgery except airway intervention such as intubation or tracheostomy when obstruction cannot otherwise be managed. Supportive care includes fluids without overload, nutrition, aspiration prevention, treatment of heart failure/arrhythmia, renal support, and rehabilitation for neuropathy. Corticosteroids for diphtheritic cardiomyopathy remain inadequately established; small observational findings should not replace guideline care.

Experimental and recent therapeutic development

A fully human anti-DT monoclonal antibody, S315, completed a randomized, triple-masked phase I study in 41 healthy adults (NCT04075175; started 23 April 2019, completed 7 October 2019). The study assessed safety and pharmacokinetics, not efficacy in patients with diphtheria. ClinicalTrials.gov. (NCT04075175 chunk 1)

Preclinical recombinant-antibody combinations neutralized multiple DT domains and are intended to overcome equine-DAT limitations such as serum sickness, batch variation, and animal dependence. The authoritative investigators concluded that these combinations were “candidates for further clinical and regulatory development to replace equine DAT,” but clinical replacement has not yet been established in the evidence reviewed. (wenzel2020humanantibodiesneutralizing pages 1-2)

Gene, cell, RNA, CRISPR, or personalized genotype-guided therapies have no current clinical role.

13. Prevention

Primary prevention: complete diphtheria-toxoid-containing vaccination and boosters across the life course. Toxoid induces neutralizing antitoxin and primarily prevents toxin-mediated disease; it does not guarantee elimination of colonization by non-toxigenic or zoonotic CdSC organisms. Outbreak responses combine catch-up vaccination, community engagement, mobile/access-focused delivery, and surveillance. (osarenren2024globalstrategiesfor pages 1-2, osarenren2024globalstrategiesfor pages 2-4, chene2024cutaneousdiphtheriafrom pages 1-2)

Secondary prevention: rapidly identify and isolate cases; notify public health; culture/PCR close contacts; give recommended antibiotic prophylaxis; update contacts’ vaccination; exclude infected carriers from high-risk settings until eradication is documented. Healthcare workers require appropriate PPE and documented immunization.

Tertiary prevention: early DAT, antibiotics, airway protection, telemetry, renal/neurologic monitoring, and rehabilitation prevent death and long-term disability. Antitoxin shortages are a major expert-identified contributor to mortality in low-resource outbreaks. (osarenren2024globalstrategiesfor pages 1-2, medugu2023areviewof pages 1-2)

Serosurveillance can reveal hidden adult immunity gaps, but assay calibration is essential. Dried blood spots performed well against TNT in the 2023 study and offer a lower-cost implementation option in low- and middle-income settings. (kitamura2023evaluationandvalidation pages 9-11, kitamura2023evaluationandvalidation pages 1-2, kitamura2023evaluationandvalidation pages 3-6)

A randomized, blinded phase I pediatric DT-acellular-pertussis vaccine study (NCT06184542) began 23 December 2023 and targeted 460 participants aged two months to six years. It evaluates solicited/unsolicited adverse events and antibody concentration, seropositivity, seroconversion, and neutralization outcomes. The retrieved registry record listed it as recruiting with estimated completion in November 2026. ClinicalTrials.gov. (NCT06184542 chunk 1)

14. Other species and natural disease

C. ulcerans naturally infects numerous mammals and is an important zoonotic source of diphtheria-like disease. C. pseudotuberculosis causes caseous lymphadenitis in sheep/goats and other veterinary syndromes; toxin-producing isolates are rare. C. silvaticum has been recovered from wild boar, while C. rouxii is an emerging CdSC species. (prygiel2022newcorynebacteriumspecies pages 1-2, museux2023corynebacteriaofthe pages 1-2)

A 2023 French study screened 18,308 symptomatic companion animals. It found 51 C. ulcerans cases, 24 toxigenic; rhinitis was most common (18/51). Eleven were monoinfections. German shepherds were overrepresented among dogs (9/28; P<0.00001). Two horses carried tox-positive C. diphtheriae, and 11 animals had tox-negative C. rouxii. The authors emphasized reference-laboratory tox testing and coordinated management of animals and human contacts. This is strong veterinary surveillance evidence for One Health relevance, not proof that every colonized animal transmits to humans. (museux2023corynebacteriaofthe pages 1-2)

Suggested taxa include dog NCBITaxon:9615, cat 9685, horse 9796, rat 10116, guinea pig 10141, mouse 10090, and human 9606. Breed-level VBO annotation may include German Shepherd Dog, subject to current VBO verification. There is no orthologous “disease gene” model because diphtheria is infectious; relevant orthologs are host HBEGF and EEF2 and pathogen virulence genes.

15. Model organisms and experimental systems

Guinea pig: classical mammalian toxin-intoxication and antitoxin-potency model; sensitive to DT and useful for in-vivo neutralization, pathology, and antitoxin lot testing. S315’s registry cites guinea-pig potency work (PMID 27070129). Limitations include intoxication rather than full natural respiratory colonization and species-specific dosing. (NCT04075175 chunk 1)
Mouse/rat: naturally relatively resistant because their proHB-EGF receptor interacts poorly with DT. Transgenic mice expressing a toxin-sensitive receptor permit systemic/respiratory-pathogenesis studies. This species restriction is a limitation but also a powerful receptor-mechanism experiment. (cerdenotarraga2003thecompletegenome pages 1-2)
Cell culture: Vero-cell toxin neutralization is a functional reference assay; human respiratory epithelial lines and other HB-EGF-expressing cells support entry/cytotoxicity studies. Limitations include absence of intact airway, immunity, circulation, and organ interactions. (kitamura2023evaluationandvalidation pages 9-11, kitamura2023evaluationandvalidation pages 3-6)
Invertebrate models: Caenorhabditis elegans and Galleria mellonella can screen non-toxin virulence and bacterial fitness but do not reproduce human DT receptor biology or myocarditis.
Ex-vivo/advanced systems: airway organoids and organ-on-chip systems are plausible for adhesion, epithelial injury, and antitoxin studies, but no validated routine diphtheria model was identified in the retrieved evidence.

Relevant repositories include MGI/IMSR for transgenic mice, RGD for rats, ATCC/Cellosaurus for cell lines, NCBI/ENA for pathogen genomes, and Institut Pasteur’s BIGSdb/PubMLST-type resources for strain epidemiology.

Selected exact abstract quotations and evidence classification

Human clinical/surveillance, French Guiana (published August 2024): “Estimated incidence increased from 0.7 cases/100,000 population in 2016 to 7.7 cases/100,000 population in 2021.” DOI. (gaillet2024retrospectivestudyof pages 1-2)
Human clinical, cutaneous cohort (accepted 19 September 2024): “Lesions involved the lower limbs (86.9%), corresponded to ulcerations in 82% of cases.” DOI. (chene2024cutaneousdiphtheriafrom pages 1-2)
Human clinical, pediatric prognosis (published 9 August 2024): “Patients with airway obstruction were 13 times more likely to have an increase in mortality compared to patients without airway obstruction.” DOI. (dinanti2024determinantsofmortality pages 1-2)
Laboratory/serosurveillance (published June 2023): “DBS is an effective low-cost alternative to serum for future serological studies for diphtheria.” DOI. (kitamura2023evaluationandvalidation pages 1-2)
Veterinary/One Health (published 6 April 2023): “C. ulcerans represents an important zoonotic risk, and C. rouxii may represent a novel zoonotic agent.” DOI. (museux2023corynebacteriaofthe pages 1-2)
Molecular/in-vitro and animal neutralization (published January 2020): “These recombinant antibody combinations are candidates for further clinical and regulatory development to replace equine DAT.” DOI. (wenzel2020humanantibodiesneutralizing pages 1-2)

Overall expert assessment

Current evidence supports a simple but urgent interpretation: diphtheria resurgence is primarily a failure of population immunity, timely recognition, and access to antitoxin—not emergence of a human genetic disorder. The highest-yield real-world actions are complete toxoid vaccination with boosters, resilient routine-immunization systems, immediate DAT for compatible respiratory disease, microbiologic confirmation including phenotypic toxigenicity, antibiotic eradication, and aggressive contact management. The most important recent research developments are better recognition of cutaneous and zoonotic CdSC disease, pathogen genomic surveillance, improved low-cost serosurveillance using DBS, and human monoclonal-antitoxin development. Major evidence gaps remain in standardized contemporary phenotype frequencies, long-term quality of life, randomized treatment trials, clinically validated omics, and equitable DAT availability.

References

(osarenren2024globalstrategiesfor pages 2-4): Jolaawo Osarenren, Pius Omoruyi Omosigho, and Olalekan John Okesanya. Global strategies for addressing diphtheria resurgence epidemiology clinical impact and prevention. Discover Public Health, Dec 2024. URL: https://doi.org/10.1186/s12982-024-00352-1, doi:10.1186/s12982-024-00352-1. This article has 20 citations and is from a peer-reviewed journal.
(prygiel2022newcorynebacteriumspecies pages 1-2): Marta Prygiel, Maciej Polak, Ewa Mosiej, Karol Wdowiak, Kamila Formińska, and Aleksandra Zasada. New corynebacterium species with the potential to produce diphtheria toxin. Pathogens, 11:1264, Oct 2022. URL: https://doi.org/10.3390/pathogens11111264, doi:10.3390/pathogens11111264. This article has 33 citations.
(chene2024cutaneousdiphtheriafrom pages 1-2): Laure Chêne, Jean-Jacques Morand, Edgar Badell, Julie Toubiana, Fréderic Janvier, Hugo Marthinet, Jean-philippe Suppini, Aude Valois, Gaetan Texier, Sylvain Brisse, and Fabien Dutasta. Cutaneous diphtheria from 2018 to 2022: an observational, retrospective study of epidemiological, microbiological, clinical, and therapeutic characteristics in metropolitan france. Sep 2024. URL: https://doi.org/10.1080/22221751.2024.2408324, doi:10.1080/22221751.2024.2408324. This article has 15 citations and is from a domain leading peer-reviewed journal.
(museux2023corynebacteriaofthe pages 1-2): Kristina Museux, Gabriele Arcari, Guido Rodrigo, Melanie Hennart, Edgar Badell, Julie Toubiana, and Sylvain Brisse. Corynebacteria of the diphtheriae species complex in companion animals: clinical and microbiological characterization of 64 cases from france. Jun 2023. URL: https://doi.org/10.1128/spectrum.00006-23, doi:10.1128/spectrum.00006-23. This article has 22 citations and is from a domain leading peer-reviewed journal.
(muhammed2018diphtheriathestrangling pages 2-3): S. Muhammed, Y. Muhammed, R. Gupta, and V. Sondhi. Diphtheria: the strangling angel of (older) children. Pediatric Oncall, Jan 2018. URL: https://doi.org/10.7199/ped.oncall.2018.25, doi:10.7199/ped.oncall.2018.25. This article has 0 citations.
(dinanti2024determinantsofmortality pages 1-2): Shinta P. Dinanti, Oke R. Ramayani, and Ayodhia P. Pasaribu. Determinants of mortality in relationship between clinical and laboratory characteristics with the outcomes of children with diphtheria: a cross-sectional study at a national hospital of sumatra region in 2020–2023. Narra J, 4(2):e776, Aug 2024. URL: https://doi.org/10.52225/narra.v4i2.776, doi:10.52225/narra.v4i2.776. This article has 1 citations.
(wenzel2020humanantibodiesneutralizing pages 1-2): Esther Veronika Wenzel, Margarita Bosnak, Robert Tierney, Maren Schubert, Jeffrey Brown, Stefan Dübel, Androulla Efstratiou, Dorothea Sesardic, Paul Stickings, and Michael Hust. Human antibodies neutralizing diphtheria toxin in vitro and in vivo. Scientific Reports, Jan 2020. URL: https://doi.org/10.1038/s41598-019-57103-5, doi:10.1038/s41598-019-57103-5. This article has 89 citations and is from a peer-reviewed journal.
(cerdenotarraga2003thecompletegenome pages 1-2): A. Cerdeño-Tárraga, A. Efstratiou, L. Dover, M. Holden, M. Pallen, S. Bentley, G. Besra, C. Churcher, K. James, A. D. Zoysa, T. Chillingworth, A. Cronin, L. Dowd, T. Feltwell, N. Hamlin, S. Holroyd, K. Jagels, S. Moule, M. Quail, E. Rabbinowitsch, Kim M Rutherford, N. Thomson, L. Unwin, S. Whitehead, B. Barrell, and J. Parkhill. The complete genome sequence and analysis of corynebacterium diphtheriae nctc13129. Nucleic Acids Research, 31(22):6516-6523, Nov 2003. URL: https://doi.org/10.1093/nar/gkg874, doi:10.1093/nar/gkg874. This article has 420 citations and is from a highest quality peer-reviewed journal.
(gaillet2024retrospectivestudyof pages 1-2): Mélanie Gaillet, Mélanie Hennart, Vincent Sainte Rose, Edgar Badell, Céline Michaud, Romain Blaizot, Magalie Demar, Luisiane Carvalho, Jean François Carod, Audrey Andrieu, Félix Djossou, Julie Toubiana, Loic Epelboin, and Sylvain Brisse. Retrospective study of infections with corynebacterium diphtheriae species complex, french guiana, 2016–2021. Emerging Infectious Diseases, 30:1542-1551, Aug 2024. URL: https://doi.org/10.3201/eid3008.231671, doi:10.3201/eid3008.231671. This article has 2 citations and is from a domain leading peer-reviewed journal.
(kitamura2023evaluationandvalidation pages 1-2): Noriko Kitamura, Akira Endo, Lien T. Le, Trieu B. Nguyen, Hung T. Do, Michiko Toizumi, Lay-Myint Yoshida, Yoshio Mori, Samuel Rose, Androulla Efstratiou, Norman K. Fry, and David Litt. Evaluation and validation of a commercial elisa versus the in vitro toxin neutralization assay for determination of diphtheria anti-toxin in human serum. Jun 2023. URL: https://doi.org/10.1099/jmm.0.001721, doi:10.1099/jmm.0.001721. This article has 3 citations and is from a peer-reviewed journal.
(kitamura2023evaluationandvalidation pages 6-9): Noriko Kitamura, Akira Endo, Lien T. Le, Trieu B. Nguyen, Hung T. Do, Michiko Toizumi, Lay-Myint Yoshida, Yoshio Mori, Samuel Rose, Androulla Efstratiou, Norman K. Fry, and David Litt. Evaluation and validation of a commercial elisa versus the in vitro toxin neutralization assay for determination of diphtheria anti-toxin in human serum. Jun 2023. URL: https://doi.org/10.1099/jmm.0.001721, doi:10.1099/jmm.0.001721. This article has 3 citations and is from a peer-reviewed journal.
(kitamura2023evaluationandvalidation pages 3-6): Noriko Kitamura, Akira Endo, Lien T. Le, Trieu B. Nguyen, Hung T. Do, Michiko Toizumi, Lay-Myint Yoshida, Yoshio Mori, Samuel Rose, Androulla Efstratiou, Norman K. Fry, and David Litt. Evaluation and validation of a commercial elisa versus the in vitro toxin neutralization assay for determination of diphtheria anti-toxin in human serum. Jun 2023. URL: https://doi.org/10.1099/jmm.0.001721, doi:10.1099/jmm.0.001721. This article has 3 citations and is from a peer-reviewed journal.
(osarenren2024globalstrategiesfor pages 1-2): Jolaawo Osarenren, Pius Omoruyi Omosigho, and Olalekan John Okesanya. Global strategies for addressing diphtheria resurgence epidemiology clinical impact and prevention. Discover Public Health, Dec 2024. URL: https://doi.org/10.1186/s12982-024-00352-1, doi:10.1186/s12982-024-00352-1. This article has 20 citations and is from a peer-reviewed journal.
(muhammed2018diphtheriathestrangling pages 1-2): S. Muhammed, Y. Muhammed, R. Gupta, and V. Sondhi. Diphtheria: the strangling angel of (older) children. Pediatric Oncall, Jan 2018. URL: https://doi.org/10.7199/ped.oncall.2018.25, doi:10.7199/ped.oncall.2018.25. This article has 0 citations.
(medugu2023areviewof pages 1-2): N. Medugu, T.O. Musa-Booth, B. Adegboro, A.O. Onipede, M. Babazhitsu, and R. Amaza. A review of the current diphtheria outbreaks. African Journal of Clinical and Experimental Microbiology, 24:120-129, Apr 2023. URL: https://doi.org/10.4314/ajcem.v24i2.2, doi:10.4314/ajcem.v24i2.2. This article has 30 citations.
(NCT04075175 chunk 1): Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy Subjects. MassBiologics. 2019. ClinicalTrials.gov Identifier: NCT04075175
(NCT06184542 chunk 1): Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine. Institute of Medical Biology, Chinese Academy of Medical Sciences. 2023. ClinicalTrials.gov Identifier: NCT06184542
(kitamura2023evaluationandvalidation pages 9-11): Noriko Kitamura, Akira Endo, Lien T. Le, Trieu B. Nguyen, Hung T. Do, Michiko Toizumi, Lay-Myint Yoshida, Yoshio Mori, Samuel Rose, Androulla Efstratiou, Norman K. Fry, and David Litt. Evaluation and validation of a commercial elisa versus the in vitro toxin neutralization assay for determination of diphtheria anti-toxin in human serum. Jun 2023. URL: https://doi.org/10.1099/jmm.0.001721, doi:10.1099/jmm.0.001721. This article has 3 citations and is from a peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	11
Resolved	11
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	11
On topic	2
Off topic	1

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

DOI:10.1128/spectrum.00006-23 (5 mentions) - Corynebacteria of the diphtheriae Species Complex in Companion Animals: Clinical and Microbiological Characterization of 64 Cases from France
shared terms: clinical

Weighed against this report's own most characteristic terms: disease, clinical, human, diphtheria, gene, toxin, include, genetic, respiratory, cell, airway, system, contact, vaccination, treatment, age, genome, antitoxin, model, cutaneous.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	61
Resolved	57
Unresolved (possible confabulation)	0
Obsolete	2
Unverifiable	2
Terms whose name was checked	1
Terms named correctly	0
Terms named as a different term	1

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

MONDO:0005015 (1 mention) - the report calls it "diphtheria; verify against the current MONDO release"; MONDO calls it diabetes mellitus

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

GO:0009405 (obsolete pathogenesis) (2 mentions)
GO:0006471 (obsolete protein ADP-ribosylation) (1 mention)

Ask OpenScientist

OpenScientist Report

Classifications

Subtypes

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Progression

Prevalence

Infectious Agent

Clinical Burden

Clinical Trials

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Disease Characteristics Research Template

Target Disease

Research Objectives

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Citation Requirements

Output Format

Diphtheria: comprehensive disease-characteristics report

1. Disease information

2. Etiology, risks, and protective factors

Causal factors

Risk factors

Protective factors and gene–environment interaction

3. Phenotypes

4. Genetic and molecular information

Human genetics

Pathogen genetics

5. Environmental, lifestyle, and infectious-agent information

6. Mechanism and pathophysiology

Causal chain

Molecular profiling and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population epidemiology

10. Diagnostics

Clinical and laboratory diagnosis

Serology and omics

Differential diagnosis and screening

11. Outcome and prognosis

12. Treatment

Immediate algorithm

Experimental and recent therapeutic development

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Selected exact abstract quotations and evidence classification

Overall expert assessment

Artifacts

Reference Validation

References that may not be about this subject

Term Validation

Terms the report names something else

Obsolete terms